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 Rôle(s) du récepteur aux cannabinoïdes mitochondrial 
de type 1 dans le cerveau 
 
Le récepteur aux cannabinoïdes de type 1 (CB1) est un récepteur couplé aux 
protéines G, abondamment exprimé dans le cerveau et régulant plusieurs processus 
physiologiques. Cependant, les mécanismes cellulaires par lesquels les CB1 régulent 
ces processus n’ont été que peu analysés. Bien que les CB1 localisés dans les 
membranes plasmiques sont connus pour induire la transduction de signal; une 
partie de ces récepteurs sont aussi fonctionnels au niveau des mitochondries 
(mtCB1), où leur stimulation réduit la respiration mitochondriale. L’objectif de cette 
thèse fut d’évaluer l’impact de l’activation des récepteurs mtCB1 du cerveau sur les 
effets connus des cannabinoïdes. Afin de distinguer la fonction des mtCB1 de celle 
des autres populations de récepteurs, nous avons développé des outils basés sur la 
signalisation induite par les mtCB1. Dans les mitochondries isolées de cerveau, 
l’activation des protéines Gαi/o, dépendante des mtCB1 diminue l’activité de l’adénylyl 
cyclase soluble (sAC). L'inhibition locale de l’activité de sAC prévient l’amnésie, la 
catalepsie et partiellement l’hypolocomotion induite par les cannabinoïdes. De plus, 
nous avons généré une protéine fonctionnelle mutante CB1 (DN22-CB1) dépourvue 
des 22 premiers acides aminés des CB1 ainsi que de sa localisation mitochondriale. 
Contrairement aux CB1, l'activation des DN22-CB1 n’affecte pas l'activité 
mitochondriale. Enfin, l’expression des DN22-CB1 dans l’hippocampe bloque à la fois 
la diminution de la transmission synaptique et l’amnésie induites par les 
cannabinoïdes. Ces travaux démontrent l’implication des mtCB1 dans certains effets 
des cannabinoïdes et le rôle clé des processus bioénergétiques contrôlant les 
fonctions cérébrales. 
Mots clés: récepteurs mtCB1, mitochondrie, adénylyl cyclase soluble, 
phosphorylation oxydative, bioénergétique, mémoire de reconnaissance d’objet, 
contrôle moteur, hippocampe, Substance Noire réticulée. 
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 Résumé substantiel 
 
Introduction générale 
 
Il y a des millénaires, le peuple chinois cultivait le Cannabis à des fins nutritives, 
médicinales et/ou psychoactives (Russo et al., 2008). Ce n’est qu’au 19ème siècle 
que le cannabis fut importé en Europe par le docteur irlandais William Brooke 
O'Shaughnessy. Il étudia les effets aigues du Cannabis de façon expérimentale sur 
des animaux et humains et publia ces résultats (O'Shaughnessy, 1843). Peu après, 
le Cannabis entra dans la pharmacopée occidentale où il était recommandé pour ses 
propriétés anticonvulsivantes, antiémétiques, antinociceptives et hyperphagiques. 
Ces effets thérapeutiques étaient souvent accompagnés par des effets indésirables 
tels que des troubles psychotiques, troubles mnésiques et une perturbation dans les 
performances motrices.  
L’intérêt scientifique se porta alors sur la caractérisation pharmacologique des 
molécules contenues dans le cannabis, les cannabinoïdes. La compréhension de 
leur mode d’action fut le fruit d’une recherche laborieuse. Il faudra attendre les 
années 1940 pour que les études de Roger Adams et celles de Raphaël Mechoulam 
en 1964 identifient et établissent définitivement la structure chimique du principal 
composant psychoactif du cannabis, nommé le ∆9-tetrahydrocannabinol (THC ; 
Adams, 1942 ; Gaoni et Mechoulam, 1964).  
Malgré la nature lipidique du THC et sa faculté de perturber la fluidité des 
membranes, l’hypothèse d’un mode d’action par l’activation de récepteurs fut 
avancée. En 1988, Allyn Howlett et ses collaborateurs montrèrent que la plupart des 
effets attribués aux cannabinoïdes étaient dus à leur capacité d’activer des 
récepteurs spécifiques (Howlett et al., 1988). Deux types de récepteurs appartenant 
à la famille des récepteurs couplés aux protéines G (noté GPCR) furent clonés; le 
récepteur aux cannabinoïdes de type 1 (CB1 ; Matsuda et al., 1990) et de type 2 
(CB2 ; Munro et al., 1993). Les récepteurs CB1 sont abondamment exprimés dans le 
cerveau et avec des niveaux plus faibles dans beaucoup de tissus périphériques 
(Matsuda et al., 1990). Quant aux récepteurs CB2, ils sont principalement localisés 
en périphérie dans des cellules immunitaires et hématopoïétiques et avec en faible 
densité dans le système central. De par cette distribution différentielle et par des 
outils génétiques et pharmacologiques, il a été établit que la plupart des effets 
centraux des cannabinoïdes impliquent les récepteurs CB1 et leur effets 
immunomodulateurs sont dus, au contraire, principalement à l’activation des CB2 
(Munro et al., 1993).  
 
Les deux principaux ligands endogènes des récepteurs aux cannabinoïdes, 
appelés endocannabinoïdes (eCBs), ont été identifiés dans les années 1990 et 
connus sous le nom d'anandamide et du 2-arachidonoylglycerol (Devane et al., 1992; 
Mechoulam et al., 1995; Sugiura et al., 1995). A l’inverse de neurotransmetteurs 
classiques, les aCBS sont des composés lipidiques synthétisés de novo à partir de 
précurseurs lipidiques membranaires et se comportent comme des messagers 
neuronaux rétrogrades. Les eCBs sont synthétisés à la demande suite à une 
augmentation de calcium intracellulaire de l’élément post-synaptique induite par une 
dépolarisation. Les eCBS vont ensuite aller activer les récepteurs CB1 pré-
synaptique localisés sur les terminaisons axonales (Kim et Alger, 2004).  Une fois 
stimulé par leur ligands, les récepteurs CB1 déclenchent de nombreuses cascades 
intracellulaires, telles que la phosphorylation de protéines (par ex : la protéine ERK, 
extracellular signal-regulated kinase), la synthèse protéique et la modulation de 
certains canaux ioniques. Ces changements rapides induits par la stimulation des 
CB1 hyperpolarisent la présynapse et conduisent à une inhibition transitoire ou 
persistante de la libération des neurotransmetteurs, un des mécanismes synaptiques 
les mieux caractérisé des cannabinoïdes (Mackie et al., 1993; Deadwyler et al., 
1995; Hampson et al., 1995; Mu et al., 1999).  
De par leur large distribution en terme de structures et de cellules cérébrales, 
les récepteurs CB1 régulent un vaste éventail de fonctions cognitives et somatiques. 
Ainsi, la compréhension des rôles complexes des CB1 requiert une cartographie 
précise de leurs sites d'action à toutes les échelles (régional, cellulaire et 
subcellulaire). Les récepteurs CB1 sont les GPCRs les plus fortement exprimés dans 
le cerveau, avec des densités différentes d’une région à l’autre (Herkenham et al., 
1990). On les retrouve fortement exprimés dans la substance noire réticulée, le 
globus pallidus, le cervelet et l’hippocampe (Tsou et al., 1998). Ces récepteurs sont 
localisés sur différents types de populations cellulaires. Majoritairement présents sur 
les neurones GABAergiques, ils se retrouvent en plus faible densité dans les 
neurones glutamatergiques corticaux (Mailleux et al., 1992; Marsicano et al., 2003; 
Marsicano et Kuner, 2008; Marsicano et Lutz, 1999). Malgré la minorité de 
récepteurs CB1 sur des cellules glutamatergiques, ces récepteurs jouent des rôles 
importants dans effets physiologiques et pharmacologiques comme la protection 
contre la excitotoxicitée dans l’hippocampe, l'anxiété et la prise alimentaire 
(Bellocchio et al., 2010; Dubreucq et al., 2012; Metna-Laurent et al., 2012). De plus, 
les récepteurs CB1 sont fonctionnellement exprimés sur d’autres types de cellules 
non-neuronales. C’est le cas des récepteurs CB1 localisés dans les cellules 
astrocytaires où ils jouent un rôle dans la transmission synaptique et participent aux 
processus mnésiques et métaboliques (Navarrete et Araque, 2010; Navarrete et 
Araque 2008 ; Bosier et al., 2013 ; Han et al., 2012).  
 
La localisation subcellulaire semble également tenir un rôle déterminant dans la 
signalisation et la fonction des récepteurs CB1. Au niveau subcellulaire, les CB1 se 
retrouvent exprimés en majorité à la surface des cellules insérés dans la membrane 
plasmique mais la présence des CB1 sur les compartiments intracellulaires et en 
particulier sur mitochondries avait été suggéré (Ong et 1999 Mackie; Rodriguez et 
d'autres., 2001). Cependant, jusqu’à présent les effets dépendants des CB1 ont été 
exclusivement attribués aux CB1 de la membrane plasmique (pmCB1) et la possibilité 
que les récepteurs CB1 sur les mitochondries puissent participer à la transduction du 
signal induit par les cannabinoïdes n'a jamais été prise en considération et leur 
présence était contestée. Cela pour deux raisons : 
- Les immuno-marquages anti-CB1 étaient considérés comme aspécifiques à 
cause du manque de contrôle négatif approprié tel que les animaux génétiquement 
modifiés et n’exprimant pas les récepteurs CB1 (CB1 knock-out, noté CB1-/-).  
- Les GPCRs sont traditionnellement considérés comme des médiateurs de la 
communication intercellulaire et sont pour cela recrutés à la surface cellulaire où ils 
transfèrent les signaux extracellulaires aux effecteurs intracellulaires via la 
stimulation des protéines G.  
Défiant ce prédicat logique, des études ont démontrés la présence fonctionnelle 
des GPCRs sur les membranes intracellulaires, y compris, les endosomes, les 
noyaux et les mitochondries (Belous et al., 2004; Irannejad et von Zastrow, 2014). 
De façon similaire, l’équipe de Rozenfeld a observé l’activité des récepteurs CB1 
localisés dans les compartiments endosomal/lysosomal, dont la stimulation 
déclenche la signalisation dépendante de protéine G et contribuent ainsi aux 
cascades intracellulaires induites par les cannabinoïdes (Rozenfeld et Devi, 2008).  
Dans ce contexte, en 2012, une étude de notre laboratoire a démontré qu’une 
portion de récepteurs CB1 était fonctionnellement présente sur les membranes 
mitochondriales et nommé mtCB1 (Benard et al., 2012). Par microscopie électronique 
et marquage immunohistochimie, les auteurs ont montré qu'approximativement 10 à 
15 % de récepteurs CB1 totaux dans la région hippocampique CA1 sont situés dans 
les mitochondries de souris sauvages-types, en grande partie au-dessus des niveaux 
de bruit quantifiés dans les tissus de souris mutantes CB1-/-. 
Les mitochondries sont des organelles à doubles membranes essentielles pour 
la survie de nos cellules et remplissent diverses fonctions. La plus connue est la 
production d’adénosine triphosphate (ATP) au cours de la phosphorylation oxydative 
(OXPHOS). Dans la matrice mitochondriale, les intermédiaires métaboliques issues 
du cycle de Krebs vont subir des séries de réactions d’oxydo-réduction au niveau 
d’un ensemble de quatre complexes enzymatiques localisés sur la membrane interne 
de l’organelle. Ce processus libère les électrons qui sont transférés le long de cette 
chaîne respiratoire, l’oxygène, étant l'accepteur final d'électrons sera transformé en 
eau. Le flux d’électron s’accompagne d’une accumulation de protons dans l’espace 
intermembranaire à l’origine d’un gradient électrochimique de part et d’autre de la 
membrane mitochondriale interne. La dissipation de ce gradient s’opère par le retour 
de protons dans la matrice via l’ATP synthétase, permettant la synthèse d’ATP 
(Brown, 2004).   
L’approvisionnement constant en ATP est fondamental pour le cerveau et 
représente le pilier de toutes les fonctions cérébrales. Chez les mammifères, le 
cerveau est un des les organes les plus exigeants en ATP. Au repos, alors qu’il 
représente seulement  2 % de la masse corporelle totale, le cerveau consomment 25 
% de l'énergie de corps totale et 20 % de l'oxygène total (Erecinska et Argent, 2001; 
Kety, 1957; Rolfe et Brun, 1997; Sokoloff, 1960). L’ATP cellulaire est principalement 
produit par les mitochondries et utilisée pour mobiliser les vésicules synaptiques, 
maintenir les flux d'ions et l’excitabilité neuronale, les réarrangements du 
cytosquelette des cellules du cerveau, et la régulation l'activité synaptique (Attwell et 
Laughlin, 2001).  
Les travaux menés par Benard et ses collègues ont démontrés que l’activation 
des mtCB1, exprimés sur la membrane externe mitochondriale, régulent la fonction 
respiratoire des mitochondries (Benard et al., 2012). En effet sur des mitochondries 
isolées de cerveau de souris sauvage, l’application exogène d’agonistes aux CB1 tel 
que le THC, l’anandamide et le HU210 diminue significative la consommation 
d’oxygène mitochondrial,  alors qu’aucun changement n’est observé sur des 
mitochondries de cerveau de souris CB1-/-, indiquant une inhibition directe de la 
respiration mitochondriale par cannabinoïdes via les récepteurs CB1 (Benard et al., 
2012).  
 
Objectif de la thèse 
 
Alors que le dysfonctionnement à long terme de l’activité mitochondriale peut 
avoir des conséquences dramatiques sur la neurotransmission (Cai et al., 2011) et 
conduire à de nombreuses maladies neurologiques et psychiatriques (Mattson et al., 
2008), on en sait peu sur les rôles physiologiques de la régulation de l'activité 
mitochondriale dans le cerveau et quant à leur rôle dans la régulation aiguë du 
comportement. L'activation des CB1 représente un potentiel thérapeutique important, 
tels que des effets analgésiques, mais cause également des effets indésirables. 
L’objectif de ma thèse était de déterminer la potentielle participation des mtCB1 
dans le cerveau dans ces effets pharmacologiques induit par les cannabinoïdes et 
dépendants des CB1. En particulier, j’ai étudié le potentiel rôle des mtCB1 dans les 
effets secondaires des cannabinoïdes, y compris l'altération de la mémoire, la 
réduction d'activité locomotrice spontanée (hypolocomotion) et l'incapacité d'initier le 
mouvement (la catalepsie; Holtzman et d'autres., 1969). 
 
Mise en place d’outils génétiques et pharmacologiques 
 
Le premier défi de ce projet consistait à développer des outils expérimentaux 
pharmacologiques et génétiques capables de distinguer la fonction des mtCB1 de 
celle des autres populations de récepteurs. L'approche pharmacologique a été basée 
sur la signalisation induite par les mtCB1 impliquée dans la réduction de l'activité 
respiratoire mitochondriale. Dans les mitochondries isolées de cerveau, l’activation 
des protéines Gαi/o, dépendante des mtCB1 diminue l’activité OXPHOS par l'inhibition 
de la cascade intra-mitochondriale soluble adénylyl cyclase/ adénosine 
monophosphate cyclique/ phosphate kinase A, noté sAC/cAMP/PKA. L'inhibition de 
l’activité de sAC, par un inhibiteur pharmacologique spécifique, le KH7, bloque les 
effets de l’activation des mtCB1 sur la fonction respiratoire mitochondrial dans des 
cultures cellulaires et les mitochondries isolées de cerveau. En combinaison, nous 
avons utilisé l’Hemopressin, un agoniste inverse des récepteurs CB1 qui de par sa 
nature peptidique est non-perméable aux membranes cellulaires, ce qui permet de 
distinguer le rôle des pmCB1 par rapport a celui des CB1 intracellulaires (Heimann et 
al., 2007, Dodd 2013). Pour élargir la palette d'outils pour étudier les fonctions des 
mtCB1, nous avons généré une protéine mutante CB1 (DN22-CB1) dépourvue des 22 
premiers acides aminés des CB1 ainsi que de sa localisation mitochondriale. 
Contrairement aux CB1, l'activation des DN22-CB1 n’affecte pas l'activité respiratoire 
mitochondriale. Néanmoins, cette protéine est fonctionnellement couplée aux 
protéines G et son activation déclenche une voie de signalisations bien connue des 
CB1 qui est la phosphorylation de la protéine ERK.  
 
Résultats :  
 
Par ces approches innovantes, nous avons utilisé ces outils pharmacologiques 
et génétiques, afin d'évaluer le rôle potentiel des récepteurs mtCB1 in vivo dans la 
régulation de mémoire de reconnaissance d'objets et le contrôle moteur. Les 
données actuelles suggèrent fortement que le contrôle direct de l'activité 
mitochondriale par les récepteurs mtCB1 dans différentes régions du cerveau 
participe aux effets comportementaux induits cannabinoïdes y compris troubles de la 
mémoire et de l'altération de l’activité motrice. Plusieurs éléments convergent pour 
soutenir cette conclusion: 
1. Des enregistrements électrophysiologiques sur des tranches d'hippocampes 
ont révélé que le KH7 bloque la diminution de la libération glutamatergique 
dépendante des récepteurs CB1. Cet effet est rétablit chez les souris CB1 -/- par la 
réexpression virale de CB1, mais pas par la réexpression fonctionnelle des protéines 
DN22-CB1.  
2. Dans l’effet amnésique des cannabinoïdes sur la mémoire de la 
reconnaissance d’objets (ORM) des précédentes études ont mis en évidence la 
participation des CB1 dans l’hippocampe, une région cérébrale responsable de 
processus mnésiques. L’injection locale de KH7 prévient l’effet amnésiant des 
cannabinoïdes chez les souris sauvages. De plus, ce test est adéquat pour nos 
études car les souris CB1 -/- ne répondent pas à l'administration de cannabinoïdes et 
ne montrent aucune altération spontanée des performances mnésiques 
(Puighermanal et al ., 2009), permettant ainsi la réexpression virales dans 
l’hippocampe des protéines CB1 sauvages ou des DN22-CB1. La réexpression de 
CB1 viral intra-hippocampal chez les souris CB1-/-, est suffisante pour rétablir 
l'altération des performances mnésiques induite par les cannabinoïdes. Au contraire, 
la réexpression de DN22 -CB1 chez les souris CB1-/- ne restaure pas l'effet du WIN 
sur l’ORM, indiquant l'implication de mtCB1 dans cet effet.  
3. En utilisant les outils pharmacologiques, nous avons identifié le SNr comme 
une région du cerveau où les cannabinoïdes exercent les effets cataleptiques et 
hypolocomoteurs. En effet, l’administration intra-SNr de l’agoniste inverse lipidique 
des récepteurs CB1 perméable aux membranes (AM251) bloque l’hypolocomotion et 
la catalepsie. Au contraire, l’hemopressin, un agoniste inverse peptidique et non-
perméable, injecté localement ne prévient partiellement l’hypolocomotion mais pas 
l'effet cataleptique du THC, suggérant la participation de récepteurs CB1 
intracellulaires.  
4. Après identification par microscopie électronique de l’expression de mtCB1 
au sein de la SNr, l’infusion locale du KH7, inhibiteur de la sAC, bloque l’effet 
cataleptique du THC et réduit fortement sont effet hypolocomoteur.  
 
Conclusion 
 
Les résultats obtenus durant ma thèse démontrent l’implication des mtCB1 dans 
certains effets secondaires des cannabinoïdes (catalepsie et troubles de la mémoire) 
et le rôle clé des processus bioénergétiques contrôlant les fonctions cérébrales.  
L’identification des partenaires de signalisation des CB1 intramitochondriaux 
tels que la protéine Gi/o s’accompagne d’un couplage étroit entre le récepteur et la 
sAC. Cette cascade cause l’inhibition de la fonction respiratoire mitochondriale et 
contribue aux effets comportementaux des cannabinoïdes. Au delà de leur fonction 
respiratoire, les mitochondries exercent une myriade de fonctions essentielles à 
l’activité synaptique et aux fonctions cérébrale, tel que la production d’espèces 
réactives à l’oxygène (ROS), le métabolisme des neurotransmetteur, l’homéostasie 
du calcium et beaucoup d'autres processus physiologiques. Il est difficile de 
connaître précisément par quel mécanisme "post-mitochondrial" l'activation de 
récepteur mtCB1 est couplé aux les effets cognitifs ou moteur observés puisque les 
fonctions mitochondriales différentes sont interdépendantes (Gunter et Sheu, 2009, 
Vos et d'autres., 2010). Des travaux de recherche sont en cours pour identifier 
d’autres possibles régulations des mtCB1 sur les fonctions mitochondriales tel que 
l’homéostasie du calcium ou la dynamique mitochondriale. 
 
Ces données rassemblées pendant mon doctorat démontrent de façon causale 
que la régulation des fonctions mitochondriales dans le cerveau par l’activation des 
mtCB1 participe aux effets comportementaux caractéristiques des cannabinoïdes 
comme la catalepsie et l'amnésie. Ainsi, la régulation l’activité mitochondriale 
représente un mécanisme central qui sous-tend les fonctions cérébrales complexes, 
ce qui jusqu'à présent était sous-estimé. De par l’utilisation de cannabinoïdes pour 
des indications thérapeutiques, la mise en évidence des mtCB1 dans les effets 
secondaires des cannabinoïdes chez la souris, offre potentiellement de nouvelles 
alternatives dans le développement d’agonistes CB1 qui ciblerai exclusivement  les 
pmCB1 pour induire des effets thérapeutiques en limitant les effets secondaires. 
C’est pourquoi, il serait nécessaire de disséquer les effets des cannabinoïdes 
dépendants des fonctions mitochondriales de ceux qui sont indépendants. 
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Role(s) of the mitochondrial type-1 cannabinoid receptor in 
the brain 
 
Type-1 cannabinoid receptor CB1 is a G protein-coupled receptor (GPCR), 
widely expressed in the brain, which regulates numerous physiological processes. 
However, the cellular mechanisms of CB1-mediated control of these functions are 
poorly understood. Although CB1 are known to signal at the plasma membrane, a 
portion of these receptors are also present in mitochondria (mtCB1), where mtCB1 
activation decreases mitochondrial activity. The goal of this thesis was to dissect the 
impact of brain mtCB1 signaling in known behavioral effects induced by 
cannabinoids. To distinguish the functions of mtCB1 from other receptor pools, we 
developed tools based on the characterization of the intra-mitochondrial molecular 
cascade induced by mtCB1 receptors. In isolated brain mitochondria, we found that 
intra-mitochondrial decrease of soluble-adenylyl cyclase (sAC) activity links mtCB1-
dependent activation of Gαi/o proteins to decrease cellular respiration. Local brain 
inhibition of sAC activity blocks cannabinoid-induced amnesia, catalepsy and 
contributes to the hypolocomotor effect of cannabinoids. In addition, we generated a 
functional mutant CB1 protein (DN22-CB1) lacking the first 22 amino acid of CB1 and 
its mitochondrial localization. Differently from CB1, activation of DN22-CB1 does not 
affect mitochondrial activity. Hippocampal in vivo expression of DN22-CB1 abolished 
both cannabinoid-induced impairment of synaptic transmission and amnesia in mice. 
Together, these studies couple mitochondrial activity to behavioral performances. 
The involvement of mtCB1 in the effects of cannabinoids on memory and motor 
control highlights the key role of bioenergetic processes as regulators of brain 
functions. 
 
Key words: mtCB1 receptors, mitochondria, soluble adenylyl cyclase, oxidative 
phosphorylation, bioenergetic, object recognition memory, motor control, 
hippocampus, and Substantia Nigra pars reticulata. 
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I. THE	  ENDOCANNABINOID	  SYSTEM	  
I.1 Cannabis	  and	  humans:	  a	  long	  history	  
The transmission of knowledge between generations is a determinant factor for 
the well-being and human survival. For example, awareness of the medicinal 
proprieties of plants has been used to cure diseases and alleviate discomfort.  
Already about 2700 years ago, in the ancient China, the Cannabis was cultivated for 
providing food from comestible seeds, oil and textiles but also probably employed as 
a medicinal or psychoactive agent (Russo et al., 2008). In the Middle East, historical 
traces reveal that Cannabis was recommended for its benefits against malaria, 
constipation and rheumatic pains and taken with wine, as a surgical analgesic 
(Mechoulam, 1986).It was not until the 19th century that Dr. William Brooke 
O'Shaughnessy, an Irish scientist and physician working for the British Army, 
observed the use of Cannabis in India and brought it to Western medicine 
(O'Shaughnessy, 1843). He experimentally tested the seeds from the plant on 
animals and humans and concluded about their utility in the treatment of pain, 
convulsions, spams, and as an appetite stimulant. Thereafter, studies in Europe and 
North America on the plant emerged and private laboratories developed a market of 
Cannabis extracts in response to scientific and medical demand (e.g. Merck, Eli Lilly 
or Parke-Davis; Mathre, 1997). 
General introduction 
 
Tifany	  Desprez	  -­‐	  Doctoral	  Thesis	  –	  University	  of	  BORDEAUX	  
	   	   	   42 
Despite the potential therapeutic effects of Cannabis, its administration was 
often hampered by undesired effects (Miller and Branconnier, 1983; Hall and Solowij, 
1998). In all history of Cannabis use, consumption of this plant was known to 
produce a range of adverse effects depending on the dose, including hallucinations, 
psychosis, motor disorders and memory impairments (Hall and Solowij, 1998; Miller 
and Branconnier, 1983; O'Shaughnessy, 1843). Because of the adverse effects of 
Cannabis and a parallel development of new compounds effective for pain relief and 
migraine such as the aspirin or opioids, the consumption of Cannabis-based 
compounds as potential therapeutics was progressively discarded and they were 
eventually banned for their psychotropic effects and their abuse liability (Sznitman et 
al., 2008). Thereby, the early 20th century was marked by the decrease of legal use 
of cannabinoids and the progressive application of a stringent control of Cannabis 
market at the international level. Then, following the ratification of Geneva 
Convention (1925), cannabis use was outlawed in Europe and US and removed from 
Europe and North America pharmacopeia. However, biological and clinical 
cannabinoid research was almost abandoned since the active component(s) of the 
plant were not identified yet and oral administration of Cannabis extracts was leading 
to variable and unpredictable responses, making difficult scientific interpretations 
(Sznitman et al., 2008).  
From the late 1940s until 1964, scientific studies performed by Adams and 
Mechoulam, respectively, led to the identification of the chemical identity of specific 
Cannabis molecules, called the cannabinoids, including Δ9-tetrahydrocannabinol 
(THC; Gaoni and Mechoulam, 1964). Numerous reports on the pharmacology of THC 
showed that this compound mediates the major psychoactive properties of the plant 
including sedative, hyperphagic and antinociceptive effects (Carlini et al., 1974; 
Kiplinger and Manno, 1971). Prof. Raphael Mechoulam and colleagues then 
achieved the complete synthesis of the pure compounds, established their molecular 
structures, and began to study their structure-activity relationships (Mechoulam et al., 
1972; Razdan, 1986). The consequences of cannabis consumption were thus 
rediscovered and precisely characterized by systemic administration of various doses 
of THC in animals (Kiplinger and Manno, 1971).  
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Cannabis is, nowadays, the most widely illegal consumed drug plant and 
probably one of the most accessible illegal drugs on the market. There are between 
119 and 224 million cannabis users worldwide (World Drug Report 2012 United 
Nations publication, Sales No. E.12. XI.1). However, due to the progress in the 
understanding of cannabis’ effect on physiological processes, cannabis-based 
compounds have been authorized in several countries of Europe (UK, Netherlands, 
Spain, Italy), in Canada, Australia, Israel, Switzerland and in 23 American States. 
Clinical trials have demonstrated their efficacy on: spasticity, nausea and vomiting, 
loss of appetite and chronic pain (Borgelt et al., 2013; Grotenhermen and Muller-
Vahl, 2012). They are now being used such as Marinol® (dronabinol) to stimulate 
appetite or Sativex® (THC and cannabidiol) for the symptomatic relief of neuropathic 
pain in adults with multiple sclerosis (MS) or in chemotherapy (Pertwee, 2009; 
Russo, 2007). At the end of 2013, Uruguay became the first country to fully legalize 
this drug (http://www.elpais.com.uy/informacion/marihuana-ley-senado-uruguay-
parlamento.html). In France, cannabis medications will be released in the market in 
2015, under medical supervision, for relief of spasticity and neuropathic pain in the 
context of MS pathology (http://www.metronews.fr/info/sativex-le-medicament-au-
cannabis-arrive-en-pharmacie/moaC!1aaCQ3iPDjUyE/). Nevertheless, the use of 
cannabis components for medical purposes remains a controversial issue. Therefore, 
it is crucial to unmask by which mechanisms Cannabis components mediated 
beneficial and adverse effects. 
I.2 From	  cannabinoids	  to	  the	  endocannabinoid	  system	  
Intense research has been conducted during the last decades to identify the 
chemical components of Cannabis and their biological effects, the so-called 
cannabinoids. To date, the plant is known to contain a mixture of more than 100 
cannabinoids (Mechoulam et al., 2014). One of the pioneer studies in cannabinoid 
research was the isolation of cannabinol and cannabidiol in the 1940’s (Adams, 
1940; Jacob and Todd, 1940).  Then, in 1964, Gaoni and Mechoulam succeeded in 
identifying the main psychoactive compound present in Cannabis, THC (Gaoni and 
Mechoulam, 1964). After this discovery, extensive works on the plant constituent 
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THC were carried on and several studies revisited the large range of proprieties 
mediated by Cannabis as well as their dose and time-dependent responses 
(Holtzman et al., 1969; Kiplinger and Manno, 1971). Despite this regain of interest, 
the mode of action of THC and other cannabinoids was unsolved and two possible 
mechanisms were postulated to mediate their known effects. The first hypothesis 
was that cannabinoids might act via a chemical interaction with biological 
membranes due to their highly lipophilic nature able to modify membrane properties 
(Hillard et al., 1985). The second one suggested that cannabinoids might interact 
through still undiscovered receptors, thereby inducing or inhibiting cellular signaling. 
This second hypothesis was based on the observation that THC promotes the 
decrease of adenylyl cyclase (AC) activity in particular cell types but not in others, 
indicating that this effect would not be a ubiquitous phenomenon, as it would be 
expected of cannabinoid-induced membrane fluidity changes, but rather specific 
(Howlett et al., 1988). 	  
The advances in the chemistry of the plant led to the development of potent 
synthetic cannabinoids, such as CP-55,940 (Johnson, 1986). The high-affinity-
binding sites of CP-55,940 in biological tissues sections resulted in a specific labeling 
profile. Indeed, the absence of labeling in the white matter and the low non-specific 
binding supported the view of a specific receptor on both brain membranes and brain 
sections (Devane et al., 1988; Herkenham et al., 1991c; Herkenham et al., 1990; 
Howlett et al., 1988). Moreover, the central localization of the potential cannabinoid 
receptor was found to be in accordance with the cognitive and psychotropic effects of 
cannabinoids (Herkenham et al., 1990). In 1990, the first cannabinoid receptor was 
cloned, named CB1 receptor and found to be highly expressed in the brain (Matsuda 
et al., 1990). Later on, a second receptor, CB2, was identified, whose distribution is 
mainly found in peripheral cells and the immune system (Munro et al., 1993). These 
major discoveries, suggested the potential existence of endogenous molecules that 
target these receptors in order to regulate similar functions as the exogenous 
cannabinoids. Because of the lipophilic proprieties of exogenous cannabinoids, it was 
assumed that possible endogenous cannabinoid molecules would also be lipids. In 
1992, anandamide (AEA), composed by ethanolamide and arachidonic acid, was the 
first endocannabinoid (eCB) discovered (Devane et al., 1992) followed by 2-
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arachidonoylglycerol (2-AG; Mechoulam et al., 1995; Sugiura et al., 1995). Later on, 
their specific synthesis and degradation pathways were uncovered (Marzo et al., 
1994). The identification of endogenous receptors (CB1 and CB2) and ligands (eCBs) 
promoted the concept that an “endocannabinoid system” (ECS) exists in the body, 
participating in the regulation of physiological processes (Piomelli, 2003). Notably, 
the ECS was identified not only in mammals but it was also found in non-mammalian 
vertebrates and invertebrates (Elphick et al., 2003; Soderstrom et al., 2000). The 
importance of this system is also underlined by the finding of a high degree of 
evolutionary conservation across species, which highlights the fundamental 
physiological role in animal adaptation and survival (De Petrocellis et al., 1999). 
I.3 Composition	  and	  expression	  of	  the	  endocannabinoid	  
system	  
I.3.1 Cannabinoid	  receptors:	  focus	  on	  CB1	  receptors	  
CB1 and CB2 receptors belong to the superfamily of G protein–coupled 
receptors (GPCRs), which represent the largest group of membrane receptors, in 
eukaryotes (Fredriksson et al., 2003). Cannabinoid receptors, like other GPCRs, 
structurally consist of an extracellular N-terminal domain, seven transmembrane 
domains and a C-terminal intracellular tail (Matsuda et al., 1990; Shim et al., 2011). 
However, CB1 and CB2 receptors only share 44% amino acid sequence similarity and 
have a different pattern of expression. As mentioned above, CB1 receptors are likely 
the most highly expressed GPCRs in the brain, with densities similar to GABA and 
glutamate receptors (Herkenham et al., 1991c), and they are also expressed, at 
lower levels, in many peripheral tissues (Pagotto et al., 2006). On the other hand, 
CB2 receptors are found primarily in peripheral immune and hematopoietic cells 
(Munro et al., 1993) and in microglial brain cells (Nunez et al., 2004), whereas their 
presence in neurons is still under scrutiny, due to the lack of suitable tools (Onaivi et 
al., 2006; Onaivi et al., 2012).  
In addition to CB1 and CB2 receptors, pharmacological studies have revealed 
numerous other receptors that mediate the effects of cannabinoids, including 
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vanilloid receptors, peroxisome proliferator-activated receptors and the formerly 
“orphan” designated receptors GPR55 and GPR119 (Pertwee, 2010).  
On the other hand, there is some evidence that cannabinoids, in particular 
cannabidiol, can act through cannabinoid receptor-independent mechanisms, 
possibly via an interaction with cholesterol-rich microdomains of the cell membrane, 
also known as lipid rafts (DeMorrow et al., 2007).  
However, it is now clearly established that most of central effects of 
cannabinoids in the brain are due to CB1 receptor activation (Ledent et al., 1999; 
Zimmer et al., 1999). CB1 receptor cDNA was originally cloned from rat (Matsuda et 
al. 1990) and subsequently in human (Gérard et al., 1991) and in mouse (Chakrabarti 
et al., 1995). Two splice variants of the human CB1 gene (CNR1) noted hCB1A and 
hCB1B have been described (Ryberg et al., 2005; Shire et al., 1995). Few studies 
have attempted to compare the pharmacology of the human CB1 receptors and splice 
variants. Interestingly, they have reported a differential binding proprieties and 
pharmacology (Straiker et al., 2012; Ryberg et al. 2005). Although both hCB1 
receptor variants are found in low quantity, their physiological relevance remains to 
be understood.  
I.3.1.1 Brain	  localization	  of	  CB1	  receptors	  
Cannabinoids exert a multitude of effects that depend on CB1 receptor 
activation. The comprehension of the complex roles of the CB1 protein in the 
physiological-behavioral effects of cannabinoids requires a precise mapping of their 
sites of action at the regional, cellular and subcellular level. As mentioned above, 
CB1 receptors are likely the most abundant GPCRs in the mammalian brain 
(Herkenham et al., 1990). After their cloning, in situ hybridization (ISH) studies were 
designed to detect CB1 mRNA in rodents (Matsuda et al., 1993; Marsicano and Lutz, 
1999) and in humans (Mailleux et al., 1992; Westlake et al., 1994). Later on, 
immunohistochemistry (IHC) was developed using antisera to reveal CB1 protein 
(Katona et al., 1999; Pettit et al., 1998; Tsou et al., 1998). IHC revealed the highest 
density of CB1 protein in the cerebellum and basal ganglia including the Substantia 
Nigra pars reticulata (SNr), Globus Pallidus, Entopeduncular nucleus [EP, the rodent 
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analog of the internal Globus Pallidus (GPi) in humans] and dorsolateral caudate 
putamen. CB1 receptor immunoreactivity is also dense in the hippocampus, the 
cerebral cortex and olfactory system, and moderate in the in the amygdala, 
hypothalamus, thalamus and habenula (Moldrich and Wenger, 2000; Figure 1). In-
situ hybridization studies revealed that CB1 mRNA expression in some areas does 
not correspond to CB1 protein expression.  A striking example is the Substantia Nigra 
pars reticulata. This brain region contains no or very low CB1 mRNA, but is one of the 
most densely stained regions in immunohistochemistry and ligand binding 
experiments (Matsuda et al., 1993; Herkenham et al., 1990).  This discrepancy 
resides in the fact that CB1 receptor protein is mainly expressed at pre-synaptic 
axonal terminals when observed at high magnification using electron microscopy 
(Puente et al., 2010; Reguero et al., 2011; Katona et al., 1999) that the strong CB1 
receptor expression in this region corresponds to axonal terminals of projecting cells 
towards the SNr. 
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I.3.1.2 CB1	  receptors:	  cellular	  expression	  profile	  
Despite the wide expression of CB1 receptors in the CNS, their cellular 
distribution appears to be restricted to particular cell types. Within cortical regions, 
CB1 mRNA is mainly found in GABAergic interneurons co-expressing glutamic acid 
decarboxylase (GAD65) and cholecystokinin (CCK), and are virtually absent in 
inhibitory interneurons expressing parvalbumin (Marsicano and Lutz, 1999). 
Glutamatergic neurons also contain CB1 but in considerable lower amount as 
compared to GABAergic interneurons (Mailleux et al., 1992; Marsicano et al., 2003; 
Marsicano and Kuner, 2008; Marsicano and Lutz, 1999). The progress in genetics 
greatly contributed to highlight the relevance of CB1 receptors according to their 
Figure 1.Brain distribution of the mouse CB1receptor protein.Immunolabelling of the CB1 
receptor protein in parasagittal brain slices of wild-type (A) and CB1-KO (B) mice. Note the high 
levels ofCB1expression in the anterior olfactory nucleus (AON), neocortex (M1, primary motor 
cortex; S1, primary somatosensory cortex; V1, primary visual cortex), caudate putamen (CPu), 
substantia Nigra pars reticulata (SNR), hippocampus (Hi; DG, dentate gyrus), thalamus (Th) and 
cerebellum (Cb). CB1 protein is absent in the CB1-KO mouse brain (B). NAc, nucleus accumbens, 
VP, ventral pallidum; Mid, midbrain; PO, pons; MO, medulla oblongata; EP, entopedoncular 
nucleus. Scale bars: 1 mm (A), 200 µm (B) (from Kano et al., 2009). 
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cellular localization. Genetic deletion of CB1 receptors in cortical glutamatergic 
neurons revealed their presence in pyramidal neurons in the hippocampus, 
neocortex and amygdala (Bellocchio et al., 2010; Domenici et al., 2006; Monory et 
al., 2006). Despite the minority of CB1 receptors on glutamatergic cells, these 
receptors play important roles in functions modulated by cannabinoids such as 
resistance to excitotoxic insults in the hippocampus (Monory et al., 2006), fear 
coping, stress and anxiety (Dubreucq et al., 2012; Metna-Laurent et al., 2012) and 
food intake (Bellocchio et al., 2010). These findings might be due to cell-specific CB1 
signaling proprieties as CB1 receptors on glutamatergic neurons are surprisingly 
more efficiently coupled to G protein signaling than ‘GABAergic’ CB1 receptors 
(Steindel et al., 2013). In addition, serotonin-releasing neurons projecting from the 
raphe nuclei to the basolateral amygdala and the hippocampal CA3 region also 
express CB1 receptors (Haring et al., 2007). Given the major cellular role of CB1 
receptors in decreasing neurotransmitter release, the presence of CB1 receptors 
within different neuronal types suggest a regulation of CB1 receptors upon several 
major neurotransmitter systems.  
Recently, using pharmacological tools and conditional mutants, several data 
demonstrated the low but functionally important presence of CB1 receptors on 
astrocytes (Bosier et al., 2013; Han et al., 2012; Navarrete and Araque, 2008). 
Indeed, astroglial CB1 receptors were shown to regulate synaptic transmission 
(Navarrete and Araque, 2010; Navarrete and Araque 2008), astrocyte leptin signaling 
(Bosier et al., 2013), and to be responsible for the impairment in working memory 
performance induced by cannabinoids (Han et al., 2012). 
Together, the anatomical and functional data shortly summarized above show 
that CB1 receptors expressed in specific cell types play important physiological and 
pharmacological roles independently of the relative levels of expression. Thus, 
cellular localization is likely a better predictor of the functions of CB1 receptors than 
their levels of expression (Marsicano and Kuner 2008). In addition, recent data 
suggest that also the differential subcellular localization of CB1 receptors within the 
cell determines the functional outcome of their signaling.  
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I.3.1.3 Subcellular	  localization	  of	  CB1	  receptors	  
Immuno-electron microscopy and accurate cell fractioning have been two 
indispensable techniques to investigate the subcellular localization of CB1 proteins. 
CB1 receptors are preferentially targeted to plasma membranes of presynaptic 
terminals and axons, where they likely mediate the well-known inhibitory actions on 
neurotransmitter release (Chevaleyre and Castillo, 2003; Wilson and Nicoll, 2001; 
Katona et al., 1999). Additionally, CB1 receptors were also observed in 
somatodendritic neuronal compartments in several brain regions, where they appear 
to be rather intracellular than located at plasma membranes (Ong and Mackie, 1999; 
Pickel et al., 2004; Sierra et al., 2014; Wilson-Poe et al., 2012). Due to this absence 
from plasma membranes, somatodendritic CB1 receptors are generally considered as 
inactive proteins being transported to or from their functional localization at 
presynaptic membranes (Katona et al., 1999; Freund and Hajos, 2003). However, 
electrophysiological studies strongly suggested that somatodendritic CB1 receptors 
participate in the autocrine regulation of neuronal excitability, although the signaling 
mechanisms of these functions are not fully clarified yet (Bacci et al., 2004; Marinelli 
et al., 2009). 
The classical paradigm of GPCR functioning postulates that GPCRs localize on 
the cell surface and once activated by their agonists they activate G proteins 
signaling and initiate various intracellular signaling pathways.  In contrast, their 
presence in intracellular compartments such as the endoplasmic reticulum (ER), 
where they are synthesized and trafficked to cell surface, or on endosomes, where 
the receptors are internalized after activation, was assimilated to a non-functional 
state (Ferguson et al., 2001). However, this idea was recently challenged by 
emerging evidence showing the functionality of different GPCRs at intracellular 
membranes, including ER, endosomes, nuclei and mitochondria (Belous et al., 2004; 
Irannejad and von Zastrow, 2014). CB1 receptors were recently shown to share such 
unconventional intracellular localization. Rozenfeld and colleagues showed that CB1 
receptors present in endosomal/lysosomal compartments are able to activate G 
protein-dependent signaling (Rozenfeld and Devi, 2008). Early studies in vitro 
showed the accumulation of cannabinoid-binding probes in subcellular fractions, 
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including mitochondria (Colburn et al., 1974). Interestingly, more recent studies 
reported also anatomical evidence pointing to the presence of CB1 immunolabeling in 
intracellular compartments, and in particular on mitochondria (Ong and Mackie 1999; 
Rodriguez et al., 2001). Indeed, the mitochondrion was described as one of the most 
commonly labeled organelles by CB1 immunoparticles (Rodriguez et al., 2001). 
However, the possibility that mitochondrial CB1 receptors could be functional was 
never taken into consideration: mitochondrial effects of cannabinoids were ascribed 
to the lipophilic nature of these compounds (see Chapter III for more details) and 
mitochondrial staining with CB1 receptor antisera was considered as unspecific 
background and sometimes even used to “normalize” specific plasma membrane 
staining in semi-quantitative anatomical experiments (Pedro Grandes, personal 
communication). More recently, our group performed a rigorous analysis of 
mitochondrial CB1 receptor expression in brain mitochondria, quantifying CB1 
immunogold labeling in brain tissues from wild-type and CB1-KO mice (Benard et al., 
2012). The results clearly showed low, but specific CB1 receptor localization at 
mitochondria (Figure 2). This pool of CB1 receptors was named mtCB1 to distinguish 
it from other subcellular localization (Benard et al., 2012). Further experiments 
indicated that mtCB1 receptors are specifically present at mitochondrial outer 
membranes (OMs) and they have a topological orientation with a cytoplasmic protein 
N-terminus and the C terminus facing the interior of the organelle (Benard et al., 
2012). There, mtCB1 receptors impact negatively on mitochondrial respiratory chain 
activity (Benard et al., 2012; see below Chapter III for further details).  
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Taken together, the data shortly summarized above indicate that the anatomical 
localization of CB1 receptors is an extremely important determinant of their functions. 
This is evident at cellular level, with the differential roles of CB1 receptors expressed 
in different cell types (excitatory, inhibitory or modulatory neurons or astroglial cells), 
but also at subcellular level. In neurons, the localization of CB1 receptors at pre- or 
postsynaptic sites determines different functions. The presence of CB1 receptors in 
intracellular organelles such as mitochondria adds complexity to the repertoire of 
potential effects of cannabinoid signaling. This Thesis work specifically addresses the 
functional characterization of the mitochondrial localization of CB1 receptors (mtCB1). 
However, before proceeding with these aspects, the other elements of the ECS and 
the known functions and mechanisms of action of CB1 receptors in the brain will be 
described.   
Figure 2.Electron microscopy image of immunogold staining of CB1 proteins in the 
hippocampus.CB1 receptors are present on both plasma membrane (pmCB1, blue arrows) and 
mitochondrial membrane (mtCB1, orange arrows). M: mitochondria.Scale bar, 500 nm. 
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I.4 Endocannabinoids	  
The eCBs are defined as the endogenous ligands for cannabinoid receptors (Di 
Marzo et al., 1998b). They are mainly lipids derived from amides or esters of long 
chain fatty acids (arachidonic acid). The first eCB identified was arachidonoyl-
ethanolamide, named anandamide (AEA; Devane et al., 1992), from the Sanskrit 
word “ananda”, which means “bliss”. The second discovered eCB, 2-arachidonoyl-
glycerol (2-AG) was isolated from canine intestines (Stella et al., 1997; Mechoulam et 
al., 1995; Sugiura et al., 1995).  Recently, a new family of endogenous ligands of CB1 
receptors was discovered and, surprisingly these new eCBs were revealed to be 
peptides, such as Hemopressin and Pepcans (Heimann et al., 2007). In the 
paragraphs below, I will first briefly describe the molecular actors implicated in the 
synthesis, degradation and transport of the ‘classical’ lipid eCB. Later, I will present 
the newly discovered (and less characterized) peptide eCBs. 
I.4.1 Synthesis	  of	  lipid	  endocannabinoids	  
A feature that distinguishes classical eCBs from many other neurotransmitters 
is that they are lipids and, therefore, they are not stored in the aqueous medium of 
synaptic vesicles (Di Marzo et al., 1998). Rather, lipid eCBs are synthesized directly 
from cell membranes (Piomelli 2003). The main described biosynthetic pathways of 
eCBs start from the hydrolysis of membrane phospholipid precursors by specific 
enzymes. Briefly, AEA is produced from the cleavage of N-acyl-phosphatidyl-
ethanolamine (NAPE;Di Marzo et al., 1994; Piomelli 2003), catalyzed by a NAPE-
selective phospholipase D (NAPE-PLD) enzyme (Okamoto et al., 2004). In contrast, 
2-AG is derived from other arachidonic acid-containing membrane phospholipids 
such as phosphatidylinositol through the action of phospholipase C β (PLCβ) leading 
to the formation of diacylglycerol (DAG; Piomelli 2003).  DAG is further hydrolyzed by 
DAG lipase α or β, eventually forming 2-AG (Bisogno et al., 2003). Interestingly, 
these enzymes are often detected at the postsynaptic sites of brain synapses, 
providing anatomical support to the role of eCBs as retrograde synaptic modulators 
(see below for more details; Uchigashima et al., 2007; Yoshida et al., 2006). The 
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biosynthesis of the eCBs is induced by various stimuli causing intracellular Ca2+ 
elevation, such as depolarization and/or activation of metabotropic Gq/11-coupled 
receptors like group I metabotropic glutamate receptors (mGluR) or muscarinic 
acetylcholine receptors (mAChR; Kim et al., 2002; Varma et al., 2001). Thus, eCB de 
novo production in the brain likely depends on synaptic activity (Piomelli, 2003; 
Cadas et al., 1996). 
I.4.2 Transport	  of	  lipid	  endocannabinoids	  
As better detailed below, eCBs are thought to act as retrograde signaling 
molecules at brain synapses (Piomelli, 2003). This function implies that 
postsynaptically-produced eCBs travel the aqueous synaptic cleft to activate 
presynaptic CB1 receptors. But, how do these hydrophobic molecules diffuse through 
aqueous media across synaptic cleft or within the cytosol? Different hypotheses have 
been proposed to explain their trafficking in and out of the cell but it seems rather a 
complex process that remains to be elucidated. To date, several intracellular AEA 
binding proteins have been reported, including fatty acid binding proteins (FABPs; 
Elmes et al., 2015) and FAAH-like anandamide transporter (FLAT), a truncated and 
catalytically-silent variant of the degrading enzyme fatty acid amide hydrolase 
(FAAH, see below; Fu et al., 2012).  In addition to their binding, FLAT facilitates the 
transport of AEA from cell membranes to FAAH for a rapid clearance and inactivation 
(Fu et al., 2012; Leung et al., 2013). More recently, it was shown that neosynthesized 
AEA could be also released into secreted extracellular membrane vesicles from 
microglial cells, from which AEA activates CB1 receptors and inhibits presynaptic 
transmission (Gabrielli et al., 2015). If little is known concerning the transport of AEA, 
even less has been clarified on the mechanisms of 2-AG transport (Di Marzo et al., 
2015). Hence, the mechanisms by which eCBs are trafficking represent nowadays a 
hot-topic in this research field.  
I.4.3 Degradation	  of	  endocannabinoids	  
Once their molecular target is activated, the eCBs are rapidly removed and 
subsequently broken down inside the cell, thereby limiting the temporal window of 
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CB1 receptor activation.  AEA is mainly degraded by the fatty acid amide hydrolase 
(FAAH) mainly located in postsynaptic neurons (Gulyas et al., 2004). FAAH-
dependent degradation of AEA generates arachidonic acid and ethanolamine, which 
can then be re-used to generate new AEA (Cravatt et al., 1996). On other hand, 2-
AG is processed at both sites of the synapse. 2-AG is hydrolyzed trough the action of 
the monoacylglycerol lipase (MAGL), resulting in the production of arachidonic acid 
and glycerol. At lower extent, but potentially important in specific cells and cell 
locations, 2-AG can also be hydrolyzed by the α/β hydrolase domain 6 (ABHD6) 
enzymes or oxidized by the cytochrome c oxidase subunit II (COX2), a mitochondrial 
enzyme involved in the respiratory chain (Feledziak et al., 2012). Given the 
pharmacological and anatomical evidence of the presynaptic localization of MAGL 
(making it well-sited to break down 2-AG), 2-AG is considered as the main effector of 
CB1 receptor-mediated retrograde signaling (Hashimotodani et al., 2007; Kim and 
Alger, 2004; Straiker et al., 2009). However, 2-AG can also act on postsynaptic CB1 
receptors to modulate neuronal excitability (Bacci et al., 2004; Marinelli et al., 2009).  
Synthesis, transport and degradation of eCBs often occur in a short period of 
time and only when cells are under particular conditions. Thus, eCBs actions are 
often referred to as “on demand”, because they are synthetized de novo where and 
when they are required, and rapid degradation interrupts their activity (Piomelli 2003). 
Overall, the qualitative and spatial expression mitochof the enzymes involved in 
synthesis and degradation of AEA and 2-AG may allow the two eCBs to exert 
different functions in the brain (Di Marzo and De Petrocellis, 2012).  
I.4.4 Other	  endogenous	  molecules	  binding	  CB1	  receptors	  
Over the past years, the CB1 receptor has been the focus on a number of 
studies identifying putative endogenous orthosteric and allosteric ligands. A α-
hemoglobin-derived peptide composed by the amino acid sequence PVNFKFLSH 
(called hemopressin) was found to serve as an inverse agonist of CB1 receptors 
(Heimann et al., 2007). Hemopressin blocks several in vitro CB1-mediated signaling 
pathways similarly as rimonabant. In vivo, hemopressin acts through CB1 receptors 
to reduce food intake in rodents (Dodd et al., 2010). Since then, additional 
General introduction 
 
Tifany	  Desprez	  -­‐	  Doctoral	  Thesis	  –	  University	  of	  BORDEAUX	  
	   	   	   56 
endogenous peptide derivatives of hemopressin, called Pepcans were shown to act 
as negative allosteric modulators of CB1 receptors (Bauer et al., 2012). These novel 
endogenous modulators of CB1 receptor signaling are still under close investigation, 
as they likely participate in the diversity of large panel of effects exerted by CB1 
receptors.  
Other endogenous modulators have been found including the lipids oleamide 
(Leggett et al., 2004), lipoxin A4 (Pamplona et al., 2012) and pregnenolone (Vallee et 
al., 2014). Lipoxins and the neurosteroid pregnenolone also act as allosteric 
modulators, with lipoxin A4 increasing and pregnenolone inhibiting CB1 receptor 
signaling, respectively. Pregnenolone is particularly interesting, because its 
production in the brain is induced by excessive activation of CB1 receptors. By acting 
as an allosteric inhibitor, therefore, this neurosteroid represents a clear endogenous 
molecular inhibitory loop to limit the excessive activation of CB1 receptors (Vallee et 
al., 2014).  
In conclusion, the physiological activity of CB1 receptors is assured by a 
complex machinery for the synthesis, transport and degradation of several types of 
different endogenous ligands. The molecular and physiological details of these 
mechanisms, as well as the discovery of new ligands, are and will be the subject of 
many studies in the field. 
I.5 Central	  CB1	  receptor	  signaling	  and	  modulation	  of	  
synaptic	  transmission	  and	  plasticity	  
Animals have the capacity to learn and adjust their behavior in response to 
changes in the environment. It is now widely accepted that this ability relies on brain 
functional and morphological re-organizations of synaptic connections between 
neurons, which are commonly referred to as “plasticity” (Milner et al., 1998). Plasticity 
is a dynamic phenomenon, characterized by local changes of synaptic strength of 
neuronal connections in response to the use or disuse of specific synaptic pathways 
(Tsukahara, 1981). As a consequence, local structural rearrangements occur to 
rewire synaptic connections (Bernardinelli et al., 2014). Importantly, CB1 receptors 
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have a key role in regulating synaptic transmission and plasticity (Chevaleyre and 
Castillo, 2003; Han et al., 2012; Marsicano et al., 2002). Many forms of synaptic 
plasticity are induced by the regulation of diffusible second messengers such as 
cAMP or Ca2+ (Calabresi et al., 2000; Kandel et al., 2014; Chevaleyre et al., 2007). 
Synaptic plasticity can be also temporally and spatially defined. Synaptic 
modifications can last for only some seconds (short-term plasticity), or for longer 
periods of time (long-term plasticity). They can also occur at given synapses 
independently from their neighbors (Kim et al., 2011; Soler-Llavina and Sabatini, 
2006). The spatiality of plastic events is likely to be underlined by molecular signals 
confined in microdomains, rather than diffused in the whole cell (Kim et al., 2011; 
Soler-Llavina and Sabatini, 2006). Two basic mechanisms have been introduced for 
the compartmentalization of molecular transduction pathways: 1) diffusional physical 
barriers such as dendritic spines or organelles (Korkotian and Segal, 2006), 2) 
colocalization of enzymes that interact together, which is mediated via structural 
proteins that contain binding sites for various synaptic elements (anchoring proteins; 
Kim et al., 2011). In the paragraphs below, I will mention the participation of CB1 
receptors in numerous molecular cascades regulating neuronal excitability and 
plasticity. 
I.6 Classical	  CB1	  dependent	  signaling	  pathways	  
I.6.1 cAMP/PKA	  pathway	  
The first characterized pathway for agonist-stimulated CB1 receptor activation 
was the inhibition of the cAMP-protein kinase A pathway (cAMP/PKA) via the 
decrease of adenylyl cyclase (AC) activity (Cadas et al., 1996; Derkinderen et al., 
1996). Inhibition of AC and subsequently a reduction in cAMP level, the second 
messenger produced by AC was observed following the addition of cannabinoids on 
neuroblastoma cells (Howlett and Fleming, 1984). The major role of cAMP is to 
activate the cAMP-dependent protein kinase (PKA; Brandon et al., 1997). PKA is a 
serine/threonine kinase, composed of two regulatory and two catalytic subunits. 
Once they bind to cAMP, the catalytic subunits are activated and diffuse through the 
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cytosol to further phosphorylate various substrates (Rababa'h et al., 2015). In 
contrast, the decrease of cAMP/PKA signaling by CB1 receptor activation induces a 
concomitant decrease of PKA-dependent phosphorylation (Zhuang et al., 2005). The 
cAMP/PKA pathway has been implicated in learning and memory (Alberini, 1999; 
Heyser et al., 2000) and synaptic plasticity (Calabresi et al., 2000; Chevaleyre et al., 
2007). Therefore, the CB1-dependent decrease of PKA activity can explain many of 
the pharmacological effects of cannabinoids, such as memory impairment (Hampson 
and Deadwyler, 1998). Importantly, decrease of cAMP/PKA pathway is mediated 
through CB1 receptor activation coupled to G inhibitory/off (Gi/o) proteins (Di Marzo et 
al., 1998a; Howlett, 2005; Howlett et al., 1986; Piomelli, 2003) via a pertussis toxin 
(PTX)-sensitive mechanism (Howlett et al., 1986). Pertussis toxin is able to block the 
dissociation of α and β/γ subunits of Gi/o, thereby abolishing the G protein-mediated 
inhibition of AC (Howlett et al., 1986). In addition, the coupling of CB1 receptors to G-
proteins on isolated membranes can be measured by receptor-stimulated 
[35S]GTPyS binding. The technic is based on the exchange of bound GDP for GTP 
(or [35S]GTPyS) when G proteins are activated in the presence of excess GDP 
(Strange, 2010). In purified brain membranes, cannabinoids stimulate [35S]GTPyS 
binding in a CB1-depedent manner because this activation is fully blocked by CB1 
receptor antagonists (Selley et al., 1996). 
The cAMP/PKA is present at different subcellular locations. Whereas it was 
originally established that the only known source of cAMP in mammals was 
transmembrane AC (tmAC), a truncated and soluble isoform of AC (sAC) was 
purified from rat testis cytosol (Braun and Dods, 1975) and later found in the 
cytoplasm, in mitochondria, in the centriole, and within the nucleus (Feng et al., 2006; 
Zippin et al., 2003; Zippin et al., 2004). Moreover, cAMP is also localized in 
intracellular compartments together with sAC such as in the nucleus and 
mitochondria (Lefkimmiatis et al., 2013; Zippin et al., 2010).  In addition, PKA was 
reported to signal in compartmentalized microdomains within the cytosol of 
cardiomyocytes (Buxton and Brunton, 1983) as well as in the brain (Dell'Acqua et al., 
2006; Kim et al., 2011). This organization is mediated by anchoring proteins, which 
are structural proteins that contain binding sites for various enzymes. A-kinase 
anchoring proteins (AKAPs) have been shown to sequester PKA at given locations 
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such as in cytosol and in intracellular organelles, which facilitate local 
phosphorylation of PKA substrates (Wong and Scott, 2004). In particular, AKAP 121 
and SPHKAP/SKIP were identified to mediate PKA targeting to the outer 
mitochondrial membrane (OM) and intermembrane space (IMS) in proximity of local 
targets (Feliciello et al., 2005; Kovanich et al., 2010; Lieberman et al., 1988). 
Importantly, such a spatially limited cAMP/PKA signaling has been shown to regulate 
synapse plasticity in the striatum (Oliveira et al., 2012). Therefore, CB1 receptor 
stimulation could result in a compartmentalized down-regulation of cAMP/PKA 
signaling in order to locally modulate plasticity. The differential pharmacology of sAC 
versus tmAC and the impact of CB1 receptor activation on sAC signaling will be 
discussed in the 2nd and 3rd chapter.  
I.6.2 Other	  CB1	  receptor-­‐dependent	  signaling	  pathways	  
CB1 receptors are able to stimulate different cellular pathways including (among 
others):  the mitogen-activated protein kinases / extracellular signal-regulated kinase 
(MAPK/ERK), c-Jun N-terminal kinases (JNK), mammalian target of rapamycin 
(mTOR) and phosphatidylinositol 3-kinases (PI3K) pathways both in vitro and in vivo 
(Andre and Gonthier, 2010; Bouaboula et al., 1995; Puighermanal et al., 2009; 
Valjent et al., 2001; Figure 3). Among these, I will discuss more in detail the ERK 
and the mTOR pathways, which have been shown to play important roles in the 
cannabinoid-dependent regulation of behavior and synaptic plasticity (Andre and 
Gonthier, 2010; Bouaboula et al., 1995; Puighermanal et al., 2009; Valjent et al., 
2001).  
I.6.2.1 MAPK/ERK	  pathway	  
The MAPK/ERK pathway is a key signaling in cell development, differentiation 
and apoptosis, and is a well-established CB1 receptor-dependent signaling (Galve-
Roperh et al., 2002). In the brain, this pathway also controls the shape of synaptic 
terminals promotes spine formation, and has been strongly associated with synaptic 
plasticity (Wiegert and Bading, 2011). ERK is a family of two, highly homologous 
proteins denoted as ERK1 (also known as p44) and ERK2 (p42). By phosphorylating 
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their serine/threonine sites (Dalton and Howlett, 2012), activation of CB1 receptors 
stimulates both of the extracellular signal-regulated kinases in the striatum as well as 
the hippocampus and cerebellum (Daigle et al., 2011; Derkinderen et al., 2003; 
Valjent et al., 2001). These effects are prevented by SR141716A or PTX treatments 
and absent in CB1-/- mice (Bouaboula et al., 1995; Derkinderen et al., 2003), 
indicating the involvement of CB1 receptors through Gi/o signaling. ERK-dependent 
signaling activates one of the final outcomes of this signaling takes place in the 
nucleus, where several transcription factors such as c-Fos, c-Jun and CREB. ERK 
pathway has been involved in synaptic plasticity (English and Sweatt, 1997; Wiegert 
and Bading, 2011) and learning and memory (Atkins et al., 1998; Selcher et al., 
2002). Thus, protein phosphorylation and gene regulation through MAP kinase 
activation by CB1 receptors could account for some behavioral effects of 
cannabinoids.  
I.6.2.2 mTOR	  pathway	  
More recently, attention has focused on the modulation of mTOR signaling 
pathway by CB1 receptors. mTOR is a protein kinase that regulates various 
processes including protein synthesis, mitochondrial activity, cell proliferation, 
synaptic plasticity, food intake and learning and memory (Costa-Mattioli et al., 2009; 
Cota et al., 2006; Diaz-Alonso et al., 2014; Haissaguerre et al., 2014; Parsons et al., 
2006; Santini et al., 2014). mTOR is the catalytic subunit of two structurally distinct 
complexes: mTOR complex 1 (C1) and mTOR complex 2 (C2). Both complexes 
localize to different subcellular compartments and phosphorylate a different set of 
substrates, which determines their respective functions (Betz and Hall, 2013; 
Wullschleger et al., 2006). In particular, mTORC1 phosphorylates and modulates the 
activity of the ribosomal protein S6 kinase 1 (S6K1 or P70-S6 Kinase; Wullschleger 
et al., 2006). The mTOR/S6K1-signaling pathway is modulated by cannabinoids for 
controlling food intake and memory consolidation, in a CB1 receptor-dependent 
manner (Puighermanal et al., 2009; Senin et al., 2013). Indeed, gastric CB1 receptors 
modulate ghrelin production through the mTOR/S6K1 pathway to regulate food 
intake (Senin et al., 2013). In the hippocampus, activation of the mTOR/p70S6K-
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signaling pathway couples CB1 receptors stimulation to impairment of memory 
consolidation (Puighermanal et al., 2009). More recently, the implication of mTOR 
signaling in other CB1-dependent effects such as anxiolytic effect was shown 
(Puighermanal et al., 2013), indicating that the mTOR activation is a key molecular 
player of CB1 receptor-dependent regulation of different behaviors.  
I.7 CB1	  receptor	  signaling	  at	  central	  synapses	  
I.7.1 Modulation	  of	  ion	  channels	  
Synaptic activity can be modulated at three different levels: 1) neuronal 
excitability, 2) presynaptic release probability and 3) activity of postsynaptic receptors 
and their intracellular effectors. A major effect of CB1 activation is the regulation of 
both neuronal excitability and neurotransmitter release, through the modulation of 
voltage-dependent ion channels conductance (Azad et al., 2008; Chevaleyre et al., 
2007). Therefore, it is necessary to understand how CB1 receptors are coupled to ion 
channels (Figure 3).  
I.7.2 CB1	  receptors	  control	  neuronal	  excitability	  
CB1 receptors modulate potassium channel activity. Potassium (K+) currents, 
specifically A-type outward currents (K+A) contain a potential site for PKA 
phosphorylation (Deadwyler et al., 1995). This ion channel permits the movement of 
positively charged K+ ions from the intracellular to the extracellular space at resting 
potential. Activation of PKA down-regulates these channels by shifting the activation 
curve to more positive potentials (Hoffman and Johnston, 1998). In this line, early 
studies found that, in hippocampal cell culture, cAMP/PKA inhibition mediated by 
cannabinoids, reduces the PKA-dependent inhibition of this ion channel. Therefore, 
the ion channels open and produce efflux of potassium ions leading to 
hyperpolarization of the cell (Deadwyler et al., 1995; Hampson et al., 1995; Mu et al., 
1999).  
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A more direct way for cannabinoids to hyperpolarize cell membranes through 
CB1 receptors is the direct modulation of K+ ion channels. Indeed, CB1 receptor 
activation leads to the stimulation specific subunits of inwardly rectifying potassium 
channels (K+ir) called GIRK and it is mediated by Gαi/o protein signaling (Henry and 
Chavkin, 1995; Mackie et al., 1995). This effect allows the ions to flow outwardly, 
making CB1 signaling to promote the hyperpolarization of the cell.  
I.7.2.1 CB1	  receptors	  control	  the	  neurotransmitter	  release	  
At presynaptic active zones, voltage-dependent calcium (Ca2+)-channels 
activation rapidly increases intracellular Ca2+, which drives the exocytosis of vesicles, 
leading to the spread of neurotransmitters into the synaptic cleft (Schneggenburger 
and Neher, 2005). CB1 receptor activation acts negatively on these channels. Indeed, 
cannabinoids and their analogues have been found to inhibit N- and P/Q-type Ca2+ 
channels in hippocampal cell culture (Mackie et al., 1993). The addition of non-
hydrolysable analogues of cAMP or inhibitors of phosphodiesterase, the enzyme that 
hydrolyzes cAMP, did not alter the inhibitory effect of CB1 receptors onto Ca2+ 
channels, indicating an adenylyl cyclase-independent mechanism (Mackie et al., 
1993). Hence, the modulation of voltage-dependent ion channels by CB1 receptors 
results in a decrease in intracellular Ca2+ concentration and a subsequent reduction 
of synaptic transmission. 
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I.7.2.2 CB1	  receptor-­‐mediated	  modulation	  of	  synaptic	  transmission	  and	  
plasticity	  
CB1 receptor activation decreases basal neurotransmission 
Once the neurotransmitters are released, they translocate and bind 
postsynaptic receptors to generate inhibitory or excitatory inputs within the dendrites, 
named inhibitory postsynaptic potentials (IPSPs) and excitatory postsynaptic 
potentials (EPSPs), respectively (Ameri et al., 1999).The hippocampus is a suitable 
structure for extracellular recording techniques in vitro and in vivo, because of its 
Figure 3.Main intracellular CB1 receptor signaling pathways. Stimulation of CB1 receptors 
lead to 3 main cascades of events. A direct modulation of ion channels conductance including an 
inhibition of Ca2+ channel and activation of K+ir channels. Activation of A-type K+ channels (K+A) can 
be induced through the inhibition of adenylyl cyclase (AC). Activation of several protein kinases 
including ERK, JNK and mTOR leads to de novo gene expression. Adapted from Pagotto et al., 
2006. 
General introduction 
 
Tifany	  Desprez	  -­‐	  Doctoral	  Thesis	  –	  University	  of	  BORDEAUX	  
	   	   	   64 
laminar organization in which neuronal cells are tightly packed and they all receive 
synaptic inputs in the same area. According to this, it is well established that CA1 
pyramidal cells receive excitatory inputs from the pyramidal cells in the CA3 region 
via excitatory afferents called Schaffer collaterals (SCs). These SC-CA1 connections 
can be monitored by electrical stimulation and extracellular recording of different 
cells, called fields, in the well-defined stratum radiatum layer of the hippocampus; 
where the main dendritic arborization of pyramidal CA1 cells is present. Notably, it 
was shown that cannabinoids decrease field EPSPs (fEPSP) at SC-CA1 synapses in 
hippocampal slices (Ameri et al., 1999). This effect on basal neurotransmission is a 
broad and long-lasting mechanism, which reduces the strength of excitatory synaptic 
connections of a larger number of CA1 neurons (Marder and Thirumalai, 2002). 
Importantly, this effect is fully blocked by CB1 receptor antagonists and absent in CB1 
-/- mice (Bajo et al., 2009; Takahashi and Castillo, 2006). It is important to note that 
this response is not defined as plasticity because it is fully abolished by application of 
CB1 receptor antagonists 10 minutes after cannabinoid application (Chevaleyre et al., 
2006; Hajos et al., 2001; Kawamura et al., 2006). In contrast, it rather suggests the 
necessity of a continuous activation of CB1 receptors for cannabinoid depression of 
transmission at SC-CA1 synapses, a characteristic of transient synaptic depression 
but not of synaptic plasticity (Chevaleyre et al., 2006).  
CB1 receptor signaling modulates short-term synaptic plasticity 
In addition to decreasing basal synaptic transmission, CB1 receptors play a key 
role in neuroplasticity.  Plasticity is defined as the change in synaptic strength by 
either making it more efficient or weaker, known as potentiation/facilitation or 
depression, respectively, in the absence of the inducer, either chemical or electrical 
(Hebb, 1949). This process can be classified as short- or long-term, depending on its 
duration. Short-term potentiation (STP) and depression (STD) last from few seconds 
up to a minute. Conversely, long-term potentiation (LTP) and depression (LTD) have 
a longer time-scale, from minutes to hours (Blitzer, 2005). LTP is characterized by an 
increase of synaptic strength, whereas LTD is characterized by a decrease of 
synaptic strength and both long-term forms of synaptic plasticity rely on production of 
new proteins (Hoeffer and Klann, 2010).  
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CB1 receptors mediate depolarization-induced suppression of 
neurotransmitter release 
Various forms of eCB-STD have been reported and the most studied ones are 
the depolarization-induced suppression of transmission mediated by CB1 receptors 
(Kano et al., 2009; Wilson and Nicoll, 2001). This form of eCB-STD has been widely 
reported at hippocampal and cerebellar synapses (Kreitzer and Regehr, 2001; 
Wilson and Nicoll, 2001). A brief depolarization (up to few seconds) of the post-
synaptic neurons, for instance the pyramidal neurons of the hippocampus, induces a 
transient suppression (< 90 s) of either GABAergic (depolarization-induced 
suppression of inhibition, DSI) or glutamatergic synaptic inputs (depolarization-
induced suppression of excitation, DSE), as measured by the amplitudes of evoked 
inhibitory or excitatory postsynaptic currents (eIPSC and eEPSC, respectively; 
Kreitzer and Regehr, 2001; Pitler and Alger, 1992). DSI and DSE can be induced via 
increase of Ca2+ influx in the post-synaptic neuron via voltage-dependent Ca2+ 
channels (VDCCs) after depolarization, triggering eCBs synthesis and retrograde 
signaling. Both DSI and DSE are prevented by Ca2+ chelators, such as BAPTA and 
EGTA (Kreitzer and Regehr, 2001; Pitler and Alger, 1992; Wilson and Nicoll, 2001). 
The eCB 2-AG is likely to be the main mediator of these processes since specific 
blockade of 2-AG degradation (JZL184) but not AEA (URB597) prolongs DSE in 
Purkinje neurons and DSI in CA1 pyramidal neurons (Pan et al., 2009; Figure 4). 
Moreover, these short-term synaptic change resulting in the decrease of postsynaptic 
currents are a consequence of presynaptic transmission changes trough CB1 
receptors as the postsynaptic responses of GABA-A receptors induced by locally-
applied GABA are not altered by DSI induction (Pitler and Alger, 1992).  
Additionally, it is possible to induce a postsynaptic production of eCBs and to 
inhibit afferent synaptic transmission by activating postsynaptic Gq-linked receptors 
including the Group I metabotropic glutamate receptors (I-mGluRs) and the 
metabotropic muscarinic receptors (mAChRs; Maejima et al., 2001; Straiker and 
Mackie, 2005). These receptors are likely to engage phospholipase C (PLCβ) and 
diacylglycerol lipase (DGL), which synthesis 2-AG.  
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CB1 receptor signaling modulates long-term synaptic plasticity 
CB1 receptors can also take part in long-term synaptic plasticity, potentially the 
cellular mechanism responsible for CB1-dependent effects on memory and 
Figure 4.Molecular mechanisms of eCB-STD. When a large Ca2+ elevation is caused by 
activation of voltage-gated Ca2+ channels or Gq/11-coupled receptors (I-GluR and mAChR), 2-AG is 
generated in a DAGL-dependent manner. Synthesis of 2-AG from postsynaptic neurons, activates 
presynaptic CB1receptors, and induces transient suppression of transmitter release. 2-AG is degraded 
by presynaptic MAGL. In the postsynaptic neuron, 2-AG is degraded by ABHD6 or oxidized by COX-
2.Reproduced with modification from Kano 2014. 
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behavioral adaptation (Castillo et al., 2012; Huang et al., 2008; Marsicano et al., 
2002). In particular, their role in LTD has been highly documented in the neocortex 
and hippocampus (Chevaleyre et al., 2006; Rasooli-Nejad et al., 2014). Unlike eCB-
induced basal neurotransmission depression, eCB-LTDs maintenance does not 
require continuous CB1 receptor stimulation making it a form of plasticity (Chevaleyre 
et al., 2006). 
While classical LTD requires NMDA receptors activation and Ca2+ increase 
(Malenka, 2003), eCB-LTD can be triggered by activation of postsynaptic I-mGluRs 
to induce eCB synthesis via phospholipase C (PLC) activation (Heifets and Castillo, 
2009). The expression of eCB-LTD depends on the activation of presynaptic CB1 
receptors coupled to Gi/o protein, leading to reduction in neurotransmitter release 
(Chevaleyre et al., 2006; Huang et al., 2008). What makes eCBs mediating short-
term versus long-term plasticity? It has been put in evidence that the type of synaptic 
plasticity (short versus long) may depend on how long the CB1 receptor is occupied 
by eCBs or exogenous cannabinoids. For example, DSE/DSI are presumably 
induced by a brief synthesis of eCBs associated to a transient CB1 receptor 
activation, while eCB-LTD requires cannabinoid activation for several minutes 
(Chevaleyre and Castillo, 2003; Younts and Castillo, 2014). 
Typically, the modulation of synaptic activity consists in cellular events 
occurring in pre- and postsynaptic neurons. However, over the last years, astrocytes 
were identified as a third partner hosting cellular signaling cascades involved in the 
direct modulation of synaptic activity, beyond their well-recognized role in brain 
metabolism (Araque et al., 2014; Dallerac et al., 2013). In this sense, astrocytes 
could act as sensors of neuronal activity and consequently control back neuronal 
activity trough synthesis of gliotransmitters, such as glutamate, ATP or D-serine 
(Hamilton and Attwell, 2010; Navarrete and Araque, 2010; Panatier et al., 2011). In 
this context, it was found that activation of astrocytic CB1 receptors leads to 
modulation of synaptic function. For instance, in vivo exogenous application of 
cannabinoids induces a form of LTD of hippocampal synaptic transmission 
dependent on N-methyl-D-aspartate (NMDA) receptor activation (Han et al., 2012). 
This in vivo LTD was not inducible in conditional mutant mice, lacking CB1 receptor 
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expression in GFAP-positive astrocytes (Han et al., 2012). Interestingly, this form of 
plasticity was associated to impairment in working memory induced by astrocytic CB1 
receptors (Han et al., 2012). In contrast to neurons, CB1 receptors in astrocytes can 
be coupled to PLC via Gq/11-proteins and thereby can increase the intracellular 
Ca2+ levels and, plausibly, trigger an exocytotic release of gliotransmitters (Navarrete 
and Araque, 2010). However, more studies are needed to determine the precise 
mechanisms of such neuron-astrocyte regulation via astrocytic CB1 receptors. 
I.8 Effect	  of	  CB1	  receptors	  on	  memory	  and	  motor	  function	  
I.8.1 CB1	  receptors	  and	  memory	  
The research on the pharmacological proprieties of plant Cannabis Sativa has 
shown that cannabis intake can induce memory loss in humans and animals (Bolla et 
al., 2002; Castellano et al., 2003; Davies et al., 2002; Miller et al., 1977; 
Puighermanal et al., 2009; Ranganathan and D'Souza, 2006). Additionally, ECS 
signaling has been shown to be a key regulator of memory processes (Marsicano 
and Lafenetre, 2009; Marsicano et al., 2002; Rueda-Orozco et al., 2008). Large part 
of my Thesis work focuses, in particular, on the potential involvement of mtCB1 
receptors in the pharmacological effects of cannabinoids on memory. In the following 
paragraphs, I will shortly describe the current definition of memory, I will summarize 
known effects of cannabinoids on different types of memory, and I will introduce the 
memory task that I used, underlying its experimental advantages for the specific aims 
of my Thesis work. 
I.8.1.1 The	  memory	  systems	  
Short and long –lasting memories 
Memory refers to the faculty of retaining and recalling past experiences based 
on the processes of learning, retention and retrieval (Milner et al., 1998). Information 
can be retained for a short period of time (e.g. seconds to minute range), for a longer 
time period (e.g. days, months) or remote period (e.g. years; Milner et al., 1998). The 
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functional dissociation of time-dependent memory systems comes from studies of 
memory performances in brain-lesioned patients and of the cellular mechanisms 
associated to learning-induced changes in synaptic properties in invertebrates 
(Milner et al., 1998). For instance, long-term memories were shown to depend on de 
novo protein synthesis (Kandel, 2009; Milner et al., 1998). The observation that long-
term changes in synaptic plasticity require new protein synthesis represents one of 
the most important clues leading to the hypothesis that memory processes are 
indeed mediated by changes in synaptic plasticity (Kandel, 2009; Milner et al., 1998). 
Moreover, experiments in rodents led to the theory that a shift from hippocampus-
dependent to neocortical-dependent memory might delineate ancient memory 
storage (Bontempi et al., 1999; Frankland et al., 2004).  
Long-term memory systems 
The existence of multiple memory systems was already proposed at the early 
beginning of the 19th century, notably based on the distinction of memory for facts, or 
representative memory, and memory for skills, or habits (Kandel, 2009; Milner et al., 
1998). Again, the specific memory impairments described in amnesic patients across 
tasks led to neuropsychological dissociations between memory types, which were 
further identified in animal lesion studies (figure 5; Kandel, 2009; Kandel et al., 
2014). Indeed, human memory can be declarative, as defined by the capacity of 
explicit recollection about fact and events, or “knowing that” (Squire et al., 1993). 
Human declarative memory can be further dissociated in semantic memory, defined 
by general knowledge unrelated to specific experience (“Santiago is the capital of 
Chile”), and episodic memory, which is related to specific, contextualized learning 
episodes or experiences (“I went to Santiago last year”). Declarative memory allows 
referring to a remembered event so as to infer its relationships, similarities and 
contrasts with other events or items (Squire et al., 1993). In animals, this form of 
memory is often called reference or relational memory, in which the medial temporal 
lobes are critically involved (Jaffard et al., 2000; Slangen et al., 1990; Squire, 2004). 
Memory can be also non declarative, implicit, referring to several additional memory 
subtypes, requiring specialized performances such as skills and habits (“knowing 
how”), sensory learning, priming (influence of a presented stimulus on later 
General introduction 
 
Tifany	  Desprez	  -­‐	  Doctoral	  Thesis	  –	  University	  of	  BORDEAUX	  
	   	   	   70 
responses), classical or Pavlovian conditioning and non-associative learning 
(sensitization / habituation;(Squire, 2004; Squire and Zola-Morgan, 1988). It is 
important to note that these distinctions are not strict. Adapted behaviors often 
require several memory processes that interact in a given situation (Levens and 
Phelps, 2010; Phelps, 2004; Squire, 2004). 
 
I.8.1.2 Hippocampal	  CB1	  receptor	  activation	  induces	  memory	  impairment	  
The amnesic effect of cannabinoids has been widely documented. In humans, 
chronic exposure to cannabis is associated with dose-related cognitive impairments, 
most consistently in attention, working memory and verbal learning (Bolla et al., 
2002). Acutely, cannabinoids impair both encoding and recall of verbal and non-
verbal information, in a dose-dependent manner (Ranganathan and D'Souza, 2006). 
In animal studies, cannabinoids alter long-term memory in a variety of experimental 
conditions evaluating both declarative (e.g. spatial and recognition memory) and non-
declarative processes (e.g. non-associative learning, classical conditioning and 
procedural memory) (Castellano et al., 2003; Lichtman et al., 1995; Wise et al., 
2009). The pharmacological effects of cannabinoids on memory performances fully 
depend on CB1 receptors as they are absent in CB1-/-animals (Galanopoulos et al., 
2014; Puighermanal et al., 2009; Reibaud et al., 1999; Varvel and Lichtman, 2002).  
Figure 5.Long-term memory systems. Taxonomy of the mammalian long-term memory systems. 
Adapted from Squire 2004. 
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The hippocampus is a key brain structure involved in memory formation 
(Squire, 2004). Given the well-established role of the hippocampus in synaptic 
plasticity and memory processes and the high expression of CB1 receptors in this 
structure (Herkenham et al., 1990; Marsicano and Lutz, 1999), it is likely that the 
negative effects of cannabinoids on at least certain forms of memory are ascribed to 
their actions within this brain region. Indeed, several studies have demonstrated the 
negative impact of cannabinoid agonists infused intra-hippocampally in different 
memory tasks such as object-location recognition memory and spatial memory 
(Abush and Akirav, 2010; Clarke et al., 2008; Lichtman et al., 1995; Suenaga and 
Ichitani, 2008). Many of these cannabinoid on memory effects are reversed by intra-
hippocampal blockade of CB1 receptors, revealing the necessary role of hippocampal 
CB1 receptors (Clarke et al., 2008; Wise et al., 2009). 
I.8.1.3 Object	  Recognition	  memory	  to	  study	  the	  potential	  role	  of	  mtCB1	  
receptors	  
Large part of the present Thesis work aims at dissecting the potential 
involvement of mitochondrially-expressed CB1 receptors in the amnesic effects of 
cannabinoids. To this aim, I chose to use object recognition memory (ORM). This 
behavioral task evaluates episodic-like memory, which is a type of declarative 
memory (Dere et al., 2005). Additionally, the hippocampus is essential for this type of 
memory (Zola-Morgan and Squire, 1985). Medial temporal lesions in monkeys impair 
memory on a variety of tasks sensitive to human amnesia). Below, I will shortly 
describe the principles of this task and explain why, considering the available 
experimental tools, it is the best suited memory test to study the potential role of 
mtCB1 receptors. 
Principles of object recognition memory (ORM)  
Behavioral tests that evaluate the ability of recognizing a previously presented 
stimulus constitute the core of animal models of human amnesia (Baxter, 
2010).Animals have the tendency to show an innate preference for novelty. This 
preference is displayed by spending more time exploring novel than familiar stimuli 
(recognition memory; Ennaceur and Delacour, 1988). Experimentally, in the version 
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of the task that we used, a mouse is placed in an L maze (L-M/OR) containing two 
identical objects at the end of each arm and then freely allowed to explore these 
objects for several minutes (“sample” phase, which represents the memory 
acquisition; Busquets-Garcia et al., 2011; Puighermanal et al., 2013; Puighermanal et 
al., 2009). After a delay the mouse is placed back in the maze, which now contains 
one familiar object (a copy of the sample phase objects) and a novel object (“test” 
phase, which represents the memory retrieval; Winters et al., 2008). Recognition 
memory is indicated by greater exploration of the novel object (Puighermanal et al., 
2009). Thus, this memory consists in evaluating the memory performance for unique 
episodes or events (one-trial learning), which is adequately suited for studying the 
effects of cannabinoids on different stages of memory: acquisition, consolidation and 
retrieval. Moreover, a short delay (e.g. minutes) between the sample phase and the 
test phase will allow assessing the short-term memory whereas a longer delay (e.g. 
hours to days) will permit to test long-term memory. CB1 receptor activation mediates 
both short-term (personal communications) and long-term memory impairment 
(Clarke et al., 2008; Puighermanal et al., 2009).  
ORM is well-suited for the aims of this Thesis  
As compared to other hippocampal-dependent memory tasks, this test presents 
several advantages for studying the impact of mtCB1 receptor signaling on 
cannabinoid-induced amnesia: (i) the acquisition of L-M/OR occurs in one step and, 
previous studies revealed that the consolidation of this type of memory depends on 
hippocampal CB1 receptors and is deeply altered by acute immediate post-training 
administration of cannabinoids (Puighermanal et al., 2013; Puighermanal et al., 
2009); (ii) this test allows repeated independent measurements of memory 
performance in individual animals (Puighermanal et al., 2013), thereby allowing 
within-subject comparisons, eventually excluding potential individual differences in 
viral infection and/or expression of proteins (see below); (iii) importantly, CB1-/- mice 
do not respond to the administration of cannabinoids, but they do not show any 
spontaneous impairment of performance in L-M/OR (Puighermanal et al., 2009), 
thereby allowing the use of re-expression approaches to study the role of 
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hippocampal mtCB1 receptors in the cannabinoid-induced blockade of memory 
consolidation (see below).  
I.8.2 CB1	  receptors	  mediate	  the	  hypolocomotor	  and	  cataleptic	  
effects	  of	  cannabinoids	  
Typically, cannabinoids at high doses produce four characteristic behavioral 
and autonomic effects in mice, known as the “tetrad” effects of cannabinoids, whose 
study has been standardized by the team of Martin (Compton et al., 1993; Little et al., 
1988). The “tetrad” is characterized by a reduction of spontaneous locomotor activity 
(hypolocomotion), body temperature (hypothermia), sensory pain perception 
(antinociception) and the inability to initiate the movement (catalepsy; Holtzman et 
al., 1969; Little et al., 1988). This assay represented an early screening to isolate 
novel cannabinoids and emphasize the impact of cannabinoids on motor activity and 
reactivity. As previously seen, CB1 proteins are highly dense and widespread within 
the basal ganglia circuit (Herkenham et al., 1990; Matsuda et al., 1990). The basal 
ganglia are a cluster of brain nuclei participating in the planning and control of 
movements (Figure 6). As the primary input of the basal ganglia, the striatum 
receives convergent glutamatergic inputs from the cortex and thalamus onto the 
dendrites of striatal medium spiny neurons (MSNs), the principal output neurons of 
the striatum (Calabresi et al., 1996; Graybiel, 1990). In turn the GABAergic MSNs 
project onto the Entopeduncular nucleus (EPN), the rodent homologue of the internal 
Globus Pallidus (GPi) in primates and the SNr (Bolam et al., 2000). These MSNs can 
be divided into two classes, based on the expression of either the dopamine receptor 
D1 (D1R) or the dopamine receptor D2 (D2R; Gerfen et al., 1990; Le Moine and Bloch, 
1995). CB1 receptors mRNA is highly expressed in the dorsolateral part of the 
striatum where it is co-expressed with GAD65 and D1R or D2R mRNA (Hermann et 
al., 2002; Martin et al., 2008). In a simplistic view, the D1R population sends direct 
inhibitory projections to the GPi and SNr (the direct pathway; Zhou and Lee, 2011), 
facilitating movement. There, CB1 protein is found at the synaptic terminals of striatal 
neurons projecting to the SNr and GPi (Herkenham et al., 1991a; Mansour et al., 
1992). In contrast, the D2R population projects indirectly to the GPi/SNr complex 
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(indirect pathway), via the external Globus Pallidus and the subthalamic nucleus 
(STN; Gerfen and Surmeier, 2011). Activation of the indirect pathway results in the 
inhibition of movement (Gerfen, 1992; Gerfen and Surmeier, 2011; Kawaguchi, 
1997). In this context, deletion of CB1 receptor gene restricted to D1R- positive 
neurons in mice (D1-CB1-/-) abolishes the induction of catalepsy by cannabinoids, 
whereas the hypolocomotion is still present in these mice (Monory et al., 2007). 
Given that most of the double CB1- and D1-positive cells are MSNs, it is likely that the 
direct striatonigral pathway is involved in this effect. Accordingly, activation of CB1 
cannabinoid receptors inhibits GABAergic neurotransmission in the SNr, where most 
of the CB1 receptors are found on GABAergic terminal (Wallmichrath and Szabo, 
2002), suggesting that SNr could be a well-sited structure to modulate the 
hypolocomotor and cataleptic effects of cannabinoids. Part of the present Thesis 
work is dedicated to the identification of the neuronal circuits mediating 
hypolocomotor and cataleptic effects of cannabinoids, with a specific focus on the 
SNr and the potential role played by mitochondrial CB1 receptors.  
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Figure 6. Location of CB1 receptors in specific neuronal subpopulations within basal 
ganglia circuit. Excitatory inputs are indicated in blue, whereas inhibitory are indicated in red. 
Unknown neurons are shown in black. GABA, g-aminobutiric acid; GLU, glutamate; D1 and D2 
Dopamine receptors type 1 and type 2. Adapted from Fernández-Ruiz, 2009. 
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II. MITOCHONDRIA	  
The brain is one of the most energy demanding organs of the mammalian body. 
In adults, whereas the brain represents only about 2% of the total body mass, the 
brain consumes ∼25 % of the total body energy and it spends ∼20 % of the total 
oxygen (O2; Erecinska and Silver, 2001; Kety, 1957; Rolfe and Brown, 1997; 
Sokoloff, 1960). These values illustrate that brain functioning is tightly associated 
with high-energy expenditure and, therefore, requires high and constant levels of 
energy supply (Attwell et al., 2010; Mintun et al., 2001). Regarding energy 
production, mitochondria are the most important organelles able to transform energy 
supplies (e.g. from food) into ATP, which is the main source of energy used by cells 
for their survival and functioning. Indeed, one of the major roles of mitochondria is the 
generation of ATP, mainly through oxidative phosphorylation. Beyond their central 
role in energy metabolism, brain mitochondria participate to other key cellular 
functions including Ca2+ homeostasis, production of reactive oxygen species (ROS), 
synthesis and metabolism of neurotransmitters and other signaling molecules, and 
apoptotic processes (Turrens, 2003).  
Synaptic plasticity and behavior largely depend on the capacity of neurons to 
meet the energy demands imposed by neuronal activity (Attwell and Laughlin, 2001). 
Emerging evidence indicates that events associated with cellular energy balance can 
impact synaptic and cognitive function (Suzuki et al., 2011; Wu et al., 2004). 
Importantly, mitochondria were shown to serve as a node for neurotransmission, 
synaptic plasticity, network activity and behavioral processes (Benard et al., 2012; 
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Guo et al., 2005; Kann and Kovacs, 2007; Li-Byarlay et al., 2014; Sun et al., 2013). 
Consequently, mitochondrial malfunctions are associated to the onset and 
progression of several neurodegenerative diseases (Manji et al., 2012; McInnes, 
2013). Thus, understanding the functional role and consequences of metabolic 
energetic processes is a critical issue in neuroscience that needs to be further 
investigated. Altogether, these studies have opened new doors for the investigation 
of the biological basis of these diseases. Nevertheless, basic questions on synaptic 
metabolism persist: what are the regulatory mechanisms that control mitochondrial 
activity in the brain? Which features of synaptic functions require mitochondrial 
activity? How disruption of mitochondrial-dependent functions can impact on synaptic 
activity and physiological processes?   
Before addressing these issues and discussing the role of mitochondria in brain 
functions, I will shortly describe the structure, properties and function of these 
organelles in the cell. 
II.1 Origins	  of	  mitochondria	  
According to electron microscopy studies (Palade 1953), mitochondria are 
grain-­‐like shaped organelles resembling to bacteria, composed by two highly 
specialized membranes and containing their own DNA (Palade, 1953; Taanman, 
1999). Because of these characteristics, during the Sixties of the last century, Lynn 
Margulis proposed an endosymbiotic theory, postulating that eukaryotic cells have 
evolved from the acquisition of an aerobic prokaryotic bacterium (Margulis, 2001). 
Nowadays, this theory, supported by additional evidence, is commonly accepted 
(Richards and Archibald, 2011). From the evolutionary point of view, this symbiotic 
process provided eukaryotic cells with the great advantage of giving access to 
OXPHOS, a metabolic process that produces more than 15 times as much ATP as 
cytosolic glycolysis and the capacity to produce ATP from diverse substrates 
(Alberts, 2002). Throughout evolution, symbiotic bacteria likely became intracellular 
organelles (mitochondria) via a progressive transfer of genetic material to the host 
nucleus, causing a reduction of the mitochondrial genome (Dyall et al., 2004; 
Mossmann et al., 2012). Many endosymbiont genes were lost because they became 
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dispensable (such as those required for cell-wall building or motility) and many of 
them migrated to the nuclear genome (Lang et al., 1999). The transfer of genes to 
the nuclear DNA (nDNA) was accompanied by the development of protein targeting 
and transport machinery back to the organelle (Lang et al., 1999; Lucattini et al., 
2004). However, mitochondria still contain their own genome and translation 
machinery. In mammalian cells, 37 genes are encoded by the mtDNA including 13 
that encode proteins involved in cellular respiration and the rest for the transcription 
of mitochondrial DNA into protein (2 ribosomal RNA genes and 22 transfer RNAs; 
Mishra and Chan, 2014). Yet, the question why mitochondria have retained part of 
their own genome remains to be answered. Several hypotheses are debated on this 
issue, largely falling into two groups: “hydrophobicity” (Adams, 2003) and “redox 
control” (Allen, 2003). The first view holds that hydrophobic proteins are poorly 
imported by organelles; therefore, they have to be encoded by organelle’s genes 
(Adams, 2003). The second proposes that each mitochondria needs to have a proper 
control on the expression of genes that participate in the respiratory chain because 
the cellular ATP needs to fluctuate and a dysregulation of these processes could 
promote a deleterious effects (Allen, 2003).  
II.2 Mitochondrial	  structure	  and	  dynamics	  
II.2.1 Mitochondrial	  ultrastructure	  	  
To obtain a comprehensive view of mitochondrial functions in the brain, one 
might first consider the spatial organization of mitochondrial compartments. As we 
mentioned previously, mitochondria contain an outer (OM) and an inner membrane 
(IM) with differential properties and functions. These membranes create two different 
mitochondrial compartments: the internal lumen called the matrix, and a much narrow 
intermembrane space (IMS; Alberts, 2002). The OM expresses transport proteins 
called porins. The porins create large channels in the lipid bilayer and render it 
largely permeable to molecules of 5000 Daltons or less, including ATP (Shoshan-
Barmatz and Gincel, 2003). On the contrary, the IM is largely impermeable, but it 
contains a variety of carrier proteins that makes it selectively permeable. In addition, 
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the IM is highly folded, thereby increasing the total membrane surface area and the 
available “working space” (Alberts, 2002). Hence, the IM forms two domains that are 
structurally and functionally distinct: 1- the inner-boundary membrane closely 
apposed to the OM, and 2- the invaginations, called cristae (Herrmann and Riemer, 
2010). The complexes forming the respiratory chain are mainly located in the cristae 
(Stroud and Ryan, 2013). In contrast, the control of ionic exchange and the import of 
metabolites and proteins between the cytosol and the matrix take mainly place in 
inner-boundary membranes (Davies et al., 2011; Vogel et al., 2006; Wurm and 
Jakobs, 2006). This structural description represents mitochondria as rather static 
and isolated organelles, shaped as "bean-like" within the cells' cytoplasm. However, 
mitochondria are not discrete or autonomous but form highly dynamic, 
interconnected networks whose structures and shapes are highly influenced by the 
needs of the cell (Lackner, 2014), as shortly described below (Figure 7). 
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II.2.2 Mitochondria:	  a	  dynamic	  organelle	  
The traditional view of mitochondria as static organelles has evolved and it is 
nowadays recognized that they are highly mobile and they are organized in dynamic 
networks. Mitochondria undergo repetitive cycles of fusion and fission, and they are 
rapidly distributed towards active sites of the cell. These processes are necessary to 
Figure 7.Mitochondrial structure and newtwork. (A) Schema of mitochondrial structure; 
mitochondrial outer membrane (OM), mitochondrial inner membrane (IM), intermembrane space 
(IMS). (B) Tomographic slice from Perkins et al., 2001, where mitochondria (M) localized nearby 
synaptic vesicle (SV) Scale bar = 100 nm. (C) Labeled mitochondrial network in a neuron, the 
organelles are positioned throughout the axon, cell body, and dendrites, taken from Brent T. 
Harris Lab site. 
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maintain mitochondrial viability and, in brain cells, they participate in the regulation of 
synaptic functions (Frazier et al., 2006). Here below, we will see briefly the 
mechanisms governing mitochondrial dynamics (fusion/fission) and their functional 
impact onto cell physiology. 
Depending on environmental conditions, mitochondria appear in different 
shapes ranging from numerous small individual organelles to a single large 
interconnected membrane-bound tubular network (Picard et al., 2013; Rafelski, 
2013). These morphological transitions are determined by fission and fusion events 
that constantly remodel the mitochondrial network. In neurons, mitochondria are 
widely distributed in the cell, including the soma and synapse (Sheng, 2014), and the 
balance between mitochondrial fission and fusion events varies among subcellular 
compartments (Popov et al., 2005). Indeed, 3D reconstructions using electron 
microscopy revealed that, in hippocampal neurons, dendrites display elongated 
mitochondria, forming a reticular network of interconnected "tubes", whereas axonal 
processes display smaller discrete mitochondrial bodies (Popov et al., 2005). 
However, additional studies are required to uncover the functional relevance of such 
neurite-specific morphological properties of mitochondria. The key proteins that 
control mitochondrial dynamic processes are Dynamin related proteins (DRPs), 
which belong to the family of GTP-hydrolyzing enzymes (Labbe et al., 2014). Briefly, 
sequential steps process mitochondrial fusion that results in lipid content mixing. 
First, the OM membranes tether and fuse together followed by IMs association and 
fusion. The first step is mediated through mitofusin 1 and 2 (Mfn 1 and 2), whereas 
IM fusion is operated by optic atrophy 1 (OPA 1; Figure 8A). The opposing process 
of mitochondrial fission relies on the constriction of mitochondria mainly operated by 
dynamin-related protein 1 (DRP1; Picard et al., 2013;Smirnova et al., 2001; Figure 
8B). 
Mitochondrial functions are highly dependent on their dynamics, and alterations 
of these processes can lead to dramatic consequences (Itoh et al., 2013). Several 
proteins regulating mitochondrial morphology have been identified as determinants of 
OXPHOS function. Defect in mitochondrial dynamics is strongly coupled to severe 
defects in respiratory activity. Silencing of OPA1 or DRP1 in cellular cultures results 
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in the blockade of mitochondrial fusion and fission, respectively (Benard et al., 2007; 
Chen et al., 2005). In addition, mutant mice lacking mitofusins or DRP1 die before 
birth, suggesting that mitochondrial dynamics represent vital processes (Chen et al., 
2003a; Wakabayashi et al., 2009). In humans, strong evidence shows that disturbed 
mitochondrial fusion and fission are central pathological components of 
neurodegenerative disorders (Burte et al., 2015). A striking example is that genetic 
mutations of the mitofusin Mfn2 cause axonal Charcot–Marie–Tooth disease type 2A, 
a neuropathy affecting both motor and sensory nerves (Burte et al., 2015). Notably, 
this disease predominantly affects specialized neurons that require precise transport 
of mitochondria over long axonal distances (Burte et al., 2015).  
 
 
Figure 8.Mitochondrial fusion and fission in mammalian cells. The key factors in both fusion 
and fission are large GTP-hydrolyzing enzymes of the dynamin superfamily. (A) Mfn1 and 2 mediate 
OMM fusion whereas OPA1 mediates inner mitochondrial membrane fusion. (B) Mitochondrial fission 
machinery. Drp1 (Dynamin related protein 1) is found soluble in the cytosol of cells from where it 
shuttles onto and bind receptors at the surface of mitochondria. Drp1 assembles into spirals at division 
sites around the outer mitochondrial membrane to drive the fission process. Adapted from Mishra 
2015. 
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II.3 Mitochondrial	  protein	  import	  
One feature of mitochondria is their ability to import proteins and metabolites 
that are essential to their function. As previously mentioned, the ancestral organelle 
that became the mitochondrion has likely undergone an evolutionary reduction of its 
genomic content with a concomitant gene transfer to the nucleus. Based on 
proteomic analyses, mammalian mitochondria are estimated to contain ~1500 
different proteins (Giorgianni et al., 2014; Opalinska and Meisinger, 2014). Hence, 
the vast majority of mitochondrial proteins (≈98%) are synthesized in cytosolic 
ribosomes in their precursor forms. To acquire their mature and functional state these 
precursor proteins need to be imported into mitochondria and correctly distributed to 
one or more of the four mitochondrial subcompartments in order to ensure the correct 
mitochondrial biogenesis and functional maintenance of mitochondria (Lucattini et al., 
2004; Stojanovski et al., 2012).  
Molecular mechanisms underlying mitochondrial proteins targeting, 
import and sorting 
The import of precursor proteins into mitochondria generally occurs in a post-
translational manner. Cytosolic chaperones help fully translated proteins to reach 
their docking sites in the mitochondria. The chaperones shield the hydrophobic 
segments of mitochondrial precursor proteins to protect them from the aqueous 
cytosolic environment and to further prevent misfolding and aggregation (Dudek et 
al., 2013; Mossmann et al., 2012). Once they reach the organelle surface, they are 
recognized, docked and transported by mitochondrial membrane-embedded 
translocation machineries. These machineries are present at both OM and IM and 
consist of groups of associated proteins forming several different complexes. The 
first step of mitochondrial docking of proteins is their transport across the OM via the 
translocase of the outer mitochondrial membrane complex (TOM; Chacinska et al., 
2009; Dukanovic and Rapaport, 2011; Kutik et al., 2007). After import, different 
transport routes exist depending on the final destination of the precursor (OM or IMS 
or IM), which is determined by their targeting information. The translocase of the 
inner membrane (TIM) is a complex of proteins found in the IM of which facilitates 
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translocation of matrix-targeted proteins into the mitochondrial matrix. The inner 
membrane potential (Δψ) drives this transport (Dudek et al., 2013). 
The import of mitochondrial proteins is thought to occur mainly via post-
translational processes (as seen above). However, messenger RNAs of 
mitochondrial proteins are enriched at the mitochondrial surface, where they are 
recruited into mitochondria by specific RNA-binding proteins (Gadir et al., 2011; 
Saint-Georges et al., 2008). Thus, recent studies have proposed an additional model 
in which some proteins are imported by a co-translational mechanism (Weis et al., 
2013). The model involves interactions of ribosome with mitochondria OM proteins. 
Recently, an outer membrane protein (OM14) was identified as a receptor for 
cytosolic ribosome (Lesnik et al., 2014). This protein was shown to facilitate the 
import of proteins newly synthetized by ribosomes located at the mitochondrial 
surface, supporting the view of co-translational import into mitochondria (Lesnik et 
al., 2014). Further investigations need to be conducted in order to reveal the identity 
of mitochondrial mRNAs, their mode of transport and the function of this local 
translation of specific transcripts. 
Interestingly, different types of G proteins and associated signaling partners are 
nowadays known to be present within mitochondria, such as Gαi (Kuyznierewicz and 
Thomson, 2002; Lyssand and Bajjalieh, 2007), Gα12 (Andreeva et al., 2008), Gβ2 
(Zhang et al., 2010), and Gαq (Beninca et al., 2014). This fact suggests that G 
protein signaling participate in mitochondrial functions. However, the specific roles of 
G proteins and the mechanisms regulating their functions are poorly explored so far. 
For instance, the presence of G protein-coupled receptors (one of the most important 
regulators of G proteins) on mitochondrial membranes have been suggested by 
indirect pharmacological studies (e.g. P2Y purinergic receptors, Krzeminski et al., 
2007), but no direct evidence for this has been presented until some years ago. The 
demonstration that CB1 receptors are functionally present on brain mitochondrial 
membranes (Benard et al., 2012; Hebert-Chatelain et al., 2014; Koch et al., 2015) 
represents, therefore, a novel field of research. 
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These data, together with the previously described effects of cannabinoids on 
mitochondrial activity, raised the possibility that CB1 receptors could also be 
functionally present on mitochondrial membranes, in direct contact with the organelle. 
II.4 Mitochondrial	  functions	  
Within the cell, mitochondria play key roles in a number of important functions, 
including essential pathways of amino acid biosynthesis, steroid metabolism and 
apoptosis. However, the main role of mitochondria consists in providing oxidative 
energy metabolism, in the form of ATP and Ca2+ handling, which will be detailed 
below.  
II.4.1 ATP	  synthesis	  	  
ATP synthesis in the cytosol 
Energy metabolism is a highly coordinated cellular process, in which enzymes 
are organized into discrete metabolic pathways that cooperate to produce energy 
substrates from nutrients (Figure 9). In the brain, nerve cells require continuous fuel 
supply from different metabolic pathways present in the cytosol (i.e. glycolysis) and in 
the mitochondria (i.e. Krebs cycle; Alberts, 2002). The energy used by nerve cells 
mainly derives from the breakdown of glucose that is permeable through the blood–
brain barrier (Upadhyay, 2014). Once the glucose reaches the brain and is 
transported through cerebral blood flow, it is metabolized in both astrocytes and 
neurons through glucose transporters (GLUT) present at the plasma membrane 
(Leybaert, 2005). 
The first step of glucose catabolism is glycolysis, taking place in the cytosol 
under anaerobic conditions (Alberts, 2002). Glycolysis is the process by which one 
molecule of glucose is converted into two molecules of pyruvate. In turn, pyruvate 
can be converted to lactate and vice versa, by lactate dehydrogenase (LDH). In 
particular, it has been proposed that glycolysis from astrocytes serves at supporting 
neuronal energy demands by providing lactate to neurons, where it is being 
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reconverted in pyruvate. This process is called astrocyte to neurons lactate shuttle 
(ANLS; Belanger et al., 2011; Pellerin and Magistretti, 2012; Sotelo-Hitschfeld 2015).  
ATP synthesis in mitochondria 
Once pyruvate has been produced by glycolysis in the cytosol, it translocates 
into mitochondria where it undergoes enzymatic degradation to produce acetyl-CoA. 
In turn, each acetyl-CoA enters into the Krebs cycle where, after eight sequential 
enzymatic reactions, it will produce 3 NADH (nicotinamide adenine dinucleotide), 1 
FADH2 (flavin adenine dinucleotide), 1 GTP (Guanosine-5’-triphosphate) and 2 CO2. 
GTP is a molecule involved in the energy transfer within the cell and can be 
subsequently be used to produce ATP. The reducing products NADH and FADH2 will 
be used as substrates to fuel the electron transport chain (ETC) in the OXPHOS 
pathway (Nelson and Rajagopalan, 2004). In addition to glycolysis, glucose can be 
stored by astrocytes in the form of glycogen. Glycogen can be rapidly metabolized 
without the need for ATP hydrolysis to provide energy substrates during periods of 
increased tissue energy demand (Brown, 2004). 
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II.4.1.1 Oxidative	  phosphorylation	  (OXPHOS)	  
The brain is a highly oxidative organ and, as a consequence, most of the 
energy is derived from oxidative reactions (Cai et al., 2011). Neuronal communication 
depends on energetically demanding processes such as reversing the ion influxes 
involved in action potential generation and synaptic transmission, which require 
Figure 9. Main pathways of cellular and mitochondrial energy metabolism. The two 
main metabolic pathways, i.e. glycolysis and oxidative phosphorylation (OXPHOS) are linked by 
the enzyme complex pyruvate dehydrogenase (PDH). Briefly, glucose is transported inside the 
cell and oxidized to pyruvate. Under aerobic conditions, the complete oxidation of pyruvate 
occurs through the Kreb’s cycle to produce NADH and/or FADH2. These reduced equivalents are 
further oxidized by the mitochondrial respiratory chain. Adapted from Bellance 2008. 
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mitochondrial ATP production (Harris et al., 2012). Oxidative metabolism of pyruvate 
provides 32 ATP/glucose whereas glycolysis and glycogenolysis produce 2 ATP or 3 
ATP/glucose, respectively. During OXPHOS, redox reactions and the associated 
proton pumping are coupled to ATP synthesis and are mediated by 5 enzymatic 
complexes (Figure 10; Garret, 2013). Complexes I-IV are large multi-subunit 
enzymatic complexes that form the ETC whereas Complex V does not transfer 
electrons but rather produces ATP. The electrons that are moving along the ETC are 
provided by a series of oxidation-reduction (redox) reactions, realized between an 
electron donor (such as NADH and FADH2) and an electron acceptor (such as 
O2;Garret, 2013). As the electrons get transferred from one molecule to another, they 
go into lower energy state and they release energy. The free energy extracted from 
the movement of electrons drives the pumping of H+ ions (protons) from the matrix to 
the IMS by complexes I, III, and IV. In more details, complex I, known as NADH 
ubiquinone oxidoreductase, is responsible for the oxidation of NADH while Complex 
II, succinate ubiquinone reductase, oxidizes FADH2. From these two complexes, 
electrons converge to the coenzyme Q10 (CoQ; Garret, 2013). CoQ is a lipid-soluble 
electron carrier that transfers electrons from complexes I/II to complex III. By 
receiving the electrons coming from complex I and II, CoQ is reduced and takes the 
name of ubiquinol. In this form, it will carry electrons to Complex III, also called 
cytochrome bc1 complex, and it will be converted back to its oxidized state 
(ubiquinone). The oxidation of CoQ will allow the Complex III to 
catalyse the reduction of cytochrome c, another electron carrier. The electrons 
transferred to the cytochrome c are in turn delivered to the complex IV, cytochrome 
oxidase (Garret, 2013). This is the last enzyme in the respiratory chain in 
mitochondria where the electrons are transferred to an O2 molecule, forming 
two molecules of water. The translocation of protons during these processes 
generates an electrochemical proton gradient (ΔµH+) across the IM. This gradient is 
approximately 180 - 220 mV and results from the mitochondrial membrane potential 
(ΔΨm) and pH gradient (ΔpHm; Mitchell and Moyle, 1969; Nicholls, 1974). In turn, 
protons will be transported back to the matrix through the ATP synthase (complex V), 
which uses the energy produced by this transport to synthesize ATP from adenosine 
diphosphate (ADP) and inorganic phosphate (Pi). The ATP is then translocated out of 
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mitochondria, through the adenine nucleotide transporter (ANT) at the IM and 
through porins at the OM level, and is used to ensure neural cellular processes. 
 
II.4.1.2 Reactive	  oxygen	  species	  (ROS):	  by-­‐products	  of	  the	  mitochondrial	  
energy	  metabolism	  
During mitochondrial respiration, significant amounts of reactive oxygen species 
(ROS) are formed, resulting from the incomplete reduction of the O2 molecule into 
water. Any free radical involving O2 can be referred to as ROS (Datta et al., 2000). 
Free radicals such as the hydroxyl radical (OH−) and the superoxide anion (O2−) are 
transient and chemically unstable due to unpaired electrons in their atomic orbitals. 
Hence, they tend to rapidly react with other compounds, trying to capture the needed 
electron to gain stability (Balaban et al., 2005). Hydrogen peroxide (H2O2) is not a 
Figure 10. Mitochondrial respiratory chain. For mammals, the respiratory chain consists of four 
enzyme complexes (complexes I - IV) and two intermediary substrates (coenzyme Q and cytochrome c). 
The NADH and FADH2 produced by the intermediate metabolism are oxidized further by the mitochondrial 
respiratory chain to establish an electrochemical gradient of protons, which is finally used by the F1F0-
ATP synthase (complex V) to produce ATP, the only form of energy used by the cell, adapted from 
Bellance 2008. 
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free radical (no unpaired electrons) but it is included in ROS because it can be easily 
converted into OH− and could rapidly damage molecules. Mitochondria are 
considered as the major sites of ROS production in the cell (Cadenas and Davies, 
2000). When electrons are transferred along the ETC, a small quantity of electrons 
can leak out from the classical redox reactions pathway and be transferred directly to 
O2.  Complex I and III are thought to be the main ROS generation sites as compared 
to Complex II (Balaban et al., 2005). In contrast, complex IV, due to its high catalytic 
capacity of O2 reduction to water, does not normally produce ROS, but it rather 
prevents their production by keeping the cellular O2 concentration low (Papa and 
Skulachev, 1997). ROS could have either deleterious effects by promoting cellular 
damages or and physiologic roles through a signaling activity (Popa-Wagner et al., 
2013). On one hand, excessive levels of ROS can be toxic causing protein damage 
and mtDNA and nDNA mutagenesis (Marchi et al., 2012). Indeed, increased cellular 
ROS levels production is a common feature of neurodegenerative diseases such as 
Parkinson’s and Alzheimer’s diseases (Hroudova and Fisar, 2013). Importantly, 
beyond their damaging effects on cells, ROS have been proposed to act as signal 
molecules modulating a myriad of cellular processes including apoptosis, 
inflammation, synaptic plasticity and memory formation (Hu et al., 2006; Massaad 
and Klann, 2011). However, under normal conditions, ROS production only accounts 
for 2% of the overall cellular O2 consumption (Chance et al., 1979). Hence, most of 
the O2 consumption is due to the respiratory activity of mitochondria in order to 
produce ATP, which is needed for survival, function and activity of the cell.  
II.4.1.3 Cellular	  respiration	  is	  governed	  primarily	  by	  ATP	  needs:	  focus	  on	  
OXPHOS	  regulation	  
In the brain, energy requirements are very high, and vary in time and space 
according to levels of activity. Therefore, it is very likely that brain-specific regulatory 
mechanisms exist to ensure an adequate delivery of energy by mitochondria. 
Mitochondrial functions can adapt to meet cellular energetic needs by modulating 
OXPHOS performance. This regulation can occur at different levels, including the 
control of: 
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• Changes in OXPHOS capacity in response to cellular and mitochondrial 
microenvironment (e.g. energy substrate availability) 
• Changes in OXPHOS efficiency through kinetic parameters (e.g. 
supercomplexes) 
• Changes in OXPHOS chain activity (e.g. post-translational modifications)  
Changes in OXPHOS capacity in response to cellular and mitochondrial 
microenvironment (e.g. energy substrate availability) 
Mitochondria are in constant communication with the cytosol to coordinate the 
balance between the energy demands of the cell and energy production by 
OXPHOS. OXPHOS requires a supply of NADH, FADH2 (or other source of electrons 
at high potential), O2, ADP, and Pi. A well-known mechanism regulating OXPHOS is 
mediated by the availability of ADP as substrates and is called “respiratory control” 
(Brand and Nicholls, 2011). This effect was observed in isolated mitochondria where 
the respiratory activity (measured by O2 -sensitive electrode) is reversibly modulated 
by the availability of energy substrates ADP (Lardy and Wellman, 1952).  The rate of 
O2 consumption by mitochondria increases markedly when ADP is added and then 
goes back to its initial value when the added ADP has been converted into ATP. 
Because of the tight coupling between electrons transport and ATP synthesis, 
electrons do not usually flow through the electron transport chain toward O2, unless 
ADP is simultaneously phosphorylated to ATP (Garret, 2013). Thus, the physiological 
significance of this regulatory mechanism is that when ATP is consumed for cellular 
mechanisms, ADP levels increase. The further elevation of ADP will exert a positive 
feedback control on respiration. Hence, the positive regulation of OXPHOS activity by 
ADP levels indicates the strong dependence of physiological respiration on energy 
demand (Zharova and Vinogradov, 2012).  
Changes in OXPHOS efficiency through kinetic parameters (e.g. 
supercomplexes) 
The classical view of ETC as discrete enzymes diffused in the IM has been 
replaced by the “solid state model”, postulating that respiratory complexes are 
associated with each other to form supramolecular complexes, called respiratory 
supercomplexes or respirasomes (Genova and Lenaz, 2014). Using blue native 
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polyacrylamide gel electrophoresis (BN PAGE), studies in mammalian mitochondria 
showed that Complex I, III and IV were organized in supercomplexes in various 
combinations (Dudkina et al., 2011; Schagger et al., 2004). Almost all the complexes 
I are assembled into supercomplexes whereas most of complexes II were found in a 
free, non-associated form and only a small proportion is associated with 
supercomplex I/III/IV (Acin-Perez et al., 2008). Hence, remodeling of 
supercomplexes was hypothesized to facilitate OXPHOS specialization and to 
directly control OXPHOS bioenergetic functions (Acin-Perez et al., 2008; Huttemann 
et al., 2008). Consistent with this view, destabilization of supercomplexes is 
associated with a decrease in respiration (Lenaz and Genova, 2012). Thus, it is 
proposed that supercomplexes confer a kinetic advantage for substrate channeling. 
Indeed, to the spatially close arrangement of the complexes that makes the diffusion 
of the mobile electron carriers faster as the later will only travel short distances 
(Althoff et al., 2011).  
Post-translational processes regulating OXPHOS chain activity: the case 
of the mitochondrial cAMP/PKA signaling pathway mediated by sAC 
It has been shown that Complex I undergoes a multitude of post-translational 
modifications in several of its subunits (De Rasmo et al., 2010).  As an important 
point of my Thesis, I will discuss about post-translational modifications of complex I 
subunits by phosphorylation induced by the cAMP/PKA pathway. The majority of the 
complex I subunits are encoded by nDNA, whereas 7 are encoded by mtDNA (Schon 
et al., 2012). In vitro, there is strong evidence demonstrating that mitochondrial 
cAMP/PKA-dependent phosphorylation regulates complex I activity (Papa et al., 
2012).   
It was first found that pharmacological up-regulation of cAMP levels positively 
impacts on complex I activity and endogenous respiration sensitive to the Complex I 
inhibitor rotenone in mouse embryonic fibroblasts (MEFs; Scacco et al., 2000). 
Interestingly, this increase of mitochondrial activity was accompanied by serine 
phosphorylation in the 18-kDa subunit of complex I (Scacco et al., 2000) In addition, 
dibutyryl cAMP, an analog of cyclic AMP that stimulates cAMP-dependent protein 
kinases, resulted in a similar stimulation of mitochondrial respiration and subunit 
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complex I phosphorylation. Overall, these data indicate that cAMP-dependent 
phosphorylation directly regulate cellular respiration likely trough the modulation of 
complex I activity (Scacco et al., 2000). Furthermore, NDUFS4 subunit of complex I 
was identified as the target that undergoes post-translational phosphorylation, 
mediating the increase of Complex I activity (De Rasmo et al., 2010; Scacco et al., 
2003). Indeed, the serine-173 in C terminus of the NDUFS4 protein is a site 
phosphorylated by PKA (Scacco et al., 2000). 
The following question was whether cAMP and PKA could act directly within 
mitochondria. On one hand, PKA can be localized in defined microdomains such as 
the mitochondria (Kapiloff et al., 2014; Means et al., 2011). A-kinase anchoring 
proteins (AKAPs) mediate the transport of PKA into mitochondria, allowing PKA to 
phosphorylate target substrates preferentially located in the matrix Means, 2011 
(Means et al., 2011). Together, these data support the view that PKA likely signals 
within the mitochondria (Sardanelli et al., 2006) and phosphorylates Complex I 
subunit NDUFS4. As seen above, cAMP-mediated phosphorylation of mitochondrial 
enzymes plays a role in OXPHOS regulation. However, cAMP generated in the 
cytosol does not enter mitochondria (Di Benedetto et al., 2013). Thus, it was 
postulated that a source of this second messenger might reside inside mitochondria 
(Papa et al., 1999). A soluble form of adenylyl cyclase called sAC was found 
expressed in mitochondrial matrix, where it generates cAMP (Zippin et al., 2003).  
This enzyme has specific molecular characteristics, as it seems to be insensitive to 
heterotrimeric G protein regulation and forskolin stimulation and it is modulated by 
bicarbonate ions, Ca2+ and ATP (Litvin et al., 2003; Zippin et al., 2003). 	  
Interestingly, Acin-Perez demonstrated that the pharmacological inhibition of 
sAC, using a sAC inhibitor named KH7, decreases rotenone-sensitive dependent 
respiration. Conversely, sAC activation by bicarbonate increases mitochondrial 
respiratory function (Acin-Perez et al., 2009b). More recently, De Rasmo and 
colleagues showed that KH7 treatment causes a reduction in respiratory activity and 
a decrease of the expression levels of several complex I subunits (NDUFS4, 
NDUFV2 and NDUFA9; De Rasmo et al., 2015). Notably, inhibition of proteasomes 
blocked the effects of KH7 on both subunit expression levels and on complex I 
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activity, suggesting that the drug regulates post-translational events. It was then 
proposed that intramitochondrial cAMP exerts this positive effect on complex I by 
preventing digestion of nDNA-encoded complex I subunits by mitochondrial protease. 
Importantly, both effects were abolished by a non-hydrolysable cell permeant cAMP 
analog (8-Br-cAMP), but not by the increase of cytosolic cAMP induced by Beta-
adrenoreceptor agonist (De Rasmo et al., 2011). Altogether, these findings clearly 
suggest that sAC-dependent production of mitochondrial cAMP promotes respiratory 
functions via modifications of complex I activity.  
II.4.2 Mitochondrial	  role	  in	  calcium	  homeostasis	  
II.4.2.1 Mitochondrial	  use	  of	  calcium	  
Beyond their role in generating ATP, neuronal mitochondria contribute to Ca2+ 
homeostasis. Many characteristics of synaptic transmission and plasticity depend on 
changes in presynaptic and post-synaptic Ca2+ levels (Zucker, 1999). Under 
physiological resting conditions, the cytosolic Ca2+ concentration is remarkably low 
(about 50–100 nM), but it can transiently rise during electrical activity to levels that 
are ten to 100 times higher (Berridge et al., 2000). As compartmentalization is one of 
the key features of cellular signaling, the regulation of neural processes by 
intracellular Ca2+ signals depends on its spatial and temporal limitations. Indeed, 
Ca2+ signaling is highly versatile and can operate over a large time range, from 
neurotransmitter release at the microsecond scale to gene transcription, which lasts 
for minutes and hours. Similarly, the organization of discrete cellular microdomains, 
in which the Ca2+-sensitive enzymes such as AC resides, plays a key role in neuronal 
processes (Berridge et al., 2003; Willoughby et al., 2010). Together with the 
endoplasmic reticulum (ER), mitochondria play key roles in modulating the 
concentration of cytosolic Ca2+ (Grimm, 2012). Pulses in Ca2+ influx, e.g. during 
synaptic activity, is matched by Ca2+ efflux during periods of rest to avoid either Ca2+ 
buildup or depletion (Balaban, 2002). The ability of mitochondria to uptake Ca2+ 
allows modifying the shape of cytosolic Ca2+ pulses, but it also permits the 
stimulation the OXPHOS activity (Gunter et al., 2004). In excitable cells, elevation of 
Ca2+ increases OXPHOS indirectly by increasing ATP consumption, via active Ca2+ 
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transport, and by directly stimulating ATP production via activating complex V  and 
Krebs’ cycle enzyme activity (Bender and Kadenbach, 2000; Carafoli and Crompton, 
1978; Gunter et al., 2004; Lehninger et al., 1978; Vale et al., 1983). Indeed, Ca2+ ions 
have been reported to activate the rate of NADH production, one of the substrate for 
OXPHOS, by up-regulating the isocitrate dehydrogenase and α-ketoglutarate 
dehydrogenase present in the Kreb’s cycle (Denton, 2009; Gunter et al., 2004). 
Furthermore, large evidence highlights a role of Ca2+ in modulating the activity of 
Complex V and cytochrome oxidase via post-translational modifications (Balaban, 
2009; Bender and Kadenbach, 2000). More recently, it was shown that Ca2+ entry 
into the mitochondrion induces the up-regulation of mitochondrial cAMP/PKA 
signaling trough sAC, which results in the increase in ATP synthesis (Di Benedetto et 
al., 2013). Thus, it was suggested that Ca2+ could be one of the positive regulators of 
mitochondrial energy metabolism at nerve terminals by potentially acting as a feed-
forward mechanism to boost ATP synthesis in order to prevent energy drop during 
synaptic activity (Rangaraju et al., 2014).	  
II.4.2.2 Mitochondria	  buffer	  cellular	  calcium	  
Mitochondrial Ca2+ uptake depends on the strong driving force ensured by the 
membrane potential across the inner membrane (-180 mV, negative inside the 
matrix) built by the respiratory chain and inducing Ca2+ to penetrate into mitochondria 
(Bianchi et al., 2004). The use of chemical uncouplers that perturbs the proton 
gradient across the IMM and depolarizes the mitochondrial matrix, such as carbonyl 
cyanide 4-(trifluoromethoxyl)s-phenyl-hydrazone (FCCP), strongly inhibits 
mitochondrial Ca2+ uptake (Graier et al., 2007). Ca2+ import across the OM occurs 
through the voltage dependent anion channel (VDAC; Hajnoczky et al., 2006; 
Simamura et al., 2008; Szabadkai et al., 2006). However, the identification of ion 
channels responsible for Ca2+ entering the mitochondrial matrix has been a difficult 
task. Because of specific kinetic characteristics of mitochondrial Ca2+ uptake, it was 
proposed that Ca2+ is likely transported through a gated channel rather than a 
classical carrier (Kirichok et al., 2004). Only recently, De Stephani and colleagues 
revealed the molecular nature of a mitochondrial Ca2+ uniporter (MCU) embedded in 
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the IM. Thereby, using short interfering RNA (siRNA) silencing of MCU in HeLa cells, 
they observed a markedly reduced mitochondrial Ca2+ (De Stefani et al., 2011). Since 
then, additional proteins have been described that are able to modulate the function 
of MCU-dependent transport of Ca2+ and its assembly in the mitochondrial IM, such 
as mitochondrial calcium uniporter regulator 1 (MCUR1) and essential MCU regulator 
(EMRE), respectively (Mallilankaraman et al., 2012; Sancak et al., 2013). Thus, MCU 
has been characterized as a complex of molecules, but future research needs to 
characterize the exact composition and stoichiometry of MCU complexes as well 
their functional impact on synaptic activity.  In this context, the recent molecular 
identification of the MCU (De Stefani et al., 2011) allowed investigating its impact on 
neuronal excitotoxicity induced by NMDA receptor activation (Qiu et al., 2013). While 
Ca2+ uptake can stimulate the respiratory chain, excessive amounts of mitochondrial 
Ca2+ can be detrimental for the cell and lead to excitotoxicity and apoptosis (Benedict 
et al., 2012; Hajnoczky et al., 2006). Knockdown of MCU expression, using shRNA-
targeting MCU in hippocampal and cortical neurons, decreases NMDA-induced 
accumulation of mitochondrial Ca2+ (Qiu et al., 2013). This effect largely prevents 
mitochondrial depolarization and confers a resistance to NMDA-induce excitotoxic 
cell death (Qiu et al., 2013), suggesting a role of mitochondrial Ca2+ uptake capacity 
in coupling excessive Ca2+ entrance to apoptosis. However, the functional role of 
MCU remains under controversy. A recent study using MCU-/- mice has reported that 
the Ca2+ content in mitochondria of mutant cells was only partially reduced as 
compared to wild type animals (Pan et al., 2013). While the lower levels of 
mitochondrial Ca2+ levels can be relevant for neuronal toxicity (Qiu et al., 2013), MCU 
does not appear to be the only route for mitochondrial Ca2+ uptake across the IM, 
indicating the existence of alternative Ca2+ uptake pathways or that Ca2+ target other 
mitochondrial proteins without penetrating in the matrix. Interestingly, the 
identification of Ca2+-regulated mitochondrial carriers (CaMCs) revealed an additional 
target of cytosolic Ca2+ signals in neuronal mitochondria for regulation OXPHOS (del 
Arco and Satrustegui, 2004). The critical difference between these pathways is that 
Ca2+-dependent regulation of mitochondrial respiration through the carriers operates 
by the action of Ca2+ at the surface of the IM, rather than in the matrix and therefore 
does not require mitochondrial Ca2+ uptake (Llorente-Folch et al., 2015).  Cytosolic 
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Ca2+ controls OXPHOS by facilitating pyruvate supply to mitochondria through its 
action on the Ca2+-regulated mitochondrial carriers, the aspartate-glutamate carrier 
(Aralar), a component of the malate–aspartate shuttle (MAS; Llorente-Folch et al., 
2013). Indeed, the formation of pyruvate from its precursors (e.g. glucose, lactate) is 
coupled to NAD+ regeneration. NAD+ levels are promoted by cytosolic Ca2+via MAS 
activity, thereby increasing pyruvate formation (Gellerich et al., 2013). In turn, 
pyruvate mitochondrial import will boost substrates production from Kreb’s cycle 
resulting in increased energy production from OXPHOS, a process called “the 
mitochondrial gas pedal” (Llorente-Folch et al., 2013; Rueda et al., 2014). Thus, the 
mechanisms by which Ca2+ activates mitochondrial function remain a hot research 
spot and future experiments will detail the actors of such system and their 
physiological relevance (Figure 11).  
Another relevant issue for intracellular Ca2+ dynamics is the physiological 
function of the ER and mitochondrial physical apposition (Csordas et al., 2006). 
Electron tomography experiments revealed that ER and mitochondria can be tightly 
connected at specific membrane contact sites, called the mitochondria-associated 
membranes (MAMs; Csordas et al., 2006). Ca2+ is mobilized from the ER and 
subsequently transferred to mitochondria via inositol trisphosphate receptor (IP3R; 
Cardenas et al., 2010; Esterberg et al., 2014). Remarkably, IP3Rs within the ER are 
juxtaposed to the mitochondrial VDAC, by which Ca2+ enter mitochondria, supporting 
the idea of Ca2+ transfer in MAMs (Szabadkai et al., 2006). In particular, IP3R Ca2+ 
release and mitochondrial uptake likely provide an essential functional regulation of 
mitochondrial bioenergetics autophagy (Mendes et al., 2005). According to this, 
genetic deletion or pharmacological blockade using siRNA or inhibitors of IP3R 
decrease O2 consumption and lead to a reduction in mitochondrial ATP production 
(Cardenas et al., 2010). In turn, the ATP depletion causes an increase of cell death 
by autophagy (Cardenas et al., 2010). Thus, these data suggest that mitochondrial 
Ca2+ intake via IP3R has a protective role against autophagy by stimulating 
mitochondrial OXPHOS.  
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II.5 Mitochondrial	  functions	  during	  synaptic	  activity	  
The brain greatly depends on the cellular and mitochondrial metabolic pathways 
to fuel its activity, making it vulnerable to metabolic dysfunctions.  For instance, the 
Figure 11. Ca2+ modulates OXPHOS by increase NADH production. Mitochondrial Ca2+ 
directly modulates Kreb’s cycle dehydrogenase (green dotted line). Cytosolic Ca2+ regulates pyruvate 
supply to mitochondria (glue dotted line). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
lactate dehydrogenase (LDH), pyruvate (Pyr) the malate–aspartate shuttle (MAS), mitochondrial 
Ca2+ uniporter (MCU), aspartate-glutamate carrier (Aralar), inositol triphosphate receptor (IP3R), 
voltage dependent anion channel (VDAC). Adapted from Gellerich 2013. 
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mitochondria are essential components of synaptic transmission, since they are a 
major source of energy and participate to calcium buffering (Chen et al., 2010; 
MacAskill and Kittler, 2010).  Long-term disruption of mitochondrial activity, including 
impairment of OXPHOS and especially of complex I activity, results in dramatic 
effects and is involved in several neurological disorders (Moran et al., 2012; Papa et 
al., 2012; Zsurka and Kunz, 2013). However, little is known about the impact of acute 
disruption of mitochondrial function in the brain. The paragraphs below will review 
about the importance of the mitochondrial energy metabolism for the 
neurotransmission and the implication for the behavior. 
II.5.1 Neuronal	  activity	  regulates	  mitochondrial	  mobility	  
Mitochondria are mobile organelles using motor proteins and microtubules 
network to ensure their transport. Mitochondrial trafficking is essential for neuronal 
functions (Kang et al., 2008; Sun et al., 2013).In neurons, mitochondrial trafficking is 
a complex process divided into two phases: a bidirectional mobility phase and a 
stationary phase. Mitochondria move both anterogradely (from soma to cell 
extremities) to distribute towards active sites, and retrogradely (from cell extremities 
to the soma), a process involved in removing dysfunctional mitochondria by 
autophagy (Scherz-Shouval and Elazar, 2007). During their mobility phase, their 
mean velocity is approximately 0.6 µm/s (Jackson et al., 2014). In hippocampal 
neurons, labeled axonal mitochondria display different motion profiles and, at any 
given time, approximately 55% of mitochondria are stationary out of synapses site, 
around 15% are docking at synapses, 15% are moving passing through synapses, 
15 % are pausing at synapses start moving again (Sun et al., 2013). Neuronal 
mitochondria are retained at sites of high activity and Ca2+ -buffering need, including 
postsynaptic and presynaptic terminals, in active growth cones and in axonal 
branches (Perkins et al., 2010; Ruthel and Hollenbeck, 2003). At these sites, the 
organelles stop moving and become stationary in order to provide local ATP 
synthesis and Ca2+ sequestration depending on the demand (MacAskill et al., 2010). 
Knowledge of mitochondrial mobility is technically provided by kymographs from 
time-lapse live-imaging movies, which provide a spatio-temporal map of 
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mitochondrial transport activity in the neural process of interest (Wang and Schwarz, 
2009). 
Due to this complex mobility pattern of axonal mitochondria, it is likely that each 
mitochondrion is associated to machinery complexes to ensure mitochondrial 
trafficking and arrest at precise locations (Cai et al., 2011). These machineries 
consist in motor/adaptor/receptor proteins that are coupled together and are 
regulated in response to changes in neuronal activity (Figure 12; Sheng, 2014). 
Mitochondria are carried along the cytoskeleton through the activity of microtubule 
(MT)-based motor proteins, such as proteins of the kinesin superfamily (KIFs) and 
dynein (Alberts, 2002; Molecular Biology of the Cell. 4th edition). Motor proteins 
mediate long-distance transport of mitochondria (up to 1 meter in humans) as well as 
other organelles or vesicles. The direction of transport exerted by these motor 
proteins is determined by the polarity of the MTs: one end, termed the “plus end”, 
points toward axon terminal and distal dendrites, while the polarity is mixed in 
proximal dendrite microtubules (Alberts, 2002). KIF5 proteins are the main motor 
effectors of plus end-directed anterograde transport of mitochondria, whereas 
dyneins drive mitochondrial retrogradely in axons. The motor proteins contain 
catalytic domains (ATPase) mediating the motor activity, and cargo-binding domains, 
that are associated with mitochondria trough adaptor proteins. The two main adaptor 
proteins for mitochondrial transport in neurons are the mitochondrial Rho-GTPase 
Miro, anchored to the mitochondrial outer surface, and the trafficking protein kinesin-
binding (TRAK; mammalian Milton orthologue), recruiting KIF5 and associated to 
Miro (see reviews of Lin and Sheng, 2015; MacAskill and Kittler, 2010; Sheng, 2014).   
Mitochondrial mobility and subcellular distribution are tightly regulated by 
neuronal activity to meet energy demands. Increase in neuronal signaling reduces 
mitochondrial movements (MacAskill and Kittler, 2010; Sheng, 2014). 
Pharmacological blockade of synaptic activity by the voltage sensitive Na+ channels 
blocker TTX increases mitochondrial mobility and reduces axonal mitochondrial 
occupancy (Sheng, 2014). Conversely, increase of synaptic activity induced by 
electrical field stimulation leads to decreased axonal mitochondrial mobility in 
hippocampal cultures (Sheng, 2014), suggesting that synaptic activity arrests mobile 
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mitochondrial at active sites.  Neuronal activity is characterized by an increase of 
intracellular Ca2+ observed upon arrival of an action potential at the nerve terminal. In 
turn, increase of cytosolic Ca2+ down-regulates mitochondrial movement along the 
MT, suggesting that Ca2+ might mediate mitochondrial arresting in response to 
synaptic activity (Sheng, 2014). Further studies revealed that, when mobile 
mitochondria pass by active synaptic terminals, the local increase in Ca2+ levels 
disrupts the Miro–TRAK–KIF5 complex and arrests the mitochondria at the synapse 
(Macaskill et al., 2009; Wang and Schwarz, 2009). Furthermore, the group of Zu-
Hang Sheng identified Syntaphilin (SNPH) as the protein mediating anchoring of 
KIF5-bound mitochondria to the MT (Chen and Sheng, 2013). Synaptic activity and 
elevated Ca2+ levels promote the interaction between SNPH and KIF5 by disrupting 
the Miro–TRAK–kinesin complex. In neurons, the SNPH–KIF5 interaction maintains 
KIF5 attachment to mitochondria, but inhibits the motor ATPase activity, indicating 
that SNPH prevents KIF5 from moving along MTs at pre-synaptic boutons (Chen and 
Sheng, 2013). Overall, these data indicate a clear down-regulation of mitochondrial 
mobility during synaptic activity possibly to fulfill bioenergetic and Ca2+ buffering 
requirements.  
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In astrocytes, it was recently revealed that mitochondria are also distributed 
along the fine processes of astrocytes (Jackson et al., 2014). Their trafficking is 
bidirectional, depends on MT assembly and appears to be regulated by glutamate 
and neuronal activity (Jackson et al., 2014). However, mitochondria moved more 
slowly in astrocytes compared to the ones present in neurons (Jackson 2014). These 
results suggest that different motor proteins might govern astrocyte mitochondrial 
trafficking (Stephen et al., 2014). Interestingly, it has been shown that astrocytes 
Figure 12.Activity-dependent regulation of mitochondrial transport. The Miro–Milton (or 
Miro–TRAK) adaptor complex mediates KIF5-driven mitochondrial transport. Ca2+ binding to Miro 
causes the release of KIF5 motors from mitochondria. Thus, Ca2+ influx after synaptic activity arrests 
motile mitochondria at activated synapses. Additionally, a Miro-Ca2+–sensing pathway triggers the 
binding switch of KIF5 motors from the Miro–TRAK adaptor complex to anchoring protein syntaphilin, 
which immobilizes axonal mitochondria via inhibiting motor ATPase activity. Adapted from Sheng 
2014. 
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express kinesin motor proteins (KIF11 and KIF22; Cahoy et al., 2008); however, their 
involvement in regulating astrocyte mitochondrial mobility has yet to be determined. 
II.5.2 The	  necessary	  role	  of	  presynaptic	  mitochondria	  for	  
maintenance	  of	  synaptic	  activity	  	  
Presynaptic terminals have a high energetic demand and require a fine-tuning 
of Ca2+ buffering. Interestingly, these areas are often enriched in mitochondria 
(Perkins et al., 2010; Figure 13). 
 
 
The functional relevance of presynaptic mitochondria was first reported at the 
neuromuscular junctions (NMJs) of Drosophila melanogaster by two different 
laboratories (Guo et al., 2005; Verstreken et al., 2005). NMJ is the type of synapse 
connecting spinal motor neurons (presynaptic elements) to skeletal muscle cells 
(postsynaptic elements). In Drp1 or Miro (mitochondrial Rho-GTPase) loss-of-
function mutant flies, mitochondrial fission or axonal mitochondrial transport is 
inhibited, respectively. Both mutations induce lack of mitochondria at synapses 
accompanied by organelles accumulation in the cell body (Guo et al., 2005; 
Verstreken et al., 2005). Mutant Drp1 or Miro proteins lead to an impairment of 
neurotransmission during high stimulation frequencies but not during weak 
stimulations (Guo et al., 2005; Verstreken et al., 2005), suggesting that intense 
Figure 13. Mitochondrial 
presynaptic localization in 
neurons. Electron microscopy from 
mouse cerebellar section where 
mitochondria (M) (transversally 
sectioned) in the presynaptic axonal 
bouton localized nearby synaptic 
vesicle (SV).Scale = 250 nm 
(http://synapses.clm.utexas.edu/atla
s/1_1_4_2.stm) 
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synaptic activity likely rely on mitochondrial function (Guo 2005). Accordingly, 
supplementing synapses with exogenous ATP largely rescued this decrease of 
neurotransmission (Verstreken et al., 2005). Failure of the Drp1 mutants to maintain 
neuronal activity upon intense stimulations was associated with the inability to 
mobilize reserve pool (RP) vesicles and this effect is mimicked by pharmacological 
inhibition of mitochondrial respiration in an ATP-dependent manner (Verstreken et 
al., 2005).  In addition to play critical roles in the maintenance of synaptic activity, 
mitochondria may also be required for neuroplasticity. Disruption of Syntabulin, a 
KIF5 motor adaptor in sympathetic neurons, is associated with a decrease of 
presynaptic mitochondria and causes an impairment of synaptic transmission at high-
frequency firing as well as an alteration of presynaptic short-term plasticity (Ma et al., 
2009). Here again, these effects were reversed by the application of exogenous ATP, 
indicating a key role of presynaptic mitochondria in fueling short-term neuronal 
plasticity (Ma et al., 2009). Altogether, these data indirectly suggested the critical role 
of presynaptic mitochondria in providing ATP supply to sustain synaptic activity 
evoked by intense stimulation and plasticity processes. However, a recent study 
provided direct evidence of the need of presynaptic ATP for supporting synaptic 
activity (Rangaraju et al., 2014). In this study, a new quantitative optical presynaptic 
ATP reporter, called syn-ATP, was used to precisely measure pre-synaptic ATP 
levels. Surprisingly, the concentration of presynaptic ATP was shown to be rather 
constant during electrical activity or TTX application in hippocampal neuronal cultures 
(Rangaraju et al., 2014). Considering that neuronal activity is a major brain 
processes consuming brain ATP, the authors hypothesized that fast ATP turnover 
might explain this lack of activity-dependent regulation of ATP levels. Indeed, 
blockade of glycolysis and/or OXPHOS decreased ATP levels at active synapses 
and dramatically impaired synaptic transmission, suggesting that rapid de novo ATP 
synthesis is required to maintain neuronal activity (Rangaraju et al., 2014). Thus, 
neuronal activity is directly linked to presynaptic ATP consumption derived from both 
glycolytic and respiratory processes.  
Beyond the bioenergetics need for synaptic recycling (Vos et al., 2010), other 
processes require neuronal synthesis of ATP. For instance, ion pumps activity such 
as the Na+/K+-ATPases, which ensure the maintenance of ion gradients across the 
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plasma membrane, have been suggested to be mainly fueled by mitochondrial ATP 
(Fernandez-Moncada and Barros 2014). In addition, cytoskeleton reorganization or 
phosphorylation reactions and neurotransmitter metabolism are dependent of ATP 
supply (Attwell and Laughlin, 2001), but experimental data are needed for 
determining whether mitochondrial OXPHOS activity could directly impact on these 
processes. 
One of the prominent features of brain functioning is the synchronous oscillatory 
activity of neuronal networks (Duzel et al., 2010; Gloveli, 2010), and mitochondria 
have been involved in these processes (Kann et al., 2011). For instance, fast 
neuronal network oscillations in the gamma range have been involved in complex 
behavioral task such as memory formation (Nyhus and Curran, 2010). Gamma 
oscillations in the hippocampus are associated to oxidative processes and O2 
consumption (Kann et al., 2011).  Pharmacological inhibition of complex I, using 
rotenone, impairs O2 consumption and provokes a rapid and complete loss in the 
power of gamma oscillations (Kann et al., 2011), indicating the necessity of 
mitochondrial respiration to sustain network synchronization. From these results, it is 
tempting to hypothesize that disruption of mitochondrial function could also have an 
impact on memory performances associated with gamma oscillations. 
Altogether, the data shortly summarized above indicate that synaptic activity 
and network oscillations require mitochondrial activity at synapses. However, would 
such a modulatory role of mitochondrial function be sufficient to impact on animal 
behavior? 
II.5.3 Mitochondrial	  function/dysfunction	  and	  behavior	  
Many studies pointed out the role of mitochondria in different psychiatric and 
neurodegenerative diseases, including Parkinson's disease (PD), Alzheimer's 
disease (AD), Huntington's disease (HD), Amyotrophic Lateral Sclerosis (ALS) and 
Schizophrenia (Demetrius and Driver, 2013; Lezi and Swerdlow, 2012; Manji et al., 
2012; Mattson et al., 2008). These disorders result from synaptic dysfunction in 
specific brain areas. For example, PD results from a loss of the dopamine-secreting 
cells in the Substantia Nigra (SN; Damier et al., 1999), while schizophrenia likely 
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results from compromised function of a population of interconnected cells in the 
prefrontal cortex, temporal cortex and thalamus (Goldman-Rakic and Selemon, 
1997). Notably, these diseases are all accompanied by changes in mitochondrial-
dependent functions including respiratory activity, ROS production, Ca2+ buffering 
and dynamics (Lezi and Swerdlow, 2012; Mattson et al., 2008). For instance, in 
patients suffering from schizophrenia, it was observed a decrease of mitochondrial 
respiratory function (Rozenfeld and Devi, 2011), which is likely due to impairment in 
complex I activity and decrease expression levels of several subunits (Mattson et al., 
2008). 
While it is well established that mitochondrial dysfunctions are often present in 
neuropathologies and psychiatric disorders, it is still unclear whether these 
impairments contribute to the onset and progression or whether they are 
consequences of brain disorders. Recent findings suggest that mitochondria may 
serve as key mediators of the onset and progression of some types of 
neurodegeneration (McInnes, 2013). For instance, a causal relationship between 
organelle alterations and synaptic dysfunctions was reported in a genetic AD mouse 
model via excessive mitochondrial ROS production (Lee et al., 2012). In addition, 
pharmacological chronic inhibition of mitochondrial respiratory function by rotenone is 
one of the best established PD models (Betarbet et al., 2000), reproducing most 
features of the disease, including degeneration of dopaminergic neurons, 
bradykinesia, rigidity (Betarbet et al., 2002), delayed initiation of movement (Fleming 
et al., 2004), reduced motor activity (Sherer et al., 2003b) and prolong latency in the 
catalepsy test (Sharma and Nehru, 2013). Interestingly, recent computational studies 
revealed the likely causal link between bioenergetic processes and motor neuron 
degeneration, a key feature of ALS (Le Masson et al., 2014).  
Thus, mitochondrial integrity is gaining wide attention in neuropathology and 
could represent a therapeutic target (Le Masson et al., 2014; Moreira et al., 2010). 
However, which mitochondrial dependent functions predominantly participate in the 
onset of specific features of different neurodegenerative diseases is just starting to 
be addressed. A parallel action of subcellular ATP insufficiency, ROS production and 
mitochondrial DNA mutations has been proposed (Zsurka and Kunz, 2013). In 
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particular, it was shown that antioxidant therapy in preclinical stages could delay or 
prevent the onset of several neurodegenerative diseases (Lee et al., 2012; Moreira et 
al., 2010). 
Beyond the implication of mitochondria in neurodegenerative and psychiatric 
diseases, very little is known about how acute impairment of mitochondrial activity 
could be responsible for changes in animal behavior. The team of Gene Robinson 
has revealed that increased aggression in insects is associated with whole-brain 
down-regulation of several OXPHOS enzymes (Alaux et al., 2009) and has later 
found a causal relationship between mitochondrial bioenergetics and behavior (Li-
Byarlay et al., 2014). In this study, pharmacological manipulation of mitochondrial 
respiratory activity led to an increase in aggressive behavior in honey bees (Li-
Byarlay et al., 2014). Furthermore, in Drosophila, neuronal RNAi silencing of the 
complex I subunit CG2014 (NADH ubiquinone oxidoreductase-like) induces an 
elevation of aggressive performance (Li-Byarlay et al., 2014). Thus modification on 
OXPHOS pathway and in particular complex I activity, appears to modulate specific 
behavioral states. Additional studies will have to address the potential causal link 
between mitochondrial OXPHOS activity and the modulation of behavior in the 
mammalian brain. This Thesis work represents one of the first experimental attempts 
in this direction.   
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III. THE	  LINK	  BETWEEN	  THE	  
ENDOCANNABINOID	  SYSTEM	  AND	  
MITOCHONDRIA	  
In the early Seventies of last century, few years after the identification of the 
chemical structures of Cannabis compounds (the cannabinoids, Gaoni and 
Mechoulam, 1964), CB1 receptors were not discovered yet and a great interest rose 
to identify the biological mechanisms underlying the effects of this class of plant-
derived molecules, particularly of the main psychoactive component THC. Among 
other effects, some authors showed a significant impact of cannabinoids on 
mitochondrial functions. In particular, cannabinoid compounds were shown to alter 
ATPase activity and morphology of rat liver mitochondria (Chari-Bitron and Bino, 
1971; Bino et al., 1972), to decrease Complex I activity in rat brain and heart 
mitochondria (Bartova and Birmingham, 1976), and to inhibit monoamine oxidase 
(MAO) in brain human and porcine mitochondria (Schurr and Livne, 1975, 1976; 
Schurr et al., 1978). At that time, THC was thought to exert non-receptor-mediated 
effects due to the lipophilic nature of cannabinoids, which could explain cellular and 
mitochondrial effects via alteration of membrane properties (Bartova and 
Birmingham, 1976; Howlett, 2002). After the discovery of cannabinoid receptors as 
typical plasma membrane GPCRs, an indirect downstream mechanism of pmCB1 
receptor signaling on mitochondrial activity was suggested for CB1-induced apoptosis 
(Campbell, 2001). The potential implication of CB1 receptors in cannabinoid effects 
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on OXPHOS was refuted at that time, as these effects were similar in both cellular 
and isolated mitochondrial extracts (Athanasiou et al., 2007). This was due to the fact 
that CB1 receptors, as all GPCRs, could not be possibly considered to be present on 
mitochondria at that time. For instance, concluding the abstract of their paper on 
cannabinoid impact on mitochondrial activity, Athanasiou and colleagues wrote, 
"These data demonstrate that AEA, THC, and HU 210 are all able to cause changes 
in integrated mitochondrial function, directly, in the absence of cannabinoid 
receptors" (Athanasiou et al., 2007). Interestingly, the evidence of the effects of 
cannabinoids occurred "in the absence of cannabinoid receptors" was exclusively 
based on the common knowledge assuming that GPCRs cannot possibly be present 
at mitochondrial membranes and, as such, this possibility was not discussed 
(Athanasiou et al., 2007). Therefore, until few years ago, cannabinoids were known 
to directly alter mitochondrial functions, but these effects were fully ascribed to 
unspecific membrane disturbance induced by these lipid molecules. However, recent 
results challenged this idea, indicating that CB1 receptors are present also at 
mitochondrial membranes in the periphery, such as in spermatozoa (Aquila et al., 
2010) or skeletal muscles (Pedro Grandes, personal communication), and in the 
brain, where they directly regulate mitochondrial OXPHOS activity (Benard et al., 
2012; Hebert-Chatelain et al., 2014; Vallee et al., 2014). Therefore, mitochondrial 
effects of cannabinoids can be nowadays ascribed to two potential molecular 
mechanisms: unspecific alterations of membrane properties and specific receptor-
mediated intramitochondrial signaling pathways (Fisar et al., 2014). In this Chapter, I 
will mention old and new studies addressing the interplay between cannabinoids and 
mitochondrial functions.  
III.1 The	  interplay	  between	  cannabinoids	  and	  mitochondrial	  
functions	  
In the attempt to decipher the biological effects of cannabinoids, it was 
proposed that THC could potentially alter monoamine release in the brain by acting 
on the enzyme MAO, an oxidoreductase located in the mitochondrial OM and 
responsible for metabolism of monoamine neurotransmitters (Shih et al., 1999). After 
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release into the synaptic cleft, monoamines’ action is terminated by their reuptake 
into the presynaptic terminal, where they can be recycled into synaptic vesicle or 
degraded by MAO (Mukherjee and Yang, 1999). Brain monoamines such as 
dopamine, serotonin and norepinephrine play a key role in the regulation of brain 
functions in animals and humans, including motor control, mood or cognitive 
functions (Koob and Le Moal, 2001).  Interestingly, both MAO inhibitors and CB1 
receptor agonists exert antidepressant-like effect (Fiedorowicz and Swartz, 2004; Hill 
and Gorzalka, 2005). In this context, early studies found that cannabinoid 
compounds inhibit the activity of MAO in isolated brain mitochondria (Schurr and 
Livne, 1975, 1976; Schurr et al., 1978). The inhibitory effect of CB1 receptor agonists 
(THC, WIN and AEA) on MAO activity with serotonin as a substrate was confirmed in 
a crude mitochondrial fraction isolated from mammalian brain cortex (Fisar, 2010).   
Besides the regulation of mitochondrial MAO, numerous studies reported also 
effects of endogenous and exogenous cannabinoids on respiratory functions 
(Bartova and Birmingham, 1976; Bino et al., 1972; Chari-Bitron and Bino, 1971). 
Bartova and colleagues showed that acute THC treatment of mitochondria isolated 
from different brain regions strongly impairs NADH-oxidase activity (Complex I) 
(Bartova and Birmingham, 1976). Furthermore, exogenous and endogenous CB1 
receptor agonists (THC, HU210 and AEA) inhibit mitochondrial O2 consumption and 
disrupt mitochondrial membrane potential from rat heart purified mitochondria 
(Athanasiou et al., 2007; Silva et al., 2013; Zaccagnino et al., 2011). The impairment 
of mitochondrial membrane potential by THC was also found to be associated with a 
following decline in the bioavailability of cellular ATP in lung cells cultures, indicating 
a potential decrease of mitochondrial respiratory activity contributing to the cellular 
ATP depletion (Sarafian et al., 2003).  
By releasing cytochrome c in the cytosol, mitochondria are the main actors of 
programmed cell death or apoptosis (Gordman 2000). In the nervous system, 
apoptotic mechanisms have been associated with various cellular processes such 
synaptic plasticity and neurodegenerative disorders (Mattson 2000, Li 2012). The 
specific action of CB1 receptors on apoptotic processes was broadly examined. 
Prolonged THC applications cause reduction of cell viability in a dose- and time- 
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dependent manner in cultured hippocampal or cortical neurons, (Campbell, 2001). 
Exposure of cultured cortical neurons to THC (30–360 min) reproduced the 
morphological and biochemical features of apoptosis including nuclear DNA 
fragmentation, release of mitochondrial cytochrome c and activation of caspase-3 
(Campbell, 2001). Importantly, the THC-induced apoptosis was blocked by the CB1 
receptor antagonist AM251 and pertussis toxin (PTX), suggesting that CB1-
dependent apoptosis via mitochondria involves receptor-mediated activation of the 
G-protein subtypes Gi/o (Campbell, 2001).  
CB1 receptors also participate in the regulation of mitochondrial transport along 
processes (Boesmans et al., 2009). As described above, mitochondrial trafficking 
towards active sites of neurons is an essential mechanism to support ATP supply 
during synaptic activity (Rangaraju et al., 2014; Verstreken et al., 2005). Interestingly, 
the number of mitochondria transported in enteric neuronal fibers is decreased by 
CB1 receptor agonists and conversely enhanced by CB1 receptor inhibition, indicating 
a role of CB1 receptors in slowing down mitochondrial trafficking (Boesmans et al., 
2009).  
Overall, these results emphasized the effects exerted by cannabinoids on 
mitochondrial functions and regulation. Some of these effects were considered to be 
CB1 receptor-independent and due to membrane-perturbing properties of lipophilic 
cannabinoids (e.g. modulation of OXPHOS or of MAO activity in isolated 
mitochondria; (Athanasiou et al., 2007; Fisar, 2010). Conversely, other effects, such 
as induction of apoptosis and regulation of mitochondrial mobility, were shown to 
involve CB1 receptors (Campbell, 2001).  However, given the predominant idea that 
functional GPCRs are exclusively present at cellular plasma membranes, the 
involvement of CB1 receptors in mitochondrial effects of cannabinoids has been long 
considered to be indirect, through cytoplasmic signaling pathways. Recent data 
challenged this idea. 
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III.2 The	  ECS	  directly	  regulate	  brain	  mitochondrial	  
respiration	  via	  mtCB1	  receptors	  
In 2012, a study from our laboratory demonstrated the functional presence of 
CB1 receptors on mitochondrial membranes, identifying mitochondrial CB1 receptors 
(mtCB1) as a direct modulator of bioenergetics cellular processes in the brain 
(Benard et al., 2012). Pharmacological activation of CB1 receptors accompanied by 
rigorous controls using CB1-/- mutant mice showed that mtCB1 receptors directly 
impact on endogenous respiration of brain mitochondria. 
In more details, electron immunohistochemistry showed that approximately 10 
to 15% of total CB1 receptors in the CA1 hippocampal region are located in 
mitochondria of wild-type mice, largely above background levels quantified in tissues 
from CB1-/- mutants (Benard et al., 2012). MtCB1 receptors are densely present in 
GABAergic interneurons and to a lesser extent on glutamatergic neurons, which goes 
in parallel with the well-known higher densities of ‘GABAergic‘ CB1 receptors as 
compared to ‘glutamatergic’ ones (Marsicano and Lutz 1999; Marsicano and Kuner 
2008). At the subcellular level, mtCB1 receptors are equally distributed to both 
dendrites and axon terminals, which differ from the pool localized at plasma 
membranes (pmCB1), largely found at the presynaptic terminals (Benard et al., 
2012). The direct impact of mtCB1 receptors on respiratory functions of mitochondria 
was tested in purified brain mitochondria from wild-type and CB1-/- mice(Figure 14), 
in CB1-transfected primary mouse fibroblast (MFs) from CB1-/- mice and in transfected 
HEK293 (Benard et al., 2012; Hebert-Chatelain et al., 2014; Vallee et al., 2014). 
Exogenous application of the CB1 receptor agonists THC, WIN and HU210 
decreases endogenous mitochondrial respiration, whereas no changes were 
observed in control-transfected cells or brain mitochondria from CB1-/- mice, 
indicating a direct regulation of respiration by cannabinoids trough CB1 receptors 
(Benard et al., 2012; Hebert-Chatelain et al., 2014; Vallee et al., 2014).  
General introduction 
 
Tifany	  Desprez	  -­‐	  Doctoral	  Thesis	  –	  University	  of	  BORDEAUX	  
	   	   	   113 
 
 
In purified brain mitochondrial preparation, the cannabinoid-induced decrease 
of mitochondrial respiration is associated with a decrease of complex I activity as well 
as a reduction of mitochondrial cAMP levels and PKA activity (Benard et al., 2012). 
To discriminate the respective influence of pmCB1 versus intracellular CB1 receptors 
on these effects, indirect pharmacological tools were developed. A biotinylated 
version of the lipophilic CB1 receptor agonist HU210 (HU210-biotin, hereafter HU-
biot), in which the presence of the hydrophilic biotin extension prevents the cell 
penetration, was synthesized and used in vitro. Interestingly, HU-biot treatment does 
not alter O2 consumption in intact CB1-expressing cells, whereas the effect appears 
when CB1-MFs are permeabilized (Benard et al., 2012), indicating that reduction of 
the respiratory activity in living cells is limited to the action of intracellular CB1 
receptors and most likely trough mtCB1 receptors. Given the major coupling of CB1 
with protein Gi/o resulting in the decrease of cAMP and previous evidence reporting 
the presence of intra-mitochondrial cAMP/PKA signaling regulation on OXPHOS, it is 
probable that mtCB1 receptors could modulate respiration through inhibition of the 
cAMP/PKA cascade (Acin-Perez et al., 2009a; De Rasmo et al., 2010; Howlett, 2005; 
Piomelli, 2003).   
Figure 14.Direct regulation of mitochondrial activity by mtCB1 receptors in the 
brain.(A-B) Direct dose-response effect of the CB1receptor agonist WIN55,212-2 (WIN) on 
respiration and Complex I activity of purified mitochondria from WT and CB1-KO brains. From Benard 
et al., 2012. 
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The detailed characterization of the precise molecular mechanisms by which 
mtCB1 receptors induce decrease of O2 consumption is one of the subjects of the 
present thesis (see below).  
CB1 receptor signaling is at the cross of the pharmacological effects of 
cannabinoids and the physiological roles of the ECS. Thus, an important question to 
address was whether the ECS physiologically modulates mitochondrial activity via 
mtCB1 receptors. FAAH, the primary degradative enzyme for AEA, is densely present 
in the mitochondria (Benard et al., 2012) and Benard et al, (2012) found that purified 
mitochondria contain AEA- and 2-AG–degrading activity that is ascribed to FAAH and 
MAGL, representing approximately 18% and 12% from the total cellular enzyme 
activity, respectively (Benard et al., 2012). Pharmacological inhibition of MAGL in 
purified mitochondria increases 2-AG levels and decreases respiration. Interestingly, 
a strong inverse correlation was found between the levels of endogenous 2AG in 
mitochondria and O2 consumption (Benard et al., 2012), suggesting that endogenous 
mtCB1 receptor signaling within mitochondria control the respiratory activity of the 
organelles. 
The idea that mtCB1 receptors might participate in eCB-dependent modulation 
of synaptic plasticity was further tested.  As mentioned above, CB1 receptors mediate 
DSI, a form of short-term plasticity of inhibitory neurotransmission (see Chapter 1). 
To remind briefly, the depolarization of a postsynaptic cell leads to eCBs 
mobilization, which retrogradely activate presynaptic CB1 receptors and transiently 
decrease GABAergic inhibitory neurotransmission (Alger, 2002; Kano et al., 2009). 
DSI levels are proportional to the intensity and/or duration of the depolarization step, 
with stronger or longer depolarization inducing higher levels of presynaptic inhibition 
(Alger, 2002; Kano et al., 2009). DSI is blocked by CB1 receptor antagonists, but it is 
also prevented (occluded) by CB1 receptor agonists, which occupy CB1 receptors and 
impede further actions of endogenously mobilized eCBS (Alger, 2002; Kano et al., 
2009). In hippocampal slices, HU210 completely occluded “strong DSI” induced by 5-
sec depolarization steps, whereas HU-biot at saturating doses had only a partial 
effect (approximately 50% occlusion). Similarly, the cell-impermeant CB1 receptor 
antagonist, the peptide Hemopressin (Heimann et al., 2007) partially reduced “strong 
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DSI”, whereas the membrane-permeant CB1 receptor antagonist AM251 abolished it. 
Finally, rotenone, a mitochondrial complex I inhibitor, was ineffective on “strong DSI”, 
but potentiated “weak DSI”, suggesting that mitochondrial processes participate in 
the expression of “strong DSI”. Interestingly, the participation of intracellular CB1 
receptors was limited to DSI: HU-biot and HU 201 equally decreased hippocampal 
basal inhibitory transmission, suggesting that intracellular CB1 receptors do not 
participate in pharmacological effects of cannabinoids on inhibitory synaptic 
transmission. Thus, CB1 receptors are present on brain mitochondria, where they 
regulate cellular bioenergetics processes and possibly participate in eCB-dependent 
synaptic plasticity. 
However, further studies and more powerful tools than indirect pharmacology 
are needed to investigate the impact of mtCB1 on synaptic transmission, brain 
functions and behavior. This Thesis work, based on the solid anatomical and 
functional data described above, aimed at providing first answers to these questions 
by generating and using novel tools to dissect the functions of mtCB1 receptors in the 
brain. 
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As detailed in the introduction, the brain is one of the most energy-demanding 
organs in our body. Brain functions critically depend on an adequate energy supply, 
in the form of oxygen and nutrients provided by the blood. This energy is largely used 
to mobilize synaptic vesicles, maintain ion fluxes underlying neuronal excitability, to 
induce action potentials, to provide morphological rearrangements of brain cells, and 
to regulate synaptic activity (Attwell and Laughlin, 2001). The correct functioning of 
mitochondria is fundamental for the generation of most cellular ATP and its 
impairment may have dramatic consequences (Cai et al., 2011). Accordingly, 
mitochondrial dysfunction has been implicated in many neurological and psychiatric 
diseases (Mattson et al., 2008). It is well established that brain energy metabolism, 
including mitochondrial respiration, supports brain activity (Attwell and Laughlin, 
2001; MacAskill and Kittler, 2010; Rangaraju et al., 2014). However, little is known 
about the physiological roles of mitochondrial activity in the acute regulation of 
behavior. 
Progress in understanding the mechanisms of action of cannabinoids was 
made after discovery of the ECS that consists in cannabinoid receptors, their 
endogenous ligands endocannabinoids and the enzymatic machineries for the 
synthesis, degradation and transport of endocannabinoids (Di Marzo, 2006). 
Endogenous and pharmacological activation of CB1 receptors at synaptic terminals 
results in the regulation of neurotransmitter release and synaptic plasticity, which in 
turn affects physiological and behavioral processes (Kano et al., 2009). We recently 
discovered the presence of CB1 receptors on brain mitochondrial membranes 
(mtCB1) and its direct control of cellular respiration and energy production suggesting 
a potential role of mitochondria in regulating animal behavior (Bénard et al., 2012; 
Hebert-Chatelain et al., 2014). Thus, the contribution of brain mtCB1 receptor 
activation in behavioral processes deserves further investigation.  
The general aim of this thesis work is to unravel the role(s) played by 
brain mtCB1 receptors in behavioral effects of cannabinoids. In order to do 
that, we used new experimental approaches, combining pharmacological and 
genetic tools (objective 1), and to investigate the role of mtCB1 receptor 
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signaling in motor and memory effects of cannabinoid agonists (objective 2).  
Objective 1- Development of pharmacological and genetic tools to study 
mtCB1 receptors in the brain. 
To study the involvement of mtCB1 receptors in cell, network and behavioral 
functions, the first challenge resides in the functional discrimination between effects 
mediated by mtCB1 and others dependent on CB1 receptors at other cellular 
locations. This challenge implies the development, the characterization and the 
validation of tools aimed at stimulating or to inhibiting these two receptor pools, 
independently.  
First, we focused on the identification of the molecular mechanisms by which 
mtCB1 receptors modulate mitochondrial function. By exploiting the specific signaling 
cascades of mtCB1 receptors, (characterized in collaboration with Etienne Hebert-
Chatelain), we used pharmacological compounds to block mtCB1 receptor-dependent 
signaling in vivo.  
Second, we adopted a genetic approach consisting in the generation and 
functional characterization of a mutant CB1 protein (DN22-CB1) that does not localize 
at mitochondrial membranes (developed in collaboration with Luigi Bellocchio and 
Anna Delamarre).  
Objective 2- Role of mtCB1 receptor signaling on motor and memory 
performance. 
Motor alterations and deficits in memory performance are amongst the best 
characterized behavioral effects of cannabinoids (Carter and Weydt, 2002; Solowij 
and Pesa, 2010). Moreover, mitochondrial impairment and oxidative stress has been 
associated with pathologies where these functions are altered (Demetrius and Driver, 
2013; Lezi and Swerdlow, 2012; Manji et al., 2012; Mattson et al., 2008).Thus, I 
assessed the potential dependency of memory and motor alterations induced by 
cannabinoids on mtCB1 receptor activation. 
Objective 2.1: 
To evaluate the role of mtCB1 receptor signaling in the modulation of 
memory consolidation: Long-term memory is a process that has high metabolic 
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demands within the underlying active neuronal network (Suzuki et al., 2011). Post-
training injection of cannabinoids impair long-term object recognition memory (ORM), 
a subcategory of declarative memory, that is mediated by hippocampal CB1 
receptors (Clarke et al., 2008; Puighermanal et al., 2009). The goal of this first study 
was to assess the contribution of mtCB1 receptor signaling to ORM consolidation. In 
vitro electrophysiological recordings in mouse hippocampus allowed us to describe 
the implication of mtCB1 receptors on hippocampal basal excitatory 
neurotransmission (in collaboration with Federico Massa and Geoffrey Terral). Once 
established this role, I addressed the following questions: 
! Does pharmacological inhibition of intra-hippocampal mtCB1-dependent 
signaling prevent cannabinoid effects of ORM consolidation? 
! Is viral re-expression of CB1 or of DN22-CB1 receptors in the hippocampus of 
CB1-/- mice sufficient to rescue the cannabinoid-dependent alteration of ORM 
consolidation? 
Objective 2.2: 
To determine the role of mtCB1 receptor signaling in the modulation of 
motor control: It is well established that high doses of cannabinoids induce 
decreased locomotor activity and catalepsy, via activation of CB1 receptors (Zimmer 
1999, Monory 2007). The Substantia Nigra (SNr) is a structure integrated in the basal 
ganglia circuit, controlling motor functions and expressing considerably high level of 
CB1 receptors (Herkerham 1991). Thus, I addressed the following questions: 
! Is the SNr a brain site where cannabinoids alter locomotor performance in 
mice? 
! Are intracellular CB1 receptors in the SNr necessary for locomotor and 
cataleptic effects of cannabinoids? 
! Do mitochondrial effects of cannabinoids via mtCB1 receptors in the SNr 
contribute to cannabinoid-induced regulation of motor control? 
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The work described below is under consideration for publication in these two 
articles (see annex for manuscripts): 
1- Etienne Hebert-Chatelain*, Tifany Desprez*, Edgar Soria-Gomez, Luigi 
Bellocchio, Anna Delamarre, Geoffrey Terral, Peggy Vincent, Arnau 
Busquets-Garcia, Laurie M. Robin, Michelangelo Colavita, Nagore Puente, 
Leire Reguero, Uzaskun Elezgarai, Gabriel Barreda-Gómez, Maria-Luz 
Lopez-Rodriguez, Federico Massa, Pedro Grandes, Giovanni Bénard*, 
Giovanni Marsicano*. Mitochondrial CB1 receptors are required for 
amnesic effects of cannabinoids. Submitted. 
2- Tifany Desprez, Edgar Soria-Gomez*, Etienne Hebert-Chatelain*, Julia 
Goncalves, Lea Moreau, Luigi Bellocchio, Nagore Puente, Pedro Grandes, 
Giovanni Benard, Giovanni Marsicano. The subcellular localization of CB1 
receptors shapes its effect on motor control. In preparation  
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Mice 
All experimental procedures were approved by the Committee on Animal Health 
and Care of INSERM and the French Ministry of Agriculture and Forestry 
(authorization number 3306369). Mice were maintained under standard conditions 
(food and water ad libitum; 12h/12h light/dark cycle, light on 7 a.m.; experiments 
were performed between 9 a.m. and 5 p.m.). Wild-type (CB1+/+) and KO (CB1-/-) 
female and male mice (2–4 months old) were obtained, bred and genotyped as 
described (Marsicano et al., 2002). Only male mice were used for behavioral 
experiments. For most experiments CB1+/+ and CB1-/-were littermates. For primary 
cell cultures, pups were obtained from homozygote pairs. C57BL/6-N mice were 
purchased from Janvier (France). 
Drugs 
THC was obtained from THC Pharm GmbH (Frankfurt, Germany). HU210 and 
HU210-Biotin were synthesized as described (Martin-Couce et al., 2012). WIN55-
212-2, KH7, PTX, Bicarbonate (HCO3-), Forskolin, FCCP, Oligomycin, Picrotoxin and 
the rest of chemicals used in this study were purchased from Sigma Aldrich (St-
Louis, IL, USA) were obtained from Sigma Aldrich (France).  
For behavioral experiments, THC (10mg/kg) was dissolved in 5% ethanol, 4% 
cremophor and saline. WIN55,212-2, (10mg/kg) was dissolved in a mixture of saline 
(0.9% NaCl) with 2% DMSO and 2% cremophor. KH7 (2 µg/0.5 µl/injection) was 
dissolved in 10% cremophor, 2.5% DMSO and saline. Hemopressin (5 µg/0.5 
µl/injection) was dissolved in saline. AM251 (4 µg/0.5µl/injection) was dissolved in 
10% dimethyl sulfoxide (DMSO) and 10% cremophor. Rotenone (1 µg/2 µl/injection) 
was dissolved in a mixture of saline (0.9% NaCl) with 2% DMSO and 2% cremophor. 
All vehicles solutions contained the same amounts of solvents. All drugs were 
prepared freshly before the experiments.  
For biochemical experiments, PTX (1 µg/ml), HCO3- (5 mM) and Forskolin (10 
µM) were dissolved in water. KH7 (5 µM) and WIN (100 nM and 1 µM) were 
dissolved in DMSO. THC (800 nM and 1 µM), Oligomycin (2 µg/ml) and FCCP (1 µM) 
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were dissolved in ethanol. Corresponding vehicle solutions were used in control 
experiments. 
Cell culture and transfection  
Mouse 3T3 cells (3T3 F442A) and HEK293 cells were grown in Dulbecco 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 
4.5 g/L glucose, 2 mM glutamine, 1 mM pyruvate. HEK293 cells were transfected 
with control plasmid, CB1 or DN22-CB1 cDNA coupled with mCherry cloned in pcDNA 
3.1(+), respectively. 3T3 cells were transfected with sAC-HA kindly offered by Dr. G. 
Manfredi from Cornell University, [see (Acin-Perez et al., 2009b)]. The transfections 
were done using FugeneHD (Roche, France) according to the manufacturer’s 
protocol. 
Primary hippocampal cultures were prepared from CB1+/+ and CB1-/-P0-P1 mice. 
Briefly, after sacrifice by decapitation, hippocampi were extracted in dissection 
medium (10 mM Hepes, 0.3% glucose in Hank’s salt balanced solution, pH 7.4) and 
dissociated in 0.25% trypsin for 30 min. Where indicated, dissociated cells were 
transfected with sAC-HA using Amaxa P3 primary cell 4D-nucleofector kit (Lonza, 
France), according to the manufacturer’s protocol. Cells were plated on poly-L-lysine-
coated 96-wells dishes using neurobasal/B27 medium (supplemented with 5% FBS, 
2mM glutamine, 1 mM pyruvate, 1mM sodium lactate, 0.3% glucose and 37.5 mM 
NaCl) at a density of 50,000 cells/well. One hour after plating, the serum was 
removed. Primary hippocampal cultures contained both neurons and astrocytes, and 
were used at 3 DIV.  
Mouse fibroblasts (MFs) were generated from P0-P1 CB1-/- pups. After sacrifice 
by decapitation, the dorsal skin was excised and minced in 1x phosphate buffer 
(PBS). Cells were then separated by incubation in 0.25% trypsin solution in PBS, 
collected by centrifugation and resuspended in DMEM with 10% fetal bovine serum, 
1% L-glutamine and 2% penicillin/streptomycin solution (Invitrogen, France). Cells 
were seeded in 25 cm2 flasks and then expanded in 75 cm2 flasks until reaching 90% 
confluence. Transfections were carried out by using a BTX electroporator ECM 830 
(Harvard Apparatus, France) (175 V, 1-ms pulse, five pulses, 0.5-s interval between 
pulses). Cells were electroporated in Optimem medium (Invitrogen, France) at 
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2x107cells/ml (fibroblasts from two 75 cm2 flasks at 90% confluence in 300 µl) in a 2-
mm-gap cuvette using 30 µg of either control plasmid, CB1 or DN22-CB1 cDNA 
coupled with mCherry. After electroporation, cells were resuspended in DMEM with 
10% fetal bovine serum, 1% l-glutamine and 2% penicillin/streptomycin solution 
(Invitrogen, France) and seeded in three 100 cm2 petri dishes. All cells were 
maintained at 37°C and 5% CO2 and harvested 48h after transfection for respiration 
experiments. 
Isolation of mitochondria and cell fractionation 
The brains of CB1+/+ and CB1−/− littermates were dissected and mitochondria 
were purified using Ficoll gradient as previously described (Benard et al., 2012; 
Hebert-Chatelain et al., 2014). Briefly, mice brains were extracted in ice-cold isolation 
buffer (sucrose 250 mM, Tris 10 mM, EDTA 1 mM, pH 7.6) containing protease 
inhibitors (Roche, France) and 2 mM NaF and homogenized with a Teflon potter. 
Homogenates were centrifuged at 1,500 g for 5 min (4°C). The supernatant was then 
centrifuged at 12,500 g (4°C). The pellet was collected and the cycle of centrifugation 
was repeated. To purify mitochondria, the final pellet was resuspended in 400 µl of 
isolation buffer, layered on top of a discontinuous Ficoll gradient (10% and 7% 
fractions) and centrifuged at 100,000 g for 1 h (4°C). All experiments using freshly 
isolated brain mitochondria were performed within 3 h following purification. 
The 3T3 cells were harvested, resuspended in isolation buffer and disrupted 
with 25 strokes using a 25G needle. The total cell lysate was centrifuged at 500 g 
(4°C) to remove cells debris and nuclei. The supernatant was kept and centrifuged at 
12,500 g for 10 min (4°C). Then, the supernatant was kept (cytosolic fraction) and the 
pellet was resuspended and the centrifugation cycle was repeated. Finally, the 
mitochondrial fractions were obtained from the last pellet. 
Oxygen consumption measurements 
The oxygen consumption of isolated mitochondria and cell lines was monitored 
at 37 °C in a glass chamber equipped with a Clark oxygen electrode (Hansatech, 
U.K.). Purified mitochondria (75-100 µg) were suspended in 500 µl of respiration 
buffer (75 mM mannitol, 25 mM sucrose, 10 mM KCl, 10 mM Tris-HCl, pH 7.4, 50 
mM EDTA) in the chamber. Respiratory substrates were added directly to the 
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chamber. Pyruvate (5 mM), malate (2 mM) and ADP (5 mM) were successively 
added to follow mitochondrial respiration. The experiments using 3T3 cells were 
performed on 2 × 106 cells ml−1 in growth medium. Intact cells were transferred 
directly into the chamber and basal respiration was recorded. Drugs were added 
directly into the chambers. Mitochondria were incubated with PTX, KH7 and H89 
during 5 min before addition of CB1 receptor agonists. HCO3- and 8Br-cAMP were 
added 5 min after the addition of CB1 receptor agonists.  
Oxygen consumption of primary hippocampal cultures was monitored using 
XF96 Seahorse Bioscience analyzer (Seahorse Bioscience, Denmark), according to 
the manufacturer’s protocol. When indicated, oligomycin (2 µg/ml) and Carbonyl 
cyanide-4-(trifluoromethoxy)phenylhydrazone  (FCCP, 1 µM) were injected directly 
into the wells. Other drugs were directly added into the medium 1h before 
measurements.  
ATP content measurements 
The intracellular ATP content was measured by using the bioluminescent ATP 
kit HS II (Roche, France). CB1+/+ and CB1-/-primary hippocampal cultures (50,000 
cells/well in a 96 wells dish) were treated with THC (1 µM), WIN (1 µM) or vehicle 
(EtOH 1:30.000 for THC and DMSO 1:500 for WIN, respectively) in the presence or 
absence of rotenone (0.1 µM) during one hour. Then, ATP measurements were done 
as described (Jose et al., 2011). Briefly, cells were lysed to release the intracellular 
ATP by using the lysis buffer provided with the kit (equal volume) for 20 min. The 
lysate was then analyzed in a 96-well plate luminometer (Luminoskan, Thermo 
Scientific, France) using the luciferin/luciferase reaction system provided with the kit. 
100 µl of luciferin/luciferase was injected in the wells and after 10 s of incubation; 
bioluminescence was read (1 s integration time). Standardizations were performed 
with known quantities of standard ATP provided with the kit. The ATP content derived 
from mitochondria was determined by subtracting ATProtenone values from ATPtotal 
(ATPmito = ATPtotal – ATProtenone). 
Trypsin sensitivity assays 
100 µg of mitochondria were suspended in isolation buffer, untreated or 
incubated with 0.01% trypsin in the presence or absence of 0.05% Triton X-100 
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during 15 min at 37°C. Proteins were then processed for Western immunoblot 
analyses.  
Immunoprecipitation assays 
Freshly purified brain mitochondria were resuspended in PBS (5 mg/ml) 
supplemented with protease inhibitors cocktail (Roche, France) and 2 mM NaF, and 
solubilized with 1% lauryl maltoside for 30 min (4°C). For co-immunoprecipitation of 
sAC and Gα, mitochondria were incubated with THC (800 nM) or vehicle for 5 min at 
37°C. Proteins were incubated with a C-terminal anti-CB1antibody (Cayman, USA) or 
sAC R21 antibody (CEP Biotech, USA) overnight (4°C). Protein A/G PLUS-Agarose 
beads (Santa Cruz, USA) were then added and the incubation continued for 4h 
(4°C). The elution was performed using glycine buffer (0.2M glycine, 0.05% lauryl 
maltoside, pH 2.5) and samples were processed for Western immunoblotting.  
ERK phosphorylation assays 
Following transfection (control, CB1 or DN22-CB1, respectively), cells were 
allowed to recover in serum containing medium for 24 h. Cells were then starved 
overnight in serum-free DMEM before treatment and lysis. The cells then were 
treated at 37°C with HU210 (100 nM) or vehicle for 10 min.  The media were rapidly 
aspirated and the samples were snap-frozen in liquid nitrogen and stored at −80°C 
before preparation for western blotting.  
Protein Extraction and Western immunoblotting 
Lysis buffer (1 mM EGTA, 50 mM NaF, 1 mM Na3VO4, 50 mM Tris pH 7.5 , 1 % 
Triton X-100, protease inhibitors, 30 mM 2-mercaptoethanol) was added and the 
cells were then collected by scraping and pelleted by centrifugation at 12,500 g (4°C) 
for 5 min to remove cell debris. Protein concentrations were measured using the 
Pierce BCA protein assay kit (Thermo Scientific), loaded with Laemmli buffer and 
kept at −80 °C. 
For Western Immunoblotting, the proteins were separated on Tris-glycine 7, 10 
or 12% acrylamide gels and transferred to PVDF membranes. Membranes were 
soaked in 5% milk (or 5% BSA for phosphorylation immunoblots) in TBS-Tween20 
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(0.05%). Mitochondrial proteins were immunodetected using antibodies against 
complex III core 2 (Abcam, 1:1,000,  
1 h, room temperature), SDHA (Abcam, 1:10,000, 1 h, room temperature) and 
TOM20 (Santa Cruz, 1:1,000, 1 h, 4 °C). Cytosolic proteins were probed with LDHa 
(Santa Cruz, 1:500, overnight, 4 °C). Samples were also probed with antibodies 
against Gα proteins (Enzo Life Science, 1:1,000, 1 h, room temperature), sAC (sAC 
R21, CEP Biotech, 1:500, overnight, 4°C), PKA (cAMP protein kinase catalytic 
subunit, Abcam, 1:1,000, 1 h, room temperature), an antiserum directed against the 
C terminus of CB1receptor (Cayman, 1:200, overnight, 4°C), HA (Abcam, 1:500, 
overnight, 4°C), P-ERK (Phospho-p44/42 MAPK) corresponding to residues around 
Thr202/Tyr204 (Cell signaling, 1:1000, overnight, 4°C ) and ERK (p44/p42 MAPK; 
Cell signaling, 1:2000, 1 h, room temperature). 
Then, membranes were washed and incubated with appropriate secondary 
HRP-coupled antibodies (1 h, room temperature). Finally, HRP signal was revealed 
using the ECL plus reagent (Amersham) and detected by the Bio-Rad Quantity One 
system. Labelings were quantified by densitometric analysis using Image J (NIH) 
software. 
PKA activity and cAMP content assays 
Cyclic AMP levels and PKA activity were assayed on brain-isolated 
mitochondria using the Direct Correlate-EIA cAMP kit (Assay Designs Inc., USA) and 
an ELISA kit (Enzo Life Science), respectively, according to the manufacturers' 
instructions. The different treatments described in the main text were performed at 37 
°C for 1 h. 
Cloning of DN22-CB1 receptors 
The deletion of the first 22 aminoacids (66 base pairs) of the N-terminal in the 
mouse CB1 receptor coding sequence was generated by polymerase chain reaction 
(PCR). Briefly a forward primer hybridizing from the 67th base starting from ATG was 
coupled to a reverse primer hybridizing to the end of the coding sequence, including 
TGA stop codon. In order to guarantee proper translation of the construct the forward 
primer included an ATG codon upstream the hybridizing sequence. The cDNA for 
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∆N22-CB1 was amplified using HF Platinum DNA polymerase (Invitrogen) and 
inserted into PCRII-Topo vector (Invitrogen) according to manufacturer instruction. 
The absence of amplification mismatches was then verified by DNA sequencing. 
Then the cDNA sequence for ∆N22-CB1 was inserted into pcDNA3.1 mammalian 
expression vector using BamHI-EcoRV according to standard cloning procedures. 
Primers used were: forward 5’-ATGgtgggctcaaatgacattcag-3’ (in bold the inserted 
ATG), reverse 5‘-TCAcagagcctcggcagacgtg-3’ (in bold the stop codon). 
Preparation of adeno-associated viruses (AAV) 
The cDNAs coding for mouse CB1, ∆N22-CB1 and hrGFP were subcloned into 
pAM-CBA vector using standard molecular cloning techniques (Soria-Gomez et al., 
2014). The resulting vectors were transfected by Calcium Phosphate precipitation in 
HEK 293 cells together with rAAV helper plasmid pFd6 and AAV1/2 serotype 
packaging plasmids pRV1 and pH21 (McClure et al., 2011). The viruses were then 
purified and tittered as previously described (Benard et al., 2012; Chiarlone et al., 
2014; Soria-Gomez et al., 2014). Virus titers expressed as genomic copies/ml were 
2.9*1010 for rAAV-GFP, 3.5*1010 for rAAV-CB1 and 8.3*1010 for rAAV-∆N22-CB1. 
[35S]GTPγS binding studies 
[35S]GTPγS binding studies were carried out according to the patented 
methodology for the screening of molecules that act through G protein-coupled 
receptors using Cell Membrane Microarrays (Rodriguez and Gutierrez-de-Teran, 
2013). Briefly, Cell Membrane Microarrays were dried 20 min at room temperature 
(RT), then they were incubated in assay buffer (50 mM Tris-Cl; 1 mM EGTA; 3 mM 
MgCl2; 100 mM NaCl; 0,5% BSA; pH 7,4) for 15 min at RT. Microarrays were 
transferred into assay buffer containing 50 µM GDP and 0.1 nM [35S]GTPγS, with 
the cannabinoid agonist, WIN55.212-2, at increasing concentrations (0, 10 nM, 100 
nM, 1 µM and 10 µM), and incubated at 30ºC for 30 min. Non-specific binding was 
determined with GTPγS (10 µM). Finally, microarrays, together with ARC [14C]-
standards, were exposed to films, developed, scanned and quantified. Protein 
concentration in each spot was measured by the Bradford method and used to 
normalize the [35S]GTPγS binding results to nCi/ng protein. Data from the dose–
response curves (5 replicates in triplicate) were analyzed by using the program 
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PRISM (Graph Pad Software Inc., San Diego, CA) to yield EC50 (Effective 
concentration 50%) and Emax (maximal effect) for WIN55,212-2. 
Surgery and drug/virus administration 
C57BL/6-N, CB1+/+ and CB1-/-mice (7-9 weeks of age) were anesthetized by 
intraperitoneal injection of a mixture of ketamine (100mg/kg, Imalgene 500®, Merial) 
and Xylazine (10mg/kg, Rompun, Bayer) and placed into a stereotaxic apparatus 
(David Kopf Instruments) with mouse adapter and lateral ear bars. Mice were allowed 
to recover for at least one week in individual cages before the beginning of the 
experiments. Mice were weighed daily and individuals that failed to regain the pre-
surgery body weight were excluded from the following experiments.  
For intra-HPC injections of drugs, C57BL/6-N mice were bilaterally implanted 
with 1.0 mm stainless steel guide cannulae targeting the hippocampus (HPC) with 
the following coordinates: anterior/posterior (AP) −3.1; medial/lateral(ML) 
±1.3; dorsal/ventral (DV) -0.5. Guide cannulae were secured with cement anchored 
to the skull by screws. The drug injections intra-HPC was performed by using 
injectors protruding 1 mm from the tip of the cannula.  
For viral intra-HPC AAV delivery, CB1+/+ and CB1-/-mice were submitted to 
stereotaxic surgery (as above) and AAV vectors were injected with the help of a 
microsyringe (10 µl Hamilton syringe with a 30-gauge beveled needle) attached to a 
pump (UMP3-1, World Precision Instruments). Mice were injected directly into the 
HPC (0.5 µl per injection site at a rate of 0.5 µl per min), with the following 
coordinates: dorsal HPC, AP -1.8; ML ±1; DV -2.0 and -1.5 ; ventral HPC: AP -3.5; 
ML ±2.7; DV -4 and -3. Following virus delivery, the syringe was left in place for 1 
minute before being slowly withdrawn from the brain. CB1+/+  mice were injected with 
AAV-GFP to generate CB1+/+(GFP) mice; CB1-/- mice were injected with AAV-GFP, 
AAV-CB1 or AAV-DN22-CB1, to obtain CB1-/-(GFP), CB1-/-(CB1) and CB1-/-(DN22-CB1) 
mice, respectively.  Animals were used for experiments 4-5 weeks after injections. . 
CB1 receptor expression was verified by immunofluorescence or electron microscopy 
(see below).  
For intra-SNr injections of drugs, C57BL/6-­‐N	  mice	  were bilaterally implanted with 
3.5 mm stainless steel guide cannulae (Plastics One, USA) targeting the SNr with the 
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following coordinates: AP -3.1, L ± 1.3, DV –3.5, according to Paxinos and Franklin 
(Paxinos, 2004) . Guide cannulae were secured with cement anchored to the skull by 
screws. The drug injections intra-HPC and intra-SNr were performed by using 
injectors protruding 1 mm from the tip of the cannula.  
Fluorescent immunohistochemistry 
Mice were anesthetized with chloral hydrate (400 mg/kg body weight), 
transcardially perfused with Ringer solution [NaCl (135 mM), KCl (5.4 mM), MgCl2 
6H2O (1 mM), CaCl2 2H20 (1.8 mM), HEPES (5 mM)].  Heparin choay (25000 UI/5 
mL) was added extemporarily and tissues were then fixed with 500 ml of 4% 
formaldehyde dissolved in PO4 buffer (0.1M, pH 7.4) and prepared at 4°C. After 
perfusion, the brains were removed and incubated several additional hours in the 
same fixative. Serial vibrosections were cut at 50 µm and collected in PO4 buffer at 
room temperature (RT). Sections were pre-incubated in a blocking solution of 10% 
donkey serum, 0.1% sodium azide and 0.3% Triton X-100 prepared in PO4 buffer for 
30 minutes at RT. Free-floating sections were incubated for 48h (4oC) with goat anti-
CB1 polyclonal antibodies raised against a 31 aminoacid C-terminal sequence 
(NM007726) of the mouse CB1 receptor (CB1-Go-Af450-1; 2 µg/ml; Frontier Science 
Co. Ltd). The antibody was prepared in 10% donkey serum/PB containing 0.1% 
sodium azide and 0.5% Triton X-100. Then, the sections were washed in PO4 buffer 
for 30 minutes at RT. After, the tissue was incubated with fluorescent anti-goat Alexa 
488 (1:200, Jackson ImmunoResearch) for 4 hours and then washed in PO4 at RT, 
before being incubated with DAPI (1:20000) during 10 min for nuclear 
counterstaining. Finally, sections were washed, mounted, dried, and coverslipped 
with DPX (Fluka Chemie AG). The slides were analyzed with an epifluorescence 
Leica DM6000 microscope (Leica).  
Immuno-electron microscopy 
For the characterization of DN22-CB1 protein, CB1+/+(GFP), CB1-/-(GFP), CB1-/-
(CB1) and CB1-/-(DN22-CB1) mice (n = 3 each) were processed for electron 
microscope pre-embedding immunogold labeling as recently described (Benard et 
al., 2012; Hebert-Chatelain et al., 2014). Immunodetection was performed in 50-µm-
thick sections of hippocampus with goat anti-CB1 polyclonal antibodies raised against 
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a 31 aminoacid C-terminal sequence (NM007726) of the mouse CB1 receptor (CB1-
Go-Af450-1; 2 µg/ml; Frontier Science Co. Ltd).  
For intra-SNr electron microscopy, C57BL/6-N mice were processed for 
electron microscope pre-embedding immunogold labeling as recently described 
(Benard et al., 2012; Hebert-Chatelain et al., 2014). Immunodetection was performed 
in 50-µm-thick sections of hippocampus with goat anti-CB1 polyclonal antibodies 
raised against a 31 aminoacid C-terminal sequence (NM007726) of the mouse CB1 
receptor (CB1-Go-Af450-1; 2 µg/ml; Frontier Science Co. Ltd).  
Semi-quantification of mtCB1 receptors 
Immunogold particles were identified and counted. To exclude the risk of 
counting possible false positive mitochondrial labeling, we used a strict semi-
quantification method of mtCB1 receptors as recently described, excluding 
immunogold particles that were located on mitochondrial membranes but at a 
distance ≤ 80 nm from other cellular structures (Hebert-Chatelain et al., 2014). 
Normalized mtCB1 receptor labeling versus total CB1 showed mtCB1 proportion 
versus total CB1. 
Field excitatory post-synaptic potentials (fEPSP) recording  
Mice were anesthetized with isoflurane and killed by decapitation. Brains were 
rapidly removed and chilled in an ice-cold, carbogenated (bubbled with 95% O2-5% 
CO2) cutting solution containing 180 mM Sucrose, 2.5 mM KCl, 1.25 mM CaCl2, 12 
mM MgCl2, 1.25 mM NaH2PO4, 26 mM NaHCO3 and 11 mM glucose (pH 7.4). 
Sagittal hippocampal slices (350 µm thick) were cut using a Leica VT1200S 
vibratome and incubated with artificial cerebrospinal fluid (ACSF) containing 123 mM 
NaCl, 1.25 mM NaH2PO4, 11 mM glucose, 2.5 mM KCl, 2.5 mM CaCl2, 1.3 mM 
MgCl2, and 26 mM NaHCO3 (osmolarity of 298±7, pH 7.4) for 30 min at 34°. The 
slices were subsequently transferred to a holding chamber where they were 
maintained at room temperature until experiments. Slices were individually 
transferred to a submerged chamber for recording and continuously perfused with 
oxygenated (95% O2-5% CO2) bathing medium (3–5 mL/min). All experiments were 
performed at room temperature. Extracellular evoked field potentials (fEPSPs) were 
recorded using glass micropipettes (2–4 mOhm) filled with normal ACSF bathing 
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medium. Slices from the dorsal hippocampus were used preferentially. fEPSPs 
responses were evoked by stimulation (0.1 ms duration, 10–30 V amplitude) 
delivered to stratum radiatum to stimulate the Schaffer collateral fibers using similar 
glass electrodes used for the recordings, in the presence of picrotoxin 100uM. 
Recordings were obtained using an Axon Multiclamp 700B amplifier (Molecular 
Devices). Signals were filtered at 2 kHz, digitized, sampled, and analyzed using Axon 
Clampfit software (Molecular Devices). 
Novel object-recognition memory task 
To study the impact of mtCB1 receptor signaling on cannabinoid-induced 
amnesia, we used the hippocampal-dependent novel object recognition memory task 
in a L-maze [L-M/OR; (Busquets-Garcia et al., 2011; Puighermanal et al., 2013; 
Puighermanal et al., 2009)]. This task was performed with a L-maze made out of dark 
gray Plexiglas with two corridors (35 cm and 30 cm long respectively for external and 
internal V walls, 4.5cm wide and 15 cm high walls) set at a 90° angle and under a 
weak light intensity (50 Lux). 
	  
	  
 The task consisted of 3 sequential daily trials of 9 minutes. Day 1 (habituation): 
mice were placed at the intersection of the two arms and were let free to explore the 
maze. Day 2 (training): two identical objects were disposed at the end of each arm. 
Figure 15.Novel object recognition memory task in a L-maze (L-M/OR).	  
Materials and methods 
 
Tifany	  Desprez	  -­‐	  Doctoral	  Thesis	  –	  University	  of	  BORDEAUX	  
	   	   	   136 
After 9 min of exploration, mice were removed from the maze, injected and placed 
them in their home cages. Day 3 (test): A novel object different in shape, color and 
texture was placed at the end of one of the arm, whereas the familiar object 
remained at the other arm’s end. The position of the novel object and the 
associations of novel and familiar were randomized. Memory performance was 
assessed by the discrimination index (DI). The D.I. was calculated as the difference 
between the time spent exploring the novel (TN) and the familiar object (TF) divided 
by the total exploration time (TN+TF): DI=[TN-TF]/[TN+TF]. Mice receiving the acute 
intra-hippocampal infusion of KH7 (10mM) and WIN (5mg/kg) i.p. were submitted to a 
single L-M/OR session, whereas virally injected mice were tested twice with one 
week interval using different pairs of objects and treated the first time with vehicle 
and the following with WIN. Every pairs of objects were screened to determine 
whether the animals exhibited significant preferences for any specific item. 
Open field and horizontal bar test 
AM251, Hemopressin or KH7 were bilaterally injected into the SNr in a volume 
of 0.5 µl per side. Immediately after, THC (10 mg/kg) was injected i.p. Mice were 
tested, 30 min post-injections, successively for: locomotor activity and catalepsy. To 
evaluate locomotor activity, mice were placed in a plastic transparent box [45cm 
(length) X 34cm (width) X 20cm (height)] with a floor divided into squares. Number of 
crossed squares was measured during five minutes. Then, catalepsy was determined 
by the time of immobility on a bar. To this aim, mice were positioned in a new plastic 
cage (identical to their home cage) without bedding with on a horizontal cylindrical 
bar (0.7cm Diameter) placed at 4.5 cm high with their forepaws gripping the bar and 
its hind paws in the plastic box. The time spent in its initial position on the bar was 
scored for two minutes. All equipment was cleaned with ethanol 25% and dried with 
paper towels between all the trials. 
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Figure 16. Open field and horizontal bar test. 
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Cannabinoid administration in humans induces several therapeutic-relevant 
effects accompanied with undesired side effects, particularly a decline in memory 
performance (Howlett, 2002; Koppel et al., 2014; Pacher et al., 2006). Genetic and 
pharmacological approaches demonstrated that most of these effects are mediated 
by CB1 receptors in the brain (Monory et al., 2007; Pacher et al., 2006; Puighermanal 
et al., 2009; Wise et al., 2009). Nevertheless, the molecular mechanisms involved 
have been only partially explored so far.  
Cannabinoid receptors type-1 are G protein coupled receptor (GPCRs) highly 
expressed in the brain and particularly enriched in the hippocampus, cortex and 
basal ganglia structures (Herkenham et al., 1990; Marsicano and Kuner, 2008). 
These receptors are expressed in different cell types and, at cellular level, they are 
found at both plasma membrane and intracellular compartments (Benard et al., 2012; 
Hebert-Chatelain et al., 2014; Rozenfeld and Devi, 2008). However, to what extent 
the sub-cellular localization of CB1 receptors shapes their functions is virtually 
unknown.  
The fact that the brain, weighing 2% of the body, consumes up to 20% of body 
energy, indicates that bioenergetics processes play peculiar roles in this organ, 
beyond mere “housekeeping” metabolic processes (MacAskill and Kittler, 2010; 
Mattson et al., 2008; Rangaraju et al., 2014). Mitochondria, the main organelles 
devoted to the processing of energy sources and their transformation into ATP, play 
a central role in the modulation of synaptic plasticity and associated physiological 
and pathological brain processes (Kann and Kovacs, 2007; Mattson et al., 2008). By 
providing local ATP supply, buffering of intracellular calcium and other ions, 
modulation of reactive oxygen species, metabolism of steroid synthesis, production 
of several neurotransmitters and many other key cellular functions, mitochondria are 
involved in the large majority of brain functions (MacAskill and Kittler, 2010; Mattson 
et al., 2008; Rangaraju et al., 2014). Accordingly, mitochondrial dysfunctions can 
contribute to the development of neurodegenerative diseases and memory deficits 
(Gibson and Shi, 2010; Mattson et al., 2008; Papa et al., 2012). However, whereas 
the impact of long-term mitochondrial dysfunctions on the brain is the subject of 
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intense research, these studies cannot establish a direct link between mitochondrial 
functions and behavioral outcomes. In fact, long-term mitochondrial dysfunctions lead 
to altered cellular processes, including cell damage and death, which can produce 
behavioral impairments as secondary effects. Conversely, the acute involvement of 
mitochondria in the regulation of animal behavior might establish a more solid link 
between brain bioenergetics processes and functions. However, likely due to the lack 
of specific pharmacological and molecular targets, the acute impact of mitochondrial 
function on memory processes has not been deeply explored so far. 
Our previous studies demonstrated that CB1 receptors are functionally present 
at mitochondrial membranes of brain cells (Benard et al., 2012; Vallee et al., 2014), 
for methodological discussions see (Hebert-Chatelain et al., 2014; Morozov et al., 
2013).  Despite the fact that mtCB1 receptor activation by cannabinoids decreases 
mitochondrial respiration and consequently leads to decrease of ATP cell production 
in brain cells (Benard et al., 2012; Hebert-Chatelain et al., 2014; Vallee et al., 2014), 
the impact of these processes in the central effects of cannabinoids is still unknown. 
Addressing this issue is a difficult task, because it implies the functional 
discrimination, at single cell level in intact animals and tissues, between mtCB1 
receptors located at mitochondrial membranes and CB1 receptors located at other 
subcellular sites. Therefore, the development of new tools is necessary to specifically 
investigate the functional roles of mtCB1 receptors both in vitro and in vivo. 
The following results have been submitted for publication (Tools and amnesic 
effects of cannabinoids) or are in preparation (involvement of sAC signaling in 
cannabinoid-induced locomotor effects). The manuscripts are presented in Annexes. 
In sake of brevity, some data panels are presented only in the Annexes and specific 
references to these panels is made in the text. 
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I. DEVELOPING	  THE	  TOOLS	  
Since no tool is currently available to specifically target mtCB1 receptor activity, we 
decided to deeply investigate the molecular mechanisms linking mtCB1 receptor 
activation to mitochondrial respiration, aiming at identifying specific signaling 
elements, which might be then experimentally targeted in vivo. 
I.1 MtCB1	  receptors	  decrease	  brain	  mitochondrial	  
respiration	  through	  Gαi/o	  proteins	  
Activation of mtCB1 receptors decreases respiration of purified brain 
mitochondria, but this effect was not investigated in living brain cells (Benard et al., 
2012; Hebert-Chatelain et al., 2014; Vallee et al., 2014). The prototypical plant-
derived and synthetic CB1 receptor agonist THC, decreased basal, oligomycin-
insensitive and uncoupled respiration states (using FCCP, see methods) by 
approximately 25 % in primary hippocampal cultures derived from wild-type mice, but 
bore no effect in cultures from CB1-/- mice (Figure 17A-B). These effects were 
associated with reduced cellular and mitochondrial ATP levels (Figures 17C). 
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The presence of G protein signaling has been identified in mitochondria 
(Andreeva et al., 2008; Beninca et al., 2014; Kuyznierewicz and Thomson, 2002; 
Lyssand and Bajjalieh, 2007), together with many downstream molecular cascades, 
such as adenylyl cyclase and protein kinase A (PKA) activities (Acin-Perez et al., 
2009b; Valsecchi et al., 2013).  Thus, we tested whether the GPCR mtCB1 regulates 
brain mitochondrial activity via this signaling cascade. Trypsin sensitivity and co-
immunoprecipitation assays revealed that Gα proteins are present inside isolated 
brain mitochondria (Figure 18A), where they physically interact with mtCB1 receptors 
(Figure 18B). Activation of mtCB1 receptors by THC induced the release of Gα 
proteins from these receptors (Figure 18C-D).  
Figure 17. CB1 receptor agonist, THC, impacts on hippocampal cellular respiration and 
ATP levels. (A-B) THC (1 µM) decreases cellular respiration of primary hippocampal cultures 
derived from CB1+/+ but not from CB1-/- mice (n=15). (C) THC (1 µM) reduces both total and 
mitochondrial (Mito) ATP levels of primary hippocampal cultures derived from CB1+/+ but not from CB1-
/- mice (n=7-8). FCCP, Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (mitochondrial 
oxidative uncoupler). Data, mean ± s.e.m. * p<0.05, ** p<0.01, *** p<0.001. 
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The inhibitor of Gαi/o proteins pertussis toxin (PTX) abolished the effects of 
cannabinoids on mitochondrial respiration, Complex I activity, cAMP levels and PKA 
activity (Figure 19A-D), but it did not alter mitochondrial cAMP levels and PKA 
activity in brain mitochondria from CB1-/- mice (Figure 19E-F). PTX treatment also 
blocked the effect of THC on respiration of primary hippocampal cultures (Figure 
19G). Thus, cannabinoids regulate brain mitochondrial respiration through mtCB1 
receptor-dependent activation of Gαi/o proteins. 
Figure 18. Intramitochondrial signaling. (A) Representative trypsin sensitivity assay (3 
independent experiments) showing the intramitochondrial localization of Gα, sAC and PKA. IB, 
immunoblotting; NDUFA9, subunit of complex I; TOM20, translocase of outer mitochondrial membrane. 
(B) Representative immunoblotting (3 independent experiments) showing that Gα proteins co-
immunoprecipitate with mtCB1 receptors in purified brain mitochondria. (C) Representative 
immunoblotting (3 independent experiments) showing that co-immunoprecipitation of Gα proteins with 
mtCB1 receptors decrease after THC treatment (1 µM) in purified brain mitochondria, indicating release 
of the G protein upon activation of mtCB1 receptors. (D) Quantification of data presented in C (n=3). 
Data are mean ± s.e.m. * p<0.05. 
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Figure 19. Activation of mtCB1 receptor impacts OXPHOS through Gαi/o. (A-D) 
Pertussis toxin (PTX: 1 µg/ml) blocks the effect of THC (800nM) on (A) mitochondrial 
respiration (n=4), (B) complex I activity (n=3), (C) cAMP levels (n=4), and (D) PKA activity 
(n=6-7) of purified brain mitochondria from CB1+/+ mice. (E, F) PTX (1 µg/ml) and THC 
(800nM) do not impact on (E) cAMP levels (n=4) and (F) PKA activity (n=5) in CB1-/- purified 
brain mitochondria. (G) Pertussis toxin blocks the effect of THC (1 µM) on basal cellular 
respiration in primary hippocampal cultures prepared from CB1+/+ mice (n=8-9). Data are mean 
± s.e.m. * p<0.05, ** p<0.01, *** p<0.001. 
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I.2 Mitochondrial	  soluble	  adenylyl	  cyclase	  (sAC)	  is	  
necessary	  for	  mtCB1	  receptor	  signaling	  
In mitochondria, cAMP is mainly produced by soluble adenylyl cyclase (sAC), 
regulating mitochondrial activity through PKA-mediated phosphorylation of OXPHOS 
components (Acin-Perez et al., 2009b). Trypsin sensitivity assays showed that sAC 
and PKA are present within purified brain mitochondria (Figure 18A). The activator of 
the non-mitochondrial transmembrane adenylyl cyclase (tmAC) forskolin had no 
effect per se and did not alter the effect of THC on mitochondrial cAMP levels 
(Figure 20A), indicating that tmACs are not involved in the regulation of OXPHOS by 
mtCB1 receptors. Conversely, the activator of sAC bicarbonate [HCO3-,(Chen et al., 
2000) fully reversed the effects of THC on cAMP in brain mitochondria (Figure 20B).  
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In addition, HCO3- abolished cannabinoid effects on respiration in isolated brain 
mitochondria (Figure 21A) and in cultured hippocampal cells (Figure 21B). 
Consistently, KH7, a sAC inhibitor that does not affect the activity of membrane-
bound adenylyl cyclase(Hess et al., 2005)completely occluded the THC-induced 
decrease of mitochondrial respiration, complex I activity and PKA activity in purified 
brain mitochondria in CB1+/+(Figure 21C-E). Neither KH7 nor THC had any effect on 
mitochondria derived from CB1-/-mice (Figure 21F). 
 
Figure 20. Soluble adenylyl cyclase (sAC) and not transmembrane adenylyl cyclase 
(tmAC) mediates the effects of mtCB1 activation. (A) Forskolin (10 µM) does not reverse 
the effect of THC (800 nM) on cAMP content of CB1+/+brain mitochondria (n=4) a-nd has no effect 
on basal cAMP levels of CB1-/- brain mitochondria (n=3-4). (B) The sAC activator bicarbonate 
(HCO3-, 5mM) reverses the effect of THC (800 nM) on cAMP content of CB1+/+brain mitochondria 
(n=4) and has no effect on basal cAMP levels of CB1-/- brain mitochondria (n=3-4). Data are mean 
± s.e.m. * p<0.05, ** p<0.01. 
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To further confirm the importance of sAC in mtCB1 receptor-dependent 
regulation of OXPHOS, the expression of mitochondrial sAC was modified in cultured 
3T3 cells using HA-tagged sAC protein (sAC-HA), present both in cytosolic and 
mitochondrial fractions, and a mitochondria-targeting form of HA-tagged sAC, 
Figure 21. Soluble adenylyl cyclase (sAC) mediates the effects of mtCB1 receptor 
activation. (A) The sAC activator bicarbonate (HCO3-, 5mM) reverses the effect of THC (800 nM) on 
mitochondrial respiration (n=4-6) in purified brain mitochondria from CB1+/+mice. (B) Bicarbonate reverses 
the effect of THC (1 µM) on basal cellular respiration of primary hippocampal cultures derived from CB1+/+ 
mice (n = 8-11).  (C) The sAC inhibitor KH7 (5 µM) blocks the effect of THC (800 nM) on mitochondrial 
respiration (n=3-4) and (D) complex I activity (n=3) of purified brain mitochondria from CB1+/+mice. (E-
F)KH7 (5 µM) blocks the effect of THC (800 nM) on PKA activity (n=6) of purified brain mitochondria from 
CB1+/+but not fromCB1-/-mice (n=5). Data are mean ± s.e.m. * p<0.05, ** p<0.01, *** p<0.001. 
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[mtsAC-HA, (Acin-Perez et al., 2009b); Figure 22A]. Trypsin sensitivity assays 
showed that CB1 receptors, Gα, endogenous sAC and PKA proteins (Figure 22B), 
and sAC-HA and mtsAC-HA proteins were present inside mitochondria of transfected 
3T3 cells (Figure 22C). The decrease of cellular respiration induced by THC in 
mock-transfected cells was completely blocked in cells transfected with sAC-HA or 
mtsAC-HA, showing the necessity of mitochondrial sAC in mtCB1 receptor-
dependent signaling (Figure 22D). Accordingly, the decrease of complex I activity 
measured on mitochondrial fractions treated with THC was completely blocked in 
3T3 cells transfected with sAC-HA (Figure 22E). In addition, sAC-HA expression 
also blocked the effect of THC on cellular respiration of primary hippocampal cultures 
(Figure 22F). Notably, Gα proteins co-immunoprecipitated with mitochondrial sAC in 
brain mitochondrial extracts, and THC treatment increased this interaction (Figure 
22G-H). Thus, the regulation of OXPHOS by mtCB1 receptors depends on 
mitochondrial sAC activity. Importantly in the present context, the sAC blocker KH7 
occludes these effects, providing a reasonable pharmacological tool to study 
mitochondrial-related effects of cannabinoids in vivo.  
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Figure 22. Soluble adenylyl cyclase (sAC) mediates the effects of mtCB1 receptor 
activation.(A) Representative immunoblot (3 independent experiments) showing that sAC-HA is present 
in cytosolic and mitochondrial fractions whereas mtsAC-HA is specifically targeted to mitochondrial 
fractions of transfected 3T3 cells. (B) Representative trypsin sensitivity assay (from 3 independent 
experiments) showing intramitochondrial localization of CB1 receptors, Gα proteins, PKA and sAC in 3T3 
cells. (C) Representative trypsin sensitivity assay (3 independent experiments) showing that sAC-HA and 
mtsAC-HA are localized inside mitochondria in transfected 3T3 cells. (D) Over-expression of sAC-HA or 
mtsAC-HA in 3T3 cells blocks the effect of THC (800 nM) on basal cellular respiration (n=4). (E) Over-
expression of sAC-HA in 3T3 cells blocks the effect of THC (1 µM) on complex I activity measured in 
mitochondrial fractions (n=3-4). (F) Expression of sAC-HA in CB1+/+ primary hippocampal cultures blocks 
the effect of THC (1 µM) on basal cellular respiration (n = 8-10). (G) Representative immunoblotting 
showing co-immunoprecipitation of Gα proteins with sAC from purified brain mitochondria, which is 
increased after THC (800 nM) treatment. (H) Quantification of data presented in G (n=3). Data are mean ± 
s.e.m. * p<0.05, ** p<0.01, *** p<0.001. 
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I.3 In	  silico	  identification	  of	  DN22-­‐CB1,	  a	  CB1	  mutant	  
protein	  theoretically	  lacking	  mitochondrial	  localization	  
The results obtained so far strongly indicate that the mitochondrial effects of 
CB1 receptor agonists mediate specific behavioral effects of cannabinoids. However, 
these data were obtained using pharmacological tools that are intrinsically exposed 
to uncontrollable potential caveats such as unspecific or off-target effects of drugs. 
Therefore, in order to extend our findings and to provide further tools to study the 
roles of mtCB1 receptors, we investigated the possibility to exclude, by genetic 
mutagenesis, CB1 receptors from mitochondrial membranes. The freely accessible 
softwares MitoProt (http://ihg.gsf.de/ihg/mitoprot.htm) and PSORT 
(http://psort.hgc.jp/) allow identifying the theoretical probability of mitochondrial 
localization of any given protein sequence (Claros, 1995). Interestingly, using these 
tools, the CB1 receptor displays an approximate 40-45% probability to be imported to 
mitochondria (40.6% for MitoProt and 46.7% for PSORT, respectively (Figure 23). 
These values are comparable to the ones of typical mitochondrial proteins and are 
more than one order of magnitude higher than the ones of many other G protein 
coupled receptors (Benard et al., 2012). By in silico “mutagenesis” tests, we found 
that the deletion of the first 22 N-terminal amino acids of the CB1 protein sequence 
decreased its theoretical probability to be imported to mitochondria to approximately 
1% for MitoProt and to 3% for PSORT, respectively (Figure 23). Interestingly, as 
calculated by PSORT, the percentage of probability of plasma membrane localization 
was unchanged by the mutation (60% for both wild type and mutant CB1 proteins 
(Figure 23). Thus, the deletion of the first 22 amino acids of the CB1 protein was 
predicted to exclude the CB1 receptor from mitochondrial membranes, but to 
maintain its presence at cellular plasma membranes. To test this in silico prediction in 
“real life”, we generated a mutant CB1 protein by deleting the first 22 amino acids of 
its sequence and we called it DN22-CB1 (for Delta N-terminus 22 amino acids 
deletion). 
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I.4 DN22-­‐CB1	  receptor	  is	  functional	  but	  it	  does	  not	  impact	  
on	  mitochondrial	  respiratory	  activity	  
To determine whether the deletion of the first 22 amino acids impacts on the 
ability of the CB1 receptor to mediate the cannabinoid effects on cellular respiration, 
we electroporated newborn mouse fibroblasts (MFs) derived from CB1-/- mice with 
plasmids expressing either wild-type CB1 or mutant DN22-CB1 proteins to obtain MF-
CB1 and MF-DN22-CB1, respectively. The synthetic CB1receptor agonists HU 210 or 
WIN did not alter respiration in mock-transfected MFs (mCherry), but they inhibited 
oxygen consumption by approximately 20% in MFs-CB1, respectively (Figure 24A). 
Interestingly, the same treatments in MF-DN22-CB1 did not alter respiration as 
Figure 23. Table of the in silico “mutagenesis” tests. The deletion of the first 22 N-terminal amino 
acids of the CB1 protein sequence decreased its theoretical probability to be imported to mitochondria. 
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compared to vehicle conditions (Figure 24A). In addition, to further confirm the 
differential participation of the intracellular versus extracellular CB1 receptor 
population, we used HU 210-biotin, a synthesized biotinylated version of the CB1 
receptor agonist HU 210, which does not penetrate plasma membranes (Benard et 
al., 2012; Martin-Couce et al., 2012).  
These data indicate that the DN22-CB1 mutant protein lost the ability to mediate 
the intracellular cannabinoid effects on respiration, suggesting that the 22 amino 
acids from the N-terminal tail of the CB1 receptor are necessary for localization 
and/or function of the receptor at mitochondrial membranes. However, this lack of 
cannabinoid effects on cellular oxygen consumption in cells expressing the DN22-
CB1 protein might be merely due to unspecific alterations of the general functionality 
of the CB1 receptor. Thus, to test the ability of DN22-CB1 to mediate CB1 receptor-
dependent cellular pathways different from the control of mitochondrial respiration, 
we transfected the HEK293 cell line with mCherry (mock), CB1 or DN22-CB1, 
respectively. On these cells, we studied the cannabinoid-induced effects on cellular 
respiration and on extracellular-regulated kinases (ERKs) signaling, which is one of 
the most important intracellular effects of CB1 receptor activation (Howlett, 2002). HU 
210 decreased oxygen consumption in HEK293 cells transfected with a plasmid 
expressing the wild-type CB1 receptor, but not in cells expressing a mock protein 
(mCherry) or DN22-CB1 (Figure 24B), confirming the lack of impact of DN22-CB1 
receptors on cannabinoid-dependent mitochondrial effects in different cell types. 
Notably, however, the administration of the CB1 receptor agonist did not alter the 
ERK pathway in mock-transfected HEK293 cells (mCherry), but it clearly stimulated 
ERKs phosphorylation in both CB1- and DN22-CB1-transfected cells to similar extent 
(Figure 24C-D), showing that the mutant CB1 protein is still able to activate CB1 
receptor-dependent pathways not directly related to control of mitochondrial activity. 
Importantly, the cannabinoid agonist WIN55,212-2 stimulated [35S]-GTP-gS binding 
in both CB1- and DN22-CB1-transfected HEK293 cells, with similar potency (214 nM 
vs 260 nM, respectively) and efficacy (74.7% vs 74.3%, respectively), demonstrating 
that the DN22-CB1 mutant receptors conserved the same ability to activate G protein 
signaling as the wild-type CB1 receptors (Figure 24E), and consequently that the 
mutation did not alter the general functionality of the receptor. 
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Figure 24. Mutant DN22-CB1 receptor does not mediate cannabinoid-induced alterations of 
mitochondrial activity, but it can efficiently activate ERK and G protein signaling. (A) Mouse 
fibroblasts (MF) were obtained from CB1-/-pups (P0-P1) and electroporated either with a vector 
expressing mCherry (mock) or the CB1 or DN22-CB1 receptors. Acute treatment with HU 
210 (100nm) reduced cellular oxygen consumption in CB1-expressing intact CB1-/-MF, whereas no 
alteration was observed in DN22-CB1-expressing CB1-/-MF (n=3-10). (B) HEK293 cells 
were transfected with plasmids expressing mCherry or CB1 or DN22-CB1 receptor. HU 210 (200 
nM) treatment decreases HEK293 cellular respiration in cells expressing CB1 but not DN22-CB1 
receptors (n=4). (C) Representative Immunoblotting showing the effect of HU 210 (100 nM) on 
pERK/ERK ratios in HEK293 transfected with plasmids expressing mCherry, CB1 or DN22-CB1, 
respectively. (D) Quantification of pERK/ERK ratios induced by HU 210, as in D (n=7-13). (E) 
Concentration response-curves of WIN55,212-2-stimulation of [35S]GTPγS binding in membranes 
isolated from HEK293 cells transfected with wild-type CB1 or mutant DN22-CB1, respectively. Data 
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Altogether, these results show that the mutant DN22-CB1 protein does not 
functionally impact on mitochondrial cellular respiration, but it still maintains other 
CB1 receptor-like signaling properties, including the ability to stimulate G protein 
signaling and ERK phosphorylation. 
I.5 DN22-­‐CB1	  is	  excluded	  from	  mitochondrial	  membranes	  
To assess the subcellular localization and function of the DN22-CB1 mutant 
protein in vivo, we generated adeno-associated viruses carrying the expression of 
wild-type CB1 or DN22-CB1 proteins (AAV-CB1 and AAV-DN22-CB1, respectively). 
Either of these AAVs was infused into the hippocampus of CB1-/- mice (Figure 25A) 
to obtain mice carrying exclusive hippocampal expression of CB1 [called CB1-/-(CB1) 
mice] or DN22-CB1 proteins [called CB1-/-(DN22-CB1) mice], respectively. 
Immunofluorescence analysis revealed that the efficiency of infection and expression 
of the two viruses were comparable (Figure 25B). 
Results 
 
Tifany	  Desprez	  -­‐	  Doctoral	  Thesis	  –	  University	  of	  BORDEAUX	  
	   	   	   157 
 
 
To determine the subcellular localization of the two proteins, we examined CB1 
receptor immunoreactivity in the hippocampal CA1 region by immunogold electron 
microscopy. As expected (Benard et al., 2012; Hebert-Chatelain et al., 2014), CB1 
receptor gold particles were observed at both plasma and mitochondrial membranes 
of tissues derived from wild-type mice locally treated with a control AAV [CB1+/+(GFP) 
mice, Figure 26A], but not in tissues from CB1-/- mice treated with the same control 
virus [CB1-/-(GFP) mice, Figure 26A). Interestingly, the hippocampal infection of CB1-
/- mice with AAV-CB1 [CB1-/-(CB1) mice] led to the expression of CB1 receptor protein 
Figure 25.Selective expression of adeno-associated virus into the hippocampus. (A) Schematic 
representation of the AAV vectors delivery used in this study (control AAV-GFP and AAV- CB1 and 
AAV-DN22-CB1). Expression was driven by the CMV promoter. High titer, purified virus was prepared 
for stereotaxic injection into the hippocampus of 7-9 weeks CB1+/+and CB1-/- mice. Mice were tested at 
least 4 weeks after gene delivery. (B) Immunofluorescence for CB1 receptors in hippocampal brain 
sections from CB1-/- mice bilaterally injected into the hippocampi with AAV-DN22-CB1 or CB1 or GFP 
(control), and their respective wild-type CB1+/+ littermates injected with GFP.  
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both at plasma and mitochondrial membranes (Figure 26A), whereas the DN22-CB1 
protein appeared to be excluded from mitochondrial membranes in CB1-/-(DN22-CB1) 
mice (Figure 26A). Semi-quantitative counting of gold particles using strict 
parameters to define mitochondrially-located CB1 receptor immunoreactivity (Hebert-
Chatelain et al., 2014) confirmed these observations. Approximately 10% of the total 
CB1 receptor-positive gold particles were identified on CA1 mitochondria in wild-type 
CB1+/+(GFP), whereas less than 2% of background gold particles were observed at 
mitochondrial membranes in hippocampi of negative control CB1-/-(GFP) mice 
(Figure 26B). The viral re-expression of the entire CB1 protein in CB1-/-(CB1) mice led 
to a similar proportion of mtCB1 gold particles as in wild-type controls (Figure 26B). 
Notably, CB1-/-(DN22-CB1) mice displayed a very similar proportion of mitochondrial 
staining as CB1-/-(GFP) littermates (Figure 26B), indicating that the mtCB1 proportion 
in these mice did not overcome background levels.  
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Thus, the mutant DN22-CB1 protein is excluded from brain mitochondria and is 
functionally unable to modulate mitochondrial functions. The mutant protein, 
however, can still localize to other subcellular sites (e.g. plasma membrane) and 
regulate CB1 receptor-dependent activation of G proteins and the ERK pathway. 
Thus, DN22-CB1 is an optimal tool to study the role of mtCB1 receptor activation in 
brain functions and behavior.  
 
Figure 26. DN22-CB1 receptors are excluded from mitochondrial membranes in 
hippocampus. (A) Electron microscopy of immunogold staining in the CA1 hippocampal region 
showing the expression of CB1 in different mutant mice. The presence of mtCB1receptors is observed 
in CB1+/+ (GFP) and CB1-/-(CB1), but not in CB1-/-(GFP) or CB1-/-(DN22-CB1). (B) Semi-quantification of 
the percentage of gold particles in mitochondria normalized by the total gold particles (n=3). 
CB1+/+(GFP) and CB1-/-(CB1) exhibit a significant higher proportion of mtCB1 proteins as compared 
toCB1-/-(DN22-CB1) and CB1-/-(GFP). Data are mean ± s.e.m. ** p<0.01 as compared to the percentage 
of the CB1+/+ (GFP). See main text for definition of the different groups of mutant mice. 
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Conclusion 
In order to address the potential role of intracellular mtCB1 receptors, we 
identified the precise intramitochondrial biochemical cascade linking mtCB1 receptor 
activation to decrease of cellular respiration and ATP production. We found that the 
soluble adenylyl cyclase (sAC), the only AC known to be present in mitochondria 
(Valsecchi et al., 2013), is necessary for these effects. 
To enlarge the tool panel to study mtCB1 receptor functions and to overcome 
potential caveats of pharmacological tools, such unspecific or off-target effects of 
drugs like KH7, we identified and generated a mutant protein, DN22-CB1, which lacks 
the first 22 amino acids of the CB1 receptor sequence. Agonist stimulation of DN22-
CB1 receptors in transfected cells does not alter mitochondrial respiration, but still 
induces other CB1 receptor-dependent signaling, such as activation of P-ERK and 
activation of G proteins. 
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II. ROLE	  OF	  HIPPOCAMPAL	  MTCB1	  RECEPTOR	  
ACTIVATION	  IN	  SYNAPTIC	  ACTIVITY	  AND	  MEMORY	  
Next, we aimed at determining the specific impact of mtCB1 receptor signaling 
on memory-disrupting effects of cannabinoids. Thus, we took advantage of the 
identification of the molecular pathways induced by mtCB1 receptor activation leading 
to decreased mitochondrial activity in brain cells, and used drugs able to block these 
pathways to investigate the specific roles of mtCB1 receptor signaling in typical 
cannabinoid effects such as reduction of neurotransmitter release and amnesia. 
Then, we strengthened these pharmacological studies by using the genetic tool 
described above (DN22-CB1) specifically designed to exclude the mitochondrial 
localization of CB1 receptors and, thereby, to lack mtCB1 receptor signaling. Our data 
demonstrate the specific roles of mtCB1 receptor signaling in cannabinoid amnesic 
effects and, thereby, establish a causal link between bioenergetics and behavioral 
memory processes.  
II.1 sAC	  activity	  is	  required	  for	  cannabinoid-­‐induced	  
decrease	  of	  hippocampal	  excitatory	  neurotransmission	  
Cannabinoids are well known to decrease neurotransmitter release in the 
hippocampus (Kano et al., 2009). Despite some initial studies on inhibitory 
neurotransmission using indirect tools (Benard et al., 2012), no data are so-far 
available concerning the potential role of mtCB1 receptors in the cannabinoid-induced 
decrease of excitatory hippocampal neurotransmission. We examined the effect of 
sAC inhibition on the cannabinoid-induced decrease of field excitatory postsynaptic 
potentials (fEPSP) at hippocampal CA3-CA1 synapses. Applications of the CB1 
receptor agonist HU 210 reduced the slope of fEPSP by almost 50% of the baseline 
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levels (Figure 27A). The application of the sAC inhibitor KH7 did not exert any 
measurable effect on baseline fEPSPs (Figure 27B), but it abolished the HU 210-
induced decrease of fEPSP slopes (Figure 27A). 
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Figure 27. Blockade of mtCB1 receptor signaling in the hippocampus impairs the 
effects of cannabinoid on glutamatergic transmission and object recognition 
memory.(A) Effects of KH7 (10 µM) on HU 210 (2.5 µM)-induced in vitro decrease of fEPSP at CA3-
CA1 synapses from C57BL/6-N mice. (Left) Plots of normalized fEPSP slopes in vitro with 
representative fEPSP traces before (1) and after (2) vehicle or HU 210 incubation. Vehicle (n=4) or 
KH7 (n=5) were pre-incubated 10 min before cannabinoid application. (Right) Histogram summarizing 
the average changes in percentage of fEPSP slope before (100% baseline, dotted line) and after HU 
210 treatment in presence or absence of KH7. (B) KH7 does not affect the basal fEPSP. (C) 
Cannabinoid-induced inhibition of object recognition memory performance is blocked by KH7 injection 
in the hippocampus.  Discrimination index values in the object-recognition test showing the effect of 
WIN55,212-2 (i.p., 5 mg/kg) in C57BL/6-N miceintra-hippocampally injected with vehicle or KH7 (2 µg 
in 0.5 µl).N=7-14 per group. Data are mean ± s.e.m. * p<0.05, ** p<0.01. 
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II.2 sAC	  activity	  is	  required	  for	  cannabinoid-­‐induced	  
impairment	  of	  object	  recognition	  memory	  
Cannabinoids strongly impair hippocampal-dependent novel object recognition 
memory tested in a L-maze [L-M/OR; (Busquets-Garcia et al., 2011; Puighermanal et 
al., 2013; Puighermanal et al., 2009)]. As expected, the systemic administration of 
the CB1 receptor agonist WIN immediately after task acquisition impaired L-M/OR 
performance in C57BL6-N mice (Figure 27C) without altering total objects 
exploration (not shown). Interestingly, however, the local intra-hippocampal 
administration of KH7 abolished this effect (Figure 27C), indicating the involvement 
of sAC activity in this cannabinoid-induced alteration of memory performance.  
Taken together, these results show that KH7 occludes the mtCB1-dependent 
reduction of mitochondrial respiration and inhibits specific effects of cannabinoids, 
such as reduction of excitatory synaptic transmission and consolidation of memory in 
the hippocampus. 
II.3 Hippocampal	  mtCB1	  receptor	  signaling	  mediates	  the	  
cannabinoid	  effects	  on	  glutamatergic	  transmission	  and	  
object	  recognition	  memory	  
The effects of cannabinoid agonists on fEPSPs in the CA3-CA1 pathway are 
known to depend on CB1 receptors and to be absent in hippocampal slices from CB1-
/- mice (Kano et al., 2009). Thus, to study the role of mtCB1 receptors in this 
electrophysiological effect, we used hippocampal slices derived from CB1-/-(CB1) and 
CB1-/-(DN22-CB1) mutant mice, respectively. Viral re-expression of CB1 receptor was 
able to rescue the effect of HU 210 in hippocampal slices derived from CB1-/-(CB1) 
mice (Figure 28A). However, the CB1 receptor agonist was not able to reduce fEPSP 
slopes in hippocampal slices derived from CB1-/-(DN22-CB1) mice (Figure 28A), 
indicating that mitochondrial localization of the CB1 receptor is required for this 
electrophysiological effect of cannabinoids.  
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To study the impact of hippocampal mtCB1 receptor signaling on cannabinoid-
induced impairment of memory, CB1+/+(GFP), CB1-/-(GFP), CB1-/-(CB1) and CB1-/-
(DN22-CB1) mice were tested in the L-M/OR task.  As expected (Puighermanal et al., 
2009), all mice treated after acquisition with vehicle displayed a normal discrimination 
index during testing 24 hours later, independently of genotype and viral treatment 
(Figure 28B). One week later, the same animals were trained with a different pair of 
objects (Puighermanal et al., 2013) and challenged immediately post-acquisition with 
the cannabinoid agonist WIN (i.p.). The drug did not alter total object exploration in 
any group (not shown). However, WIN strongly reduced the object discrimination 
index in positive controls CB1+/+(GFP) mice, but not in negative controls CB1-/- (GFP; 
Figure 28B), confirming that the amnesic effect of cannabinoids in the L-M/OR task 
depends on CB1 receptors (Puighermanal et al., 2009). Notably, the effect of WIN 
was fully restored by hippocampal viral re-expression of wild-type CB1 receptors in 
CB1-/-(CB1; Figure 28B). However, CB1-/-(DN22-CB1) carrying re-expression of the 
mutant CB1 protein lacking mitochondrial localization and function remained 
insensitive to WIN (Figure 28B). 
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Figure 28. DN22-CB1 receptors in the hippocampus impair the effects of cannabinoid 
on glutamatergic transmission and object recognition memory.(A) Effect of HU 210 (2.5 
µM) of CA3-CA1 fEPSP slopes in hippocampal slices derived from CB1-/-(CB1) and CB1-/-(DN22-CB1) 
mice. (Left) Plots of normalized fEPSP slopes in vitro with representative fEPSP traces before (1) and 
after HU 210 treatment (2). (Right) Histogram summarizing the average change in percentage of 
fEPSP slopes. CB1 but not DN22-CB1 receptors activation decreases fEPSP slope in the hippocampus. 
(B) Cannabinoid-induced alteration of object recognition memory performance is dependent of mtCB1 
activation in the hippocampus.  Discrimination index values in the object-recognition test of CB1+/+ 
(GFP) (n=7), CB1-/-(GFP) (n=16), CB1-/-(CB1) (n=12) and CB1-/-(DN22-CB1) (n=11) mice treated with 
Vehicle (white bars) and the CB1 agonist WIN55,212-2 (5 mg/kg, i.p., grey bars). Data, mean ± s.e.m. * 
p<0.05, *** p<0.001. 
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Altogether, these data indicate that hippocampal mtCB1 receptors are 
necessary for the cannabinoid-induced reduction of excitatory synaptic transmission 
and for the amnesic effects of cannabinoid drugs.  
Conclusion 
The present study shows that the direct control of brain mitochondrial activity by 
hippocampal mtCB1 receptors mediates well-known cannabinoid-induced synaptic 
and behavioral effects. Several pieces of evidence converge to support this 
conclusion (See Graphical abstract Figure 35).  
Cannabinoids are well known to reduce hippocampal synaptic transmission and 
to impair object recognition memory (Kano et al., 2009; Puighermanal et al., 2012). 
Notably, the sAC inhibitor KH7 is able to block these in vitro and in vivo hippocampal 
effects of cannabinoids, strongly suggesting that mtCB1 receptor signaling is 
necessary for these effects. Viral expression of DN22-CB1 or wild-type CB1 proteins 
in the hippocampus of CB1-/- mice revealed that the mutant protein is not addressed 
to mitochondrial membranes. In vitro electrophysiological recordings and in vivo 
object recognition memory assays revealed that CB1 receptor-dependent decrease of 
fEPSPs in hippocampal slices and the amnesic effect of cannabinoids on object 
recognition memory are rescued in CB1-/- mice bearing viral re-expression of wild-
type CB1 receptor in the hippocampus, but not by viral re-expression of the DN22-
CB1 mutant, respectively. Thus, by using several different and independent 
experimental approaches, we present converging evidence that mtCB1 receptor 
signaling in the brain is necessary for amnesic effects of cannabinoid drugs, 
demonstrating an acute role of mitochondrial activity in mnemonic processes. 
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III. SOLUBLE	  ADENYLYL	  CYCLASE	  (SAC)	  MEDIATES	  THE	  
EFFECTS	  OF	  INTRACELLULAR	  CB1	  RECEPTORS	  ON	  
MOTOR	  CONTROL	  
It is well established that cannabinoid administration induces decrease of 
spontaneous locomotor activity and impairment of movement’s initiation, also known 
as catalepsy (Daigle 2011, Monory et al., 2007, Sulcova 1998). These responses are 
mediated by CB1 receptors as they are blocked by specific CB1 receptor antagonists 
and are absent in null CB1-/- mice (Howlett, 2002; Zimmer et al., 1999; Monory et al., 
2007). CB1 receptor is the main target of cannabinoids in the central nervous system 
and it is considered as one of the most abundant G protein coupled receptor 
(GPCRs) in the brain (Herkenham et al., 1990; Marsicano and Kuner, 
2008)(Marsicano and Kuner 2008). The basal ganglia circuit, which consists in 
several nuclei participating in the planning and the control of motor behaviors, is 
particularly enriched of CB1 receptors, (Herkenham et al., 1990). Within this circuit, 
the Substantia Nigra pars reticulata (SNr) contains one of the highest densities of 
brain CB1 receptors, mainly located at axonal terminals (Herkenham et al., 1990; 
Wallmichrath and Szabo, 2002a Marsicano, 2008). The use of CB1 mutant mice 
helped to reveal the cell specificity of the cataleptic effect produced by cannabinoids. 
Particularly, D1-CB1-/- mice, carrying a CB1 receptor deletion in dopamine receptor 1 
(D1)-positive cells do not present catalepsy under cannabinoid treatment (Monory 
2007). 
Additionally, CB1 receptors are found in several cell populations and different 
subcellular compartments (Freund and Hajos, 2003; Marsicano and Kuner, 2008; 
Rozenfeld and Devi, 2011). Our previous studies demonstrated that CB1 receptors 
are functionally present at mitochondrial membranes of brain cells [mtCB1, (Benard 
et al., 2012; Vallee et al., 2014), and data above in this Thesis)]. Shortly, we have 
shown that mtCB1 receptors decrease mitochondrial respiration and complex I 
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enzymatic activity via soluble adenylyl cyclase (sAC)-dependent signaling. 
Mitochondrion in the brain is a key organelle for maintaining cellular energy 
homeostasis, but it is also involved in others processes such as calcium buffering, 
free radicals production and regulation of apoptosis (Mattson et al., 2008)(MacAskill 
and Kittler, 2010). In addition, impaired mitochondrial function negatively affects 
synaptic plasticity and leads to cognitive deficits and behavioral abnormalities (Kann 
and Kovacs, 2007; Rangaraju et al., 2014). Accordingly, mitochondrial dysfunctions 
are associated with locomotor neurodegenerative diseases, such as Parkinson's 
disease and Huntington’s disease (Chaturvedi and Flint Beal, 2013). However, the 
direct effect of acute mitochondrial impairment on motor behavior has not been 
investigated yet.  
In this part of the work, I first investigated whether the SNr is the brain region 
where THC-dependent effects on locomotor performance are exerted. Then, I 
addressed whether THC acts at plasma membrane or intracellular CB1 receptors and 
whether sAC activity is necessary to exert these effects. Finally, as suggested by the 
anatomical identification of mtCB1 receptors in the SNr, we asked whether acute 
alteration of brain mitochondrial activity might participate in these effects of THC. 
III.1 CB1	  receptors	  in	  the	  SNr	  mediate	  THC-­‐induced	  
hypolocomotion	  and	  catalepsy	  
Interestingly, the SNr is one of the brain regions containing the highest levels of 
CB1 receptor protein (Herkenham et al., 1991a; Marsicano and Kuner, 2008; 
Wallmichrath and Szabo, 2002). Immunoflurorescence experiments revealed, 
indeed, an intense CB1 receptor in the SNr of CB1+/+ mice, but not in CB1-/-mice 
(Figure 29A-B). Therefore, I decided to test whether a blockade of CB1 receptors in 
this brain region is able to inhibit the motor effects induced by THC. The systemic 
administration of a high dose of THC (10 mg/kg) induced strong hypolocomotion and 
catalepsy in C57BL/6-N mice. The local infusion of the specific CB1 receptor 
antagonist AM251 into the SNr fully blocked both the cataleptic and the 
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hypolocomotor effects of THC (Figure 29C-D).  This indicates that CB1 receptor 
activation within the SNr is necessary for the THC effects on motor performance. 
 	  
III.2 Subcellular	  localization	  of	  CB1	  receptors	  determines	  
THC-­‐induced	  motor	  effects	  
III.2.1.1 Effect	  of	  Hemopressin,	  a	  cell-­‐impermeant	  CB1	  receptor	  antagonist,	  
on	  hypolocomotion	  and	  catalepsy	  induced	  THC	  
THC and AM251 are lipophilic compounds, which can easily pass through lipid 
membranes and, thereby, can activate or antagonize both plasma membrane and 
Figure 29. CB1 receptor activation into the SNr mediates the hypolocomotor and 
cataleptic effects of THC. Immunofluorescence for CB1 protein on sagittal sections of CB1+/+ and 
CB1-/- mice confirmed the strong expression of CB1 receptor in the SNr (A and B, dotted line). (C-D) 
Intra-SNr bilateral injection of AM251 (4µg) blocks the hypolocomotor and cataleptic effects induced by 
THC (10mg/kg, i.p.) on C57BL/6-N mice (n=5-11). Data, mean ± s.e.m. *p<0.05, ** p<0.01, *** p<0.001 
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intracellular CB1 receptors, respectively. To distinguish between the relative impacts 
of these two subcellular pools of CB1 receptors on the THC-induced hypolocomotion 
effects in the SNr, we locally administered the CB1 receptor antagonist Hemopressin 
into this brain area. Hemopressin is a peptide compound, which is unable to 
penetrate intracellular compartments and, thereby, can antagonize only pmCB1 
receptors, but not intracellular ones (Benard et al., 2012; Heimann et al., 2007; 
Rozenfeld and Devi, 2008). Intra-SNr Hemopressin, without any effect by itself, 
partially blocked the hypolocomotor effect induced by THC (10 mg/kg; Figure 30A). 
In contrast, Hemopressin administered into the SNr did not reverse the THC-induced 
catalepsy (Figure 30B). 
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III.2.1.2 Presence	  of	  mtCB1	  receptors	  in	  the	  SNr	  
We have previously shown the functional presence of CB1 receptors on 
mitochondrial membranes of the hippocampus (Benard et al., 2012; Hebert-Chatelain 
et al., 2014). Thus, we examined the distribution of CB1 receptors in the SNr using 
the immunogold electron microscopy. Like in many other brain regions, the majority 
of CB1 protein is located at the plasma membrane (pmCB1) of synaptic terminals of 
the SNr (Figure 31A-B). However, semi-quantifications of gold particles using strict 
Figure 30. Plasma membrane CB1 receptors in the SNr partially mediate cannabinoid-
induced hypolocomotion. (A; Left) Hemopressin local injections cause a significant, but partial, 
blockade of THC-induced decrease of locomotor activity. (Right) Intra-SNr Hemopressin partially 
reversed the hypolocomotion induced by THC (10mg/kg, i.p.). (B) Intra-SNr Hemopressin injections do 
not block the cataleptic effect of THC (10mg/kg, i.p.) on C57BL/6-N mice. Mean ± s.e.m. *p<0.05, *** 
p<0.001 as compared to vehicle. 
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parameters to identify mitochondrial-localized immunoreactivity (Hebert-Chatelain et 
al., 2014) revealed that approximately 10-15% of SNr mitochondria contain CB1 
receptor immunoreactivity (mtCB1) whereas less than 2% of mitochondrial sections 
showed non-specific immunoreactivity in CB1-/-mice (Figure 31C). Thus, mtCB1 
receptors are present also in the SNr and might participate in the hypolocomotor 
and/or cataleptic effects of THC. 
 
Results 
 
Tifany	  Desprez	  -­‐	  Doctoral	  Thesis	  –	  University	  of	  BORDEAUX	  
	   	   	   174 
 
III.2.1.3 Locomotor	  effects	  of	  THC	  depend	  on	  sAC	  activity	  in	  the	  SNr	  
As described above, we found that mtCB1 receptor signaling within 
mitochondria involves the soluble adenylyl cyclase (sAC), and this pathway regulates 
in vivo amnesic effects induced by cannabinoids via mtCB1 receptors. Thus, we 
Figure 31.Subcellular distributions of CB1 receptors in the SNr. (A, B) Immuno electron 
detection of CB1receptors in neuronal terminals of the SNr. Pre-embedding silver-intensified 
immunogold method. (A) In CB1+/+ mice, CB1 immunoparticles are localized on presynaptic terminal 
(ter) membranes (green arrows) and on mitochondrial (m) membrane segments close to (distance ≤ 80 
nm; blue arrows) or far away from other membranes (distance ≥ 80 nm; pink arrows). (B) The CB1 
expression pattern is abolished in the SNr from CB1-/- mice. den: dendrite. Scale bars: 0.5 µm. (C) 
Semi-quantitative analysis of the proportion of CB1 immunolabeled mitochondria in the SNR from CB1+/+ 
and CB1-/- mice. Only mitochondria with particles distant from other membranes (≥ 80 nm) were 
considered (see panel A). Data are obtained from at least 15 images of each mouse (n=3 per 
genotype). These data were provided by Pedro Grandes (Bilbao, Spain). 
Results 
 
Tifany	  Desprez	  -­‐	  Doctoral	  Thesis	  –	  University	  of	  BORDEAUX	  
	   	   	   175 
decided to use the sAC inhibitor KH7 to evaluate the potential role of 
intramitochondrial mtCB1 receptor signaling in THC locomotor and cataleptic effects.  
Hypolocomotion 
Intra-SNr infusions of KH7 alone (2µg/site) did not affect locomotor activity 
(Figure 32A), whereas, as expected, THC alone (10 mg/kg, i.p.) induced strong 
hypolocomotion (Figure 32A). However, the co-administration of systemic THC and 
intra-SNr KH7 resulted in a significant reduction (albeit incomplete) of this effect, 
similarly to hemopressin (Figure 32A).  
Catalepsy 
Intra-SNr infusions of KH7 alone did not induce any observable cataleptic 
effect, whereas, the systemic injection of THC profoundly reduced the ability of mice 
to initiate movements (Figure 32B). The combination of the two treatments, however, 
strongly reduced the cataleptic effect of THC (Figure 32B). These data show that 
CB1 receptor-dependent sAC activity within the SNr is necessary for THC-induced 
catalepsy.  
Altogether, these results suggest that activation of both pmCB1 receptors and 
mtCB1-dependent signaling in the SNr participates in the regulation of hypolocomotor 
effects of THC. However, only CB1 receptor-dependent sAC activity within the SNr 
mediates the THC-induced catalepsy. 
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III.3 Reduction	  of	  brain	  mitochondrial	  activity	  facilitates	  
motor	  effects	  of	  THC	  
Why not using rescue approaches: technical considerations 
The results presented so far indicate that intracellular CB1receptor-dependent 
modulation of sAC activity in the SNr partially mediates cannabinoid-induced 
hypolocomotion, whereas it fully accounts for the cataleptic effect of THC. 
Figure 32.sAC activity in the SNr mediates cannabinoid-induced hypolocomotion and 
catalepsy. (A; Left) Intra-SNr injection of KH7 causes a significant reduction but partial of 
cannabinoid-induced decrease of locomotion. (Right)Intra-SNr KH7 injections partially reversed the 
hypolocomotion induced by THC (10mg/kg, i.p.).(B) Intra-SNr KH7 infusion fully reverses the 
cataleptic effect of THC (10mg/kg) Data, mean ± s.e.m. *p<0.05, *** p<0.001 as compared to vehicle. 
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Considering that sAC is necessary for the effects of mtCB1 receptor activation and 
that mtCB1 receptors are present at synaptic terminals in the SNr, these data suggest 
an involvement of mitochondrial processes in these effects. In this specific case, the 
use of the DN22-CB1 mutant receptor is more difficult than in the case of memory 
processes in the hippocampus(see above), because CB1 receptors in the SNr are 
expressed at neuronal terminals, whose cell bodies are likely located very distally, 
mainly in the striatum, but possibly also in other brain regions. The striatum is a large 
region and targeting all neurons projecting to the SNr by local viral injections is an 
extremely difficult task. Indeed, I made several attempts to re-express CB1 receptors 
in the dorsal striatum (the striatal part containing higher levels of CB1 transcripts, 
(Marsicano and Lutz, 1999) of CB1-/- mice, but I was never able to rescue the 
locomotor effects of THC in these mice (data not shown). This could be due to 
several reasons: (i) Viral vectors can infect only a limited number of neurons in a 
given brain region. As there is no clear topographical pattern in the distribution of 
specific nigral-projecting neurons in the striatum, it is virtually impossible to know 
which terminals of striatonigral neurons expressing CB1 receptors are the ones 
involved in the locomotor effects of THC. Therefore, the viral CB1 receptor re-
expression might simply target the “wrong” neurons in the dorsal striatum. (ii) 
Previous data suggest that D1R-expressing neurons should be the ones responsible 
of the cataleptic effects of THC (Monory et al., 2007). Therefore, we might need more 
specific expression vectors to obtain rescue of THC effects in global CB1-/- mice only 
in certain neuronal subpopulations. (iii) Besides striatal neurons, other neuronal 
populations projecting to the SNr could be the ones responsible for the locomotor 
effects of THC. For instance, local interneurons might contain CB1 receptors and 
participate in the locomotor effects of THC. Moreover, in these re-expression 
experiments, we focused our attention to the dorsal striatum, because this portion 
contains the highest amounts of CB1 receptors (Marsicano and Lutz, 1999). 
However, also neurons located in the ventral striatum (nucleus accumbens) contain 
moderate, but significant levels of CB1 mRNA (Hermann et al., 2002; Marsicano and 
Lutz, 1999; Marsicano and Kuner, 2008). A reduction of CB1 receptor expression in 
the ventral striatum has been described in conditional mutant mice lacking CB1 
receptors in D1R-positive striatal neurons has been observed, together with their loss 
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of THC-induced cataleptic effect (Monory et al., 2007). Considering that accumbal 
neurons can also directly project to the SNr (Heimer et al., 1991), it is possible that 
ventral striatal neurons might be the ones to target for viral CB1 re-expression 
experiments. 
These considerations will be taken into account for future experiments. 
However, independently of its methodological causes, the lack of rescue of THC 
locomotor effects in CB1-/- mice carrying local expression of wild-type CB1 in the 
dorsal striatum (not shown) impeded so far the comparison with DN22-CB1 local 
expression in the same area.  
Effects of central rotenone on THC-induced hypolocomotion and 
catalepsy 
Thus, to test the potential link between the hypolocomotor and cataleptic effects 
of activation of intracellular SNr CB1 receptors and mitochondrial processes, we 
adopted an indirect pharmacological approach. We evaluated whether central 
mitochondrial alteration by the classical complex I inhibitor rotenone, could impact 
THC effects on motor performance.  
As expected, the systemic administration of 10 mg/kg THC induced strong 
hypolocomotion and catalepsy in mice (Figure 33A-B). However, a lower dose of 
THC (2 mg/kg i.p.) was not sufficient to produce any observable effect on locomotion 
or catalepsy (Figure 33A-B). Similarly, intra-cerebro-ventricular (i.c.v.) injections of a 
low dose of rotenone (1 µg) did not induce any significant effect (Figure 33C-D). 
However, the co-administration of rotenone (1 µg i.c.v.) and the low dose of THC (2 
mg/Kg i.p.) produced very similar hypolocomotion and catalepsy as the higher dose 
of THC (Figure 33C-D, compared with Figure 33A-B), indicating that alterations of 
brain mitochondrial activity are able to potentiate these cannabinoid effects. Together 
with the data presented above, these results strongly suggest a role of mitochondria 
in the cannabinoid regulation of motor performance, reinforcing the idea that mtCB1 
receptors in the SNr might be responsible of these effects.  
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Conclusions	  
Using systemic and local pharmacology and neuroanatomical approaches, we 
identified the SNr as a brain region where THC exerts hypolocomotor and cataleptic 
behavioral effects. Immunogold electron microscopy revealed that CB1 receptors are 
present both at plasma and mitochondrial membranes of neuronal terminals in the 
SNr. Local injections of the cell permeable or impermeable CB1 receptor antagonists 
AM251 or Hemopressin, respectively, indicated that intracellular SNr CB1 receptors 
are necessary for hypolocomotor and cataleptic effects of THC. Intra-SNr 
administration of KH7 indicated that sAC signaling (previously shown to depend on 
Figure 33.Inhibition of mitochondrial activity potentiates CB1 dependent 
hypolocomotion and catalepsy. Effect of THC (2 and 10 mg/kg) on C57BL/6N mice on (A) 
locomotor activity in an open field, and (B) on immobility in the bar test for catalepsy. Co-
administration of rotenone (1 µg icv) and the subthreshold dose of THC (2 mg/kg) produce 
hypolocomotion (C) and catalepsy (D). Veh, vehicle. Values, mean ± s.e.m. **P < 0.01 as compared to 
control. 
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mtCB1 receptor activation) is involved in THC-induced hypolocomotion (partial 
blockade) and catalepsy (complete blockade). Finally, i.c.v. injections of a per se 
ineffective dose of the mitochondrial inhibitor rotenone were able to potentiate both 
hypolocomotor and cataleptic effects of THC.  
Thus, these data present anatomical and pharmacological compelling evidence 
suggesting that mtCB1 receptor signaling in the SNr is responsible, at least in part, of 
locomotor effects of cannabinoids in mice. 
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DISCUSSION	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IV. SUMMARY	  OF	  MAIN	  RESULTS	  
Cannabinoids affect a variety of functions including appetite, pain, mood, motor 
control, memory and perception through CB1 receptors. These receptors are widely 
distributed throughout the brain and localize at both plasma and intracellular 
membranes. Since their discovery as classical GPCRs, the impact of CB1 receptors 
on behavior is commonly assigned to the receptor pool located at plasma 
membranes, whereas CB1 receptor immunolabeling observed within the cell is 
generally considered evidence of trafficking of the protein (Jong et al., 2014). 
Recently, our laboratory has demonstrated that a portion of intracellular CB1 
receptors is functionally located at mitochondrial membranes (mtCB1), where they 
can depress brain mitochondrial activity (Benard et al., 2012). My work aimed at 
determining to which extent mtCB1 receptors participate to mnemonic and locomotor 
CB1-dependent behavioral effects of cannabinoids.  
The first challenge of this project was to tease apart the roles of mtCB1 versus 
CB1 receptors at different cellular location. To this aim, we adopted novel 
pharmacological and genetic tools. The pharmacological approach was based on the 
characterization of the intra-mitochondrial signaling cascade linking mtCB1 receptor 
activation to decrease of respiration. We found that mtCB1 receptor-dependent 
decrease of OXPHOS depends on the inhibition of the mitochondrial sAC/cAMP/PKA 
pathway. Specific pharmacological targeting of sAC, using the inhibitor KH7, blocked 
the effect of mtCB1 receptor activation in cell cultures and in brain isolated 
mitochondria. In combination, we used Hemopressin, a cell-impermeant CB1 
receptors antagonist, which permits to discriminate the role of pmCB1 versus 
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intracellular CB1 receptors (Heimann et al., 2007). To further enlarge the tool panel to 
study mtCB1 receptor functions, we designed a functional mutant protein, DN22-CB1, 
which lacks the first 22 amino acids of the CB1 sequence. Using electron microscopy 
approach, we confirmed that viral hippocampal expression of DN22-CB1 receptor is 
not addressed at the mitochondrial compartment as compared to wild-type CB1 
receptor. Furthermore, cannabinoid treatments of cells expressing DN22-CB1 did not 
alter mitochondrial respiration, but they still induced other CB1 receptor-dependent 
signaling, such as phosphorylation of ERKs and, importantly, activation of G protein. 
We further used these pharmacological and genetic tools, to evaluate the potential 
role of mtCB1 receptors in vivo in regulating long-term object recognition memory and 
motor control. The current data strongly suggest that the direct control of brain 
mitochondrial activity by mtCB1 receptors in different brain regions mediates well-
known cannabinoid-induced behavioral effects including memory impairment and 
alteration of locomotion. Several pieces of evidence converge to support this 
conclusion: 
1. Electrophysiological recordings in hippocampal slices revealed that KH7 
blocks the CB1 receptor-dependent decrease of fEPSPs. This effect is 
rescued in CB1-/- mice by viral re-expression of wild-type CB1, but not of 
DN22-CB1 protein.  
2. Intra-hippocampal infusion of KH7 prevents cannabinoid-induced ORM 
impairment and hippocampal re-expression of wild-type CB1 rescues this 
effect of cannabinoids in CB1-/- mice, whereas DN22-CB1 lost this ability. 
3. Using pharmacology, we identified the SNr as a brain region where 
cannabinoids exert both cataleptic and hypolocomotor effects. Both 
these effects are indeed blocked by a membrane permeable lipid CB1 
receptor antagonist (AM251) locally administered into the SNr. However, 
a membrane impermeable peptide antagonist (Hemopressin) blocks only 
partially the hypolocomotor but not the cataleptic effect of THC, 
suggesting the participation of intracellular CB1 receptors.  
4. The sAC inhibitor KH7 administered intra-SNr fully blocks THC-induced 
catalepsy and partially reduces hypolocomotion, strongly indicating the 
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participation of mtCB1 receptor signaling in the sedative effects of 
cannabinoids.  
In summary, the data collected during my PhD work causally link the direct 
impact of cannabinoids on brain mitochondrial functions to some of their most 
important behavioral effects, such as catalepsy and amnesia. This study establishes 
that the activation of a G protein coupled receptor can interfere with behavior via 
direct alteration of mitochondrial functions. The importance of bioenergetic processes 
is emerging as a key and so far rather underestimated element of the complex 
regulation of brain processes. The dichotomy between mitochondrial-dependent and 
-independent effects of cannabinoids opens new hopes for a targeted and specific 
exploitation of the large therapeutic potentials of this class of drugs, possibly avoiding 
undesired and limiting side effects. In the following, I will discuss more in detail the 
implications of these results. 
V. GENERATION	  AND	  VALIDATION	  OF	  TOOLS	  TO	  STUDY	  
MTCB1	  RECEPTORS	  
V.1 The	  presence	  of	  mtCB1	  receptors	  in	  the	  brain	  
Contrary to previous assumptions, functional GPCRs do not permanently reside 
on the plasma membrane, but signal within the cell on endomembranes (Beninca et 
al., 2014). GPCRs have a critical involvement in nearly all physiological processes 
(Rozenfeld and Devi, 2011), but, until recently, the functional presence of GPCRs on 
mitochondrial membranes was considered a remote and unlikely possibility. Indeed, 
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GPCRs were described as one of the most important means for cells to convert 
external stimuli to intracellular signaling, and their localization at plasma membranes 
represented a logic prerequisite to exert this function (Devi et al., 2005). However, 
recent data challenged the idea that GPCRs can signal exclusively when located at 
plasma membranes. To date, GPCRs were discovered on endosomal membranes 
(β2-adrenergic receptor; Irannejad et al., 2013), ER membranes (Metabotropic 
glutamate receptor 5 (mGluR5; Purgert et al., 2014), lysosomes (CB1 receptors; 
Rozenfeld 2008), nuclei (mGluR5; Purgert et al., 2014) and within mitochondrial 
membranes (purinergic receptors; Krzeminski et al., 2007). At endosomal locations 
these receptors can contribute to different molecular cascades and cellular 
processes, among them ERK1/2 activation (Rozenfeld and Devi, 2008) and cellular 
cAMP level (Irannejad et al., 2013), synaptic plasticity (Purgert et al., 2014).  
Thus, the discovery that metabotropic CB1 receptors are functionally present in 
mitochondria (Benard et al., 2012; Hebert-Chatelain et al., 2014; Koch et al., 2015) is 
a new but not completely unexpected finding. Indeed, other studies have previously 
observed labeling of mitochondria labeled by CB1 receptor antisera within the brain   
(Rodriguez et al., 2001; Sierra et al., 2014) and in peripheral cells, such as sperm 
and heart cells (Aquila et al., 2010), but the functional implications of these 
observations were only recently addressed (Benard et al., 2012).   
From the anatomical point of view, this study reveals that, in addition to 
hippocampus and hypothalamus (Aquila et al., 2010) mtCB1 receptors are present 
also at synaptic terminals of the SNr. Due to the low levels of mtCB1 receptors, the 
danger of false-positive results is always present in such immunogold electron 
microscopic experiments (Morozov et al., 2013) see also below). Therefore, an 
important aspect to consider for the rigorous identification of mtCB1 receptors is the 
use of negative controls and strict standard quantitative methods to avoid 
misidentification. Because several brain mitochondria are found close to other cell 
membranes, to avoid that CB1 immunogold particles were wrongly interpreted as 
mtCB1, restrictive criteria were applied for semi-quantitative analyses (Morozov et al., 
2013). By this way, only the particles located on mitochondrial membranes that are at 
least 80nm (the average dimension of gold particles) far from other membranes were 
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considered as mtCB1 receptors in the present study. According to this and similarly to 
other brain regions, approximately 13% of mitochondria of the SNr contained CB1 
particles whereas less than 3% were found in tissues from CB1-/- mice, clearly 
confirming the presence of mtCB1 also in this brain region.  
V.2 For	  CB1	  receptors,	  quantity	  is	  not	  always	  quality	  
The approximately 10-15% of total CB1 receptors located on the mitochondrial 
outer membrane of brain cells might seem a limited amount. However, this 
expression accounts for up to 25% of mtCB1-dependent reduction of respiration in 
purified brain mitochondria, suggesting a strong impact of cannabinoid signaling onto 
the specific organelles expressing mtCB1. Moreover, a general rule of CB1 receptor 
signaling is that even low amounts of the protein can bear crucial functional 
significance. For instance, less than 1% of total brain CB1 protein is expressed in 
glutamatergic neurons (Bellocchio et al., 2010; Soria-Gomez et al., 2014), but many 
of the functions of the ECS are indeed exerted by this limited percentage of 
receptors. Examples of this "paradoxical" way of functioning of the ECS can be found 
in the protection against excitotoxic seizure or in the orexigenic properties of 
endocannabinoid signaling, which are mainly exerted by "glutamatergic" CB1 
receptors (Bellocchio et al., 2010; Soria-Gomez et al., 2014). Therefore, 15% of brain 
total CB1 protein located in the mitochondrion cannot be considered a negligible 
amount from a functional point of view.  
V.3 New	  discoveries	  generate	  controversy	  
Considering that GPCRs are generally considered to be functionally present 
predominantly at plasma membranes, the discovery of mtCB1 receptors attracted the 
interest of the scientific community. Some authors performed functional studies in 
isolated mitochondria suggesting the existence of both CB1 receptor-dependent and 
–independent effects of cannabinoids on OXPHOS activity (Fisar 2014). Another 
group performed a study directly challenging the discovery, claiming that CB1 
receptors labeled on mitochondria are likely due to the unspecific binding of CB1 
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antisera to the mitochondrial stomatin-like protein 2 (Slp2), instead of CB1 protein 
(Morozov et al., 2013). An essential missing part in this study was the use and 
quantification of negative controls for determining antisera specificity, especially 
when highly sensitive methods are used. As described above, CB1-/- brain tissues 
display a dramatic reduction in mtCB1 protein labeling (Benard et al., 2012; Hebert-
Chatelain et al., 2014), clearly indicating the specificity of the antisera used in the 
experiments. Nevertheless, the possibility that the decrease in the immunolabeling in 
CB1-/- might reflect a reduction or a loss of Slp2 proteins due to off-target binding of 
CB1 antisera cannot be neglected. For this purpose, Western immunoblotting 
experiments using an antiserum against Slp2 was performed and revealed no 
differences in the amount of Slp2 protein in brain extracts from wild type and CB1-/- 
mice (Hebert-Chatelain et al., 2014). Thus, these results clearly indicate that the 
deletion of the CB1 gene does not alter the expression levels of a potential off-target 
of anti-CB1 antisera and confirm the finding of mtCB1 receptors. Nowadays, the 
presence of mtCB1 receptors seems to be accepted by the scientific community, as 
the same researchers who raised the controversy recently confirmed the presence of 
mtCB1 receptors in the hypothalamus (Koch et al., 2015).  
V.4 mtCB1	  receptor	  activation	  inhibits	  OXPHOS	  and	  ATP	  
production	  
The negative relationship between cannabinoids (eCBs and synthetic 
cannabinoids) and mitochondrial functions is well documented (Badawy et al., 2009; 
Bartova and Birmingham, 1976; Silva et al., 2012; Zaccagnino et al., 2011). These 
results can now be explained, at least in part, by the impact of mtCB1 receptors on 
endogenous respiration (Benard et al., 2012; Hebert-Chatelain et al., 2014; Vallee et 
al., 2014). In addition, high doses of cannabinoids also depress mitochondrial 
OXPHOS by a non-receptors mechanism (Fisar, 2010). Indeed, cannabinoids are 
lipophilic compounds that accumulate within cell membranes and they can negatively 
impact on mitochondrial activity by altering membrane fluidity (Fisar, 2010; 
Velenovska and Fisar, 2007). Moreover, unpublished results from our laboratory 
showed that higher doses of cannabinoids start having effects also on brain 
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mitochondrial fraction from CB1-/-, indicating a nonspecific effect. Therefore, both 
receptor- and non- receptor-mediated mechanisms of cannabinoid action on 
mitochondrial respiration are possible (Fisar, 2010). Thus, rigorous experimental 
approaches are needed to differentiate receptor-dependent and –independent effects 
of exogenous cannabinoids. 
Previous reports have found a reduction of ex vivo hypothalamic and brain 
mitochondrial respiration after systemic injections of cannabinoids in mice (Benard et 
al., 2012; Koch et al., 2015), supporting the view that cannabinoids decrease in vivo 
brain mitochondrial OXPHOS activity. However, the effect observed in isolated 
mitochondria might be different from that taking place in intact cells, where cellular 
networks and environment are undisturbed, representing a more physiologically 
relevant model for experiments on metabolism (Althoff et al., 2011). Here, we 
demonstrated that cannabinoid treatments decrease, in a CB1-dependent manner, 
rotenone-sensitive endogenous respiration by approximately 25 % in living 
hippocampal cells. Consistently, cellular and mitochondrial ATP levels were 
decreased in the cells after cannabinoid treatments. Cellular ATP levels mostly result 
from the concomitant actions of glycolysis, Kreb’s cycle activity and OXPHOS. The 
inhibition of OXPHOS, likely causing a decrease in mitochondrial ATP production, 
also impacts on the total cytosolic ATP levels. Thus, other metabolic sources of ATP 
such as glycolysis are not sufficient to compensate the mtCB1 receptor-dependent 
reduction of cellular ATP levels (approximately 35%), indicating that a decrease of 
mitochondrial respiration via mtCB1 receptor signaling is associated with an important 
reduction of cellular ATP levels that could significantly impact on the cell physiology.   
V.5 G	  protein	  signaling	  in	  the	  mitochondria	  
The alteration of rotenone-sensitive endogenous respiration induced by mtCB1 
receptors on isolated brain mitochondria is associated with a decrease in cAMP 
levels and in PKA and complex I activities (Benard et al., 2012). Whether these 
effects were mediated by Gαi/o-dependent signaling and through which molecular 
partner was still unknown.  
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 Our present data established that mtCB1 receptor-dependent inhibition of 
mitochondrial Gαi/o proteins mediates a decrease of mitochondrial cAMP levels and 
PKA activity, resulting in the inhibition of Complex I activity and respiration. Thus, 
seven transmembrane receptors located at brain mitochondria can stimulate intra 
organelle G protein signaling. It is well established that pmCB1 receptors can be 
coupled and signal through different types of Gα, including Gαi, Gαo, Gαq and Gαs 
(Turu and Hunyady, 2010). Our data show that the decrease of mitochondrial 
bioenergetic processes induced by mtCB1 receptor activation depends on their 
coupling with Gαi/o proteins. The functional coupling of mtCB1 receptors to Gαi/o is 
further supported by the finding that Gα proteins co-immunoprecipitate with mtCB1 
receptors in purified brain mitochondria and by the ability of THC to decrease this 
interaction. As pointed out in the Chapter 3 of this work, this molecular mechanism is 
in agreement with recent data showing the presence of G protein in mitochondria and 
other intracellular membranes (Andreeva et al., 2008; Beninca et al., 2014; 
Kuyznierewicz and Thomson, 2002; Lyssand and Bajjalieh, 2007; Purgert et al., 
2014). Thus, G protein-mediated signaling, previously considered an exclusive inter-
cellular communication mechanism, is emerging as a universal mechanism used to 
induce a chain of cellular cascades at different cellular membranes. In this context, 
the intracellular functional localization of CB1 receptors is particularly interesting, 
because the main endogenous and exogenous ligands of these receptors are lipid 
molecules, which can easily penetrate cells and move along intracellular membranes. 
Thus, (endo)cannabinoids reaching cells from outside or generated within cell 
membranes might directly alter mitochondrial activity, thereby directly linking 
extracellular or intracellular signals to cellular bioenergetic status (Benard 2012). 
Whether CB1 receptors can be functionally present at other intracellular membranes 
such as the ER or the nucleus is still an open question, and new tools and 
approaches will be required to study intracellular CB1 receptors. Indeed, the potential 
of intracellular and mitochondrial GPCRs signaling as regulators of cellular functions 
has been neglected for a long time (Belous et al., 2006), likely because of the 
technical difficulties in isolating intracellular GPCRs from total GPCRs signaling. 
This limitation mainly originates from the lack of methods to exert spatial control over 
GPCRs inside a living cell (O'Neill, 2014).  In this work, we introduced innovative 
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pharmacological (KH7) and genetic tools (DN22-CB1 protein) in order to directly 
study mtCB1 receptor functions. 
V.6 Downstream	  effectors	  of	  G	  proteins	  coupled	  to	  mtCB1	  
receptors:	  the	  role	  of	  sAC	  
CB1 receptors modulate brain functions through different signaling pathways 
including, among others, inhibition of transmembrane adenylyl cyclase, modulation of 
ion channels and activation of mitogen-activated and focal adhesion kinases 
(Howlett, 2005; Piomelli, 2003). Our results indicate a novel signaling pathway within 
mitochondria: activation of mtCB1 receptors decreases mitochondrial respiration and 
complex I activity through inhibition of the soluble form of AC and PKA activity. 
Indeed, we showed that mitochondrial respiration was blocked by the sAC activator 
bicarbonate and occluded by the sAC inhibitor KH7. In this line, co-
immunoprecipitation of Gα proteins with sAC from purified brain mitochondria 
revealed a physical interaction between mitochondrial sAC and Gα proteins in the 
brain, which was even promoted by mtCB1 receptor activation. Additionally, targeting 
of sAC into mitochondria rescues the decrease of O2 consumption induced by 
cannabinoids. Overall, these findings clearly established the causal role of sAC 
activity in mediating the effect of mtCB1 receptor signaling on OXPHOS within 
mitochondria. To date, this study is the first to report a direct modulation of sAC 
activity via heterotrimeric G-protein alpha subunits present in the mitochondria. This 
is actually surprising, because sAC was shown to be independent from G protein 
signaling in certain tissues, such as testis (Buck et al., 1999). This apparent 
discrepancy might underlie tissue-specific differential regulatory pathways of sAC 
activity.  
We showed that sAC inhibition induced by cannabinoids down-regulates cAMP 
level and leads to the decrease of PKA activity in the mitochondria. Indeed, both 
changes in cAMP levels and decrease of PKA activity were blocked by PTX, 
bicarbonate or KH7. Thus, the mitochondrial cAMP/PKA pathway appears to be 
involved in the decrease of complex I activity and respiratory activity produced by 
cannabinoids (Figure 34). The presence of the different components of this pathway 
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in the mitochondria has been demonstrated in numerous papers (Acin-Perez et al., 
2009b; Means et al., 2011; Sardanelli et al., 2006; Zippin et al., 2003) and their 
regulatory role on the complex I activity and on respiration has been clearly 
established (Acin-Perez et al., 2009b; Papa et al., 2012).  
The identification of which respiratory chain complex is targeted by 
mitochondrial sAC signaling is still under investigation. While cAMP/PKA pathway 
has been showed to participate in the phosphorylation and consequently in the 
maintenance of the complex I subunit NDUFS4 (De Rasmo et al., 2010; De Rasmo 
et al., 2015; Scacco et al., 2003), others have suggested that the complex IV, 
cytochrome c oxidase (COX), is an additional direct target of PKA phosphorylation 
(Acin-Perez et al., 2011). These proteins contain a PKA serine consensus site and 
genetic defects in the phosphorylation site of NDUFS4 or protein mutagenesis at Ser-
85 of COX subunit IV-1 impair OXPHOS efficiency (De Rasmo 2010, Acin-Perez 
2011a). Preliminary data from our laboratory indicate that mtCB1 activation reduces 
mitochondrial PKA-dependent phosphorylation of the complex I subunit NDUFS2, 
suggesting that this downstream mechanism might ultimately mediate the direct 
cannabinoid effects on OXPHOS (Hebert Chatelain et al., in preparation).  
Overall, the identification of a mitochondrial sAC signaling pathway clearly 
provides a mechanism for phosphorylation of mitochondrial enzymes implicated in 
OXPHOS. Further research is needed to explore whether the mitochondrial sAC 
pathway regulates additional intra-organelle processes and to complete the 
characterization of mtCB1 receptor signaling. These studies will likely reveal 
additional mitochondrial signaling pathways and will extend our knowledge on how 
GPCRs can modulate mitochondrial bioenergetics processes.  
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V.7 mtCB1	  receptor-­‐dependent	  function	  could	  rely	  on	  its	  
cellular	  distribution	  
As mentioned earlier, ex vivo brain mitochondrial respiration is modulated by 
CB1 receptor agonists in wild type (Koch et al., 2015), but not in CB1-/- mice (Benard 
et al., 2012). Interestingly, it was found that high doses of the CB1 receptor agonist, 
ACEA, negatively impact on mitochondrial respiratory activity whereas low doses 
induce an opposite effect, enhancing respiration (Koch et al., 2015). Such biphasic 
effects of cannabinoids have been already reported in vivo and were attributed to 
CB1 receptor activation on different cell types or brain regions (Bellocchio et al., 2010; 
Metna-Laurent et al., 2012; Soria-Gomez et al., 2014). As previously mentioned, CB1 
Figure 34.Soluble adenylyl cyclase (sAC) mediates the effects of mtCB1 receptor 
activation. 
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receptors are expressed on many cell types (Domenici et al., 2006; Haring et al., 
2007; Hermann et al., 2002; Marsicano and Kuner, 2008; Marsicano and Lutz, 1999). 
The use of conditional mutant mice allows controlling for the cell-type specificity of 
CB1 receptor activation or repression. These genetic tools allowed revealing that 
several cannabinoid-dependent behavioral, cellular or molecular effects are 
differentially mediated by CB1 receptors expressed on GABAergic or glutamatergic 
neurons or others. As an example, a bimodal control of food intake by CB1 receptors 
was recently shown. Whereas CB1 receptor activation in glutamatergic neurons 
promotes food intake, a contrary hypophagic function is exerted by CB1 receptor 
signaling within GABAergic neurons (Bellocchio et al., 2010). Interestingly, 
“glutamatergic” CB1 receptors are pharmacologically activated by low doses of 
exogenous cannabinoids to increase food intake, whereas higher doses exert 
hypophagic effects via “GABAergic” CB1 receptors. Accordingly, analysis of 
cannabinoid-stimulated [35S]GTPγS binding in hippocampal extracts showed that 
“glutamatergic” CB1 receptors are more efficiently coupled to G protein signaling than 
GABAergic CB1 receptors (Steindel et al., 2013), providing a potential molecular and 
cellular mechanism for the biphasic effects of cannabinoids (Bellocchio et al., 2010; 
Metna-Laurent et al., 2012). MtCB1 receptors are present in both GABAergic and 
glutamatergic neurons (Benard et al., 2012). Moreover, both terminal and 
somatodendritic neuronal compartments contain mtCB1 receptors (Benard et al., 
2012). Hence, mtCB1 receptor signaling could vary in function of its subcellular and 
cellular expression, thereby increasing the physiological repertoire of possible CB1 
receptor responses to single molecules. Thus, it is possible that mtCB1 receptors 
could exert a different role in synaptic and behavioral functions modulated by 
cannabinoids according to their cell-type localization. 
As a following of the present work, the question of whether mtCB1 receptors can 
have potentially a cell-type differential effect on OXPHOS was addressed. As 
detailed in the first chapter, CB1 receptors are functionally present in many brain cell 
types, including GABAergic and glutamatergic neurons, but also in astrocytes (Bosier 
et al., 2013; Han et al., 2012). Thus, unpublished experiments from Etienne Hebert-
Chatelain in the laboratory have investigated the role of astrocytic mtCB1 receptors. 
Indeed, preliminary results indicate that the impairment of O2 consumption following 
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cannabinoid applications is absent in brain mitochondria derived from mice lacking 
CB1 receptors from glial fibrillary acidic protein (GFAP)-expressing cells (including 
brain astroglial). Although cannabinoid effects through neuronal mtCB1 cannot be 
discarded at this stage, this interesting finding suggests that astroglial mitochondria 
might respond differently to mtCB1 receptor activation.  
Interestingly, it appears that mitochondria have cell-type-specific functional and 
morphological characteristics. For example, the cristae of astrocytic and neuronal 
mitochondria are different, presenting a parallel arrangement in neurons and a 
random arrangement in astrocytes (Kristian et al., 2006). Functionally, a higher 
respiration rate and complex I activity is found in astrocytic mitochondria as 
compared to neuronal mitochondria (Bolanos et al., 1995; Kristian et al., 2006). 
Interestingly, during short-term bioenergetic inhibition, astrocytic but not neuronal 
mitochondria exhibit characteristic morphological changes such as swelling 
(Gerencser et al., 2008), suggesting that astrocytes might be more sensible to 
oxidative stress as compared to neurons. Moreover, the mtCB1 receptor effect on 
respiration is mediated by the reduction of sAC activity, which has been found to be 5 
fold higher in glial cells as compared to neurons in cerebellum tissue (Chen et al., 
2013). Hence, the intrinsic difference of mitochondria among the cell type needs 
further attention. The understanding of the respective role of astrocytic versus 
neuronal mtCB1 receptors in cannabinoid impairment of OXPHOS will require the use 
of advanced tools in future studies. For instance, the generation of conditional knock-
in mice, expressing DN22-CB1 instead of wild-type CB1 in specific cell type will allow 
directly tackling many important questions in this new field (see below 
Perspectives). 
V.8 KH7,	  a	  tool	  to	  investigate	  the	  in	  vivo	  mtCB1	  receptor	  
dependent	  function	  
So far, sAC is the only AC known to be present in mitochondria (Valsecchi et 
al., 2013) and the present data showed that silencing of cellular sAC activity by KH7 
fully abolished the decrease of respiration induced by cannabinoids. Therefore, KH7 
was used to study the role of mtCB1 receptors in vitro and in vivo on different 
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cannabinoid-induced effects. However, it is important to keep in mind that while 
numerous studies have found sAC within mitochondria (Acin-Perez et al., 2009b; 
Kumar et al., 2009; Zippin et al., 2003), its presence was also observed in other 
subcellular compartments such as the cytoplasm (Zippin et al., 2003) and the 
nucleus (Zippin et al., 2003). As all pharmacological tools, the only commonly used 
sAC inhibitor KH7 might exert non-specific effects. Thus, careful interpretation has to 
be drawn when using KH7, and other pharmacological or genetic tools should be 
employed to confirm the implication of mtCB1 receptors. Other structurally different 
sAC inhibitors start being generated by several industrial or academic laboratories, 
and their use will be instrumental in future experiments. Cell permeable or 
impermeable CB1 receptor ligands can provide indications on the involvement of 
plasma membrane or intracellular CB1 receptors (Benard et al., 2012; Heimann et al., 
2007), present work). However, the most direct evidence for a role of CB1 receptors 
at mitochondrial membranes can be achieved by specifically excluding this location. 
This was obtained by generating the DN22-CB1 mutant protein. 
V.9 Generation	  of	  a	  truncated	  form	  of	  CB1,	  the	  DN22-­‐CB1	  
To overcome potential caveats of pharmacological tools and enlarge the tool 
panel to study mtCB1 receptor functions, we identified and generated a mutant 
protein, DN22-CB1, which lacks the first 22 aminoacids of the CB1 receptor 
sequence. Viral expression of DN22-CB1 or wild-type CB1 protein in the hippocampus 
of CB1-/- mice demonstrated that DN22-CB1 is virtually absent from mitochondrial 
membranes, thereby providing a genetic tool to dissect the functions of mtCB1 from 
other localizations of the receptor.  
Our data indicate that the first 22 aminoacid of the CB1 protein are necessary 
for mitochondrial localization of the receptor. The reasons of this function are not 
clear at the moment, but two possibilities can be identified: (i) These 22 amino-acids 
(N22) might serve as a mitochondrial leading sequence for CB1 receptors to be 
transported to the mitochondria. (ii) The N-terminal truncation might help the 
stabilization of the receptor at the plasma membrane, as proposed by other authors 
(Andersson et al., 2003; Fay and Farrens, 2013). Specific studies will be necessary 
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to test whether either or both these hypotheses are correct. On one hand, preliminary 
data from our laboratory suggest that N22 might be not sufficient to lead an 
exogenous protein (GFP) to mitochondria (data not shown). However, this does not 
exclude that the N22, which plays a necessary role for mitochondrial CB1 receptor 
localization, might co-operate with other CB1-specific sequences to favor such 
trafficking process. On the other hand, some studies suggested that deletion of 
different portions of the N-terminal part of the CB1 protein does not impair signaling, 
but “stabilize” the protein at the plasma membrane (Andersson et al., 2003; Fay and 
Farrens, 2013). In this sense, N22 might inhibit plasma membrane stability of the 
protein, rather than addressing it to other locations. However, the interpretation of 
those data was embedded by the concept that the “natural” localization of GPCRs is 
the plasma membrane. In this sense, those authors used the word “stabilization”. 
However, if we hypothesize that CB1 receptors, after translation can be addressed to 
different cellular locations, the data described above can be re-interpreted as 
“proportional increase” of plasma membrane localization, due to the lack of 
mitochondrial targeting, rather than "stabilization". For sure, the mechanisms through 
which CB1 receptors are targeted to mitochondria, plasma membranes or other 
cellular location is a very difficult and challenging issue, which will require specific 
and detailed future studies.  
However, in the present study, we could show that DN22-CB1 is functional (P-
ERK and G protein activation), but it lacks mitochondrial localization. Consistently, it 
is not able to mediate cannabinoid-induced alteration of OXPHOS. Thus, these data 
represent a strong genetic indication that the effect of cannabinoids on mitochondrial 
respiration can be fully attributed to specific activation of mtCB1 receptors. 
Importantly, the lack of respiratory effects and of mitochondrial localization makes of 
the DN22-CB1 mutant protein an optimal tool to study the specific impact of mtCB1 
receptors on cellular and behavioral functions.  
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V.10 Effect	  of	  mtCB1	  receptors	  activation	  on	  
neurotransmission	  and	  behavior	  
V.10.1 Activation	  of	  mtCB1	  receptors	  impairs	  excitatory	  
synaptic	  activity	  
V.10.1.1 SYNAPTIC	  TRANSMISSION:	  A	  HIGH	  ENERGY	  DEMAND	  PROCESS	  
Cannabinoids are well known to reduce hippocampal synaptic transmission and 
to impair ORM (Kano et al., 2009; Puighermanal et al., 2012; Puighermanal et al., 
2009). Neurotransmitter release is a very energy-demanding process, and 
mitochondria can modulate its efficiency by different means (Mattson et al., 2008). 
Accordingly, mitochondrial dysfunctions generate electrophysiological and behavioral 
abnormalities. For example, conditional deletion of Cytochrome c oxidase restricted 
to cortical fast-spiking parvalbumine interneurons, a type of neuron which has 
particularly high energy utilization, induces a decrease in inhibitory synaptic 
transmission (Kann et al., 2014). Moreover, in these mutants mice, the impairment of 
synaptic activity correlated with behavioral dysfunctions including lack of sensory 
gating, increased anxiety and impaired sociability, indicating that the bioenergetic 
impairment greatly influence behavior (Inan et al., 2015).In addition, as seen in the 
introduction, presynaptic mitochondrial activity and ATP synthesis are crucial for the 
maintenance of synaptic activity and plasticity (Guo et al., 2005; Ma and Blenis, 
2009; Verstreken et al., 2005). ATP participates in various synaptic processes such 
as restoration of the membrane resting potential following depolarization, mobilization 
of synaptic vesicles, neurotransmitter recycling and axonal and dendritic protein 
trafficking (Attwell and Laughlin, 2001; Wong-Riley, 2010). The use of cell-
impermeant CB1 receptor ligands and mitochondria-interfering drugs previously 
provided evidence that inhibition of mitochondrial activity via mtCB1 receptor 
stimulation are partially involved in the eCBs-dependent control of short-term 
synaptic plasticity at inhibitory hippocampal GABAergic synapses (Benard et al., 
2012). Notably, however, those experiments also revealed that cell permeant and 
impermeant CB1 receptor agonists (HU210 and HU 210-biotin, respectively) were 
equally able to pharmacologically reduce inhibitory basal synaptic transmission, 
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suggesting that intracellular CB1 receptors (including mitochondrial ones) are 
possibly not necessary for the exogenous cannabinoid-dependent negative 
regulation of GABAergic synaptic release (Benard et al., 2012). In contrast, the 
present data show that cannabinoids cause an mtCB1-dependent inhibition of field 
excitatory transmission at CA3–CA1 synapses. Taken together, these data clearly 
suggest that the regulation of mitochondrial activity by mtCB1 receptors participate in 
the decrease of excitatory synaptic activity and in the eCB-dependent inhibitory 
plasticity in the hippocampus (Benard et al., 2012). A recent study on energy demand 
of hippocampal synaptic transmission has revealed a considerable contribution of 
presynaptic processes, which consume approximately 50% of the O2 (Liotta et al., 
2012). Considering that CB1 receptors are highly dense at presynaptic level 
(Marsicano and Kuner, 2008) both at plasma and mitochondrial membranes (Benard 
et al., 2012), our demonstration that mtCB1 receptor activation decreases ATP 
production allows speculating that this mechanism might be responsible for the 
decrease of excitatory synaptic activity induced by cannabinoids. Accordingly, recent 
studies clearly demonstrated that even temporary interruptions of local ATP supply 
profoundly alter synaptic functions in neurons (Rangaraju et al., 2014).  
V.10.1.2 PRE	  OR	  POST-­‐SYNAPTIC	  MTCB1	  RECEPTORS	  
The portions of hippocampal mitochondria carrying mtCB1 receptors are similar 
in axonal terminals and somatodendritic compartments (Benard et al., 2012). 
Interestingly, somatodendritic CB1 receptors have been proposed to play a 
necessary role in autocrine slow self-inhibition (SSI) induced by depolarization of 
GABAergic and glutamatergic cortical neurons (Bacci et al., 2004; Marinelli et al., 
2009). Considering that many authors agree that somatodendritic CB1 receptors are 
virtually never localized at plasma membrane, these functions are likely to ascribe to 
intracellular CB1 receptors (Sierra et al., 2014). Thus, the interesting possibility 
emerges that somatodendritic mtCB1 receptors might be involved in the CB1-
dependent autocrine regulation of neuronal excitability (Bacci et al., 2004; Marinelli et 
al., 2009). 
Discussion 
 
Tifany	  Desprez	  -­‐	  Doctoral	  Thesis	  –	  University	  of	  BORDEAUX	  
	   	   	   200 
V.10.1.3 ROLE	  OF	  MTCB1	  RECEPTORS	  IN	  EXCITATORY	  VERSUS	  INHIBITORY	  BASAL	  TRANSMISSION	  
The fact that mtCB1 receptor activation is possibly not required for cannabinoid 
control of inhibitory basal transmission (Benard et al., 2012), but it is necessary for 
cannabinoid-induced decrease of excitatory transmission is quite surprising. What 
can explain this differential impact of mtCB1 signaling on basal excitatory versus 
inhibitory transmission? Assuming that mtCB1 receptors effects on neurotransmission 
are due to a depletion of mitochondrial ATP synthesis, a possibility to take into 
account would be that these two different synaptic processes require a differential 
ATP budget, making them more or less sensible to the shortage of energy 
production. Indeed, the energy budget can vary depending on the subcellular brain 
compartment (e.g. somatic/synaptic, pre-/postsynaptic), cell type, cell activity, 
synaptic processes (e.g. network oscillation, basal transmission, plasticity) and 
environmental conditions (Attwell and Laughlin, 2001; Kann et al., 2011; Wong-Riley, 
2010). For example, excitatory synapses are predicted to consume more energy as 
compared to inhibitory ones. Indeed, in the mature brain the chloride reversal 
potential is close to the resting potential so restoring postsynaptic Chlore (Cl-) 
gradients uses less energy than for Na+ gradients (Howarth 2010). It is therefore 
possible that, due to unequal energy budgets of these processes, mtCB1 receptor 
signaling might differentially affect glutamatergic and GABAergic neuronal 
transmission. However, more powerful and precise tools (e.g. conditional cell type-
specific DN22-CB1 knock-in mutant mice) will be necessary to gather detailed 
information on the differential involvement of mtCB1 receptors in distinct synaptic 
processes.  
V.10.1.4 POTENTIAL	  POST-­‐MITOCHONDRIAL	  EVENTS	  LINKING	  MTCB1	  RECEPTORS	  TO	  DECREASE	  OF	  SYNAPTIC	  
ACTIVITY	  AND	  BEHAVIOR	  
Unraveling the link between a specific mitochondrial process and its 
consequences on neuronal function is very challenging, mostly because different 
mitochondrial functions are interdependent (Graier et al., 2007; Gunter and Sheu, 
2009). Thus, experimental results obtained using drugs or mutations that interfere 
with only one aspect of mitochondrial physiology need to be interpreted with care 
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(Vos et al., 2010). Indeed, by providing ATP, regulating RedOx potentials, 
metabolizing neurotransmitters, providing Ca2+ clearance and many other 
mechanisms, mitochondria exert myriads of functions that are potentially directly 
linked to synaptic activity and brain functions (Mattson et al., 2008). Thus, we still do 
not know which “post-mitochondrial” effects link mtCB1 receptor activation to the 
observed alterations of synaptic and behavioral functions. Because ATP synthesis, 
one of the major roles of mitochondria, is altered by mtCB1 receptor activation, it is 
tempting to hypothesize that this mechanism might be implicated in cataleptic, 
hypolocomotor and amnesic effects of cannabinoids.  
As mentioned above, however, mitochondria exert many different functions, 
which are all potentially suitable to modulate brain processes, and are directly or 
indirectly linked to OXPHOS activity and ATP production. As mtCB1 receptor 
physiology is a recent field of research, very little is known concerning the possible 
“post-mitochondrial” events involved in its functions. Our present data indicate that 
the modulation of sAC activity by mtCB1 receptors is responsible for cannabinoid-
induced decrease of excitatory hippocampal transmission, impairment of ORM and 
alteration of motor performance. However, other complementary or alternative 
molecular mechanisms previously described to depend on CB1 receptor activation 
might be linked to mitochondrial activity and, thus, might involve mtCB1 receptors. 
Among them, I will discuss the interplay between CB1 receptor signaling and mTOR, 
ROS and nitric oxide (NO) that are modulated by brain CB1 receptors (Donadelli et 
al., 2011; Nunn et al., 2012; Puighermanal et al., 2009). Importantly, mTOR, ROS 
and NO signaling have been shown to modulate both mitochondrial functions and 
synaptic activity and behavior (Morita et al., 2015).  
mTOR forms two distinct complexes, mTOR complex 1 (mTORC1) and 2 
(mTORC2). In particular, mTORC1-dependent signaling regulates different 
processes such as protein synthesis, cell growth, autophagy and mitochondrial 
activity (Betz and Hall, 2013; Morita et al., 2013). Activation of CB1 receptors in the 
brain was recently shown to up regulate the mTORC1 pathway, underlying the 
amnesic effect of cannabinoids in hippocampal dependent tasks (Puighermanal et 
al., 2009). Considering that a strong link exists between mTORC1 and mitochondrial 
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respiration (Morita et al., 2013; Ramanathan and Schreiber, 2009) the possible 
interaction between mitochondrial effects of cannabinoids and the mTORC1 signaling 
cascades appears as a rational and intriguing hypothesis worth to investigate in 
future studies. 
ROS are highly reactive molecules that are known to produce cellular damage 
but also to participate in cellular physiology (Popa-Wagner et al., 2013). ROS can 
modulate hippocampal synaptic plasticity and memory (Hu et al., 2006; Kamsler and 
Segal, 2003).  It was recently shown that CB1 receptor activation leads to an increase 
of ROS production in vitro (Donadelli et al., 2011; Rajesh et al., 2010) and in vivo 
(Koch et al., 2015). Mitochondria are producing the largest amount of reactive 
oxygen species (ROS) in the cell (Massaad and Klann, 2011). Mitochondrial ROS 
generation can occur through the leaking of electrons at the mitochondrial complex I 
of the respiratory chain (Chen et al., 2003b; Paradies et al., 2004). In particular, 
blockade of Complex I activity trough sAC inhibition causes ROS elevation (De 
Rasmo et al., 2015). Given that mtCB1 receptors inhibit mitochondrial O2 
consumption through decrease of complex I activity, it is possible that cannabinoids 
generate ROS elevation via mtCB1 receptors, which could in turn affect 
neurotransmission and behavior. Supporting this hypothesis, it was shown that 
inhibition of respiratory activity by cannabinoids is coupled to an increase in 
mitochondrial hydrogen peroxide (H2O2) production (Athanasiou et al., 2007). 
Interestingly, recent unpublished data from the laboratory indicate that ROS inhibitors 
can block several acute effects of cannabinoids in vivo (Busquets-Garcia et al., in 
preparation), supporting the hypothesis that CB1 receptors (and possibly specific 
mtCB1 receptors) might act via modulation of these processes. 	  
The endocannabinoid system could modulate mitochondrial function via nitric 
oxide (Lipina et al., 2014; Nunn et al., 2012).Activation of CB1 receptors has been 
shown to increase NO production by inhibiting the expression and/or the activity of 
neuronal NO synthase, the enzyme responsible for catalyzing the synthesis of NO 
(Esposito et al., 2001; Waksman et al., 1999), in different cell types including 
monocytes and neuroblastoma cells and in brain slice preparations and (Carney et 
al., 2009; Prevot et al., 1998; Stefano et al., 1996).  NO regulates mitochondrial 
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function by inhibiting cytochrome c oxidase, the terminal acceptor in the 
mitochondrial electron transport chain (ETC), thereby inhibiting energy production 
and increasing H2O2(Brown, 2001). Thus, mtCB1 receptors could additionally mediate 
the decrease of ATP production trough inhibition of NO. Future experiments are 
needed to explore this possibility. Interestingly, THC was shown to exert normal 
analgesic effects in mice lacking the neuronal form of NOS, but locomotor effects of 
the drug were impaired by the mutation (Azad et al., 2001). These results suggest 
that NO signaling might indeed participate in some behavioral effects of cannabinoids 
involving mtCB1 receptor activation.	  
Overall, besides direct regulation of ATP levels, the data described above 
suggest that mTOR, ROS and NO signaling might represent mitochondrial processes 
linking the activity of mtCB1 receptors to brain functions. MtCB1 receptors signaling 
might contribute to the modulation of synaptic activity or plasticity (Benard et al., 
2012) by different means and systematic studies will be needed to clarify this aspect. 
V.10.1.5 DO	  MTCB1	  RECEPTORS	  IMPACT	  ON	  THE	  MOBILITY	  OF	  MITOCHONDRIA	  IN	  NEURONS?	  
The precise positioning of mitochondria at their functional locations in dendrites, 
spines, axons or synaptic terminals is of key importance in powering synapses 
(Chang et al., 2006; MacAskill et al., 2010). Principal neurons and motor neurons 
project their process far from their cell body and mitochondria are formed at the 
soma. If mitochondria were not transported to distal cellular locations, ATP 
synthesized in the soma would take over 2 min to diffuse to the end of a 200 µm-long 
dendrite, and ∼10 years to diffuse to the end of a 1 meter-long axon, preventing rapid 
adaptation of the ATP supply in response to changing pre- and postsynaptic activity. 
Instead, mitochondria are transported long distances around neurons by kinesin and 
dynein motors, moving on microtubule tracks (MacAskill et al., 2010) playing a 
fundamental role in the modulation of synaptic transmission and plasticity (Guo et al., 
2005; Kang et al., 2008; Sun et al., 2013; Verstreken et al., 2005).  Interestingly, CB1 
receptor agonists reduce the fraction of transported mitochondria in enteric nerve 
fibers (Boesman 2009) and preliminary results from our laboratory indicate that this 
effect in hippocampal neurons directly involves mtCB1 receptor signaling (Serrat et 
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al., in preparation). Thus, mtCB1 receptors could impact synaptic and behavioral 
functions also by regulating mitochondrial motility and their subcellular distribution. 
	  
V.10.1.6 DOES	  SAC	  INHIBITION	  MEDIATED	  BY	  MTCB1	  RECEPTORS	  IMPACT	  ON	  THE	  ASTROCYTE-­‐NEURON	  
COUPLING?	  
From where the metabolic substrate(s) needed for OXPHOS activity and ATP 
production are provided to synaptic mitochondria? The morphology and location of 
astrocytes, with an extensive endfoot around blood vessels, is well suited to uptake 
glucose from the blood, transform it into pyruvate or lactate and distribute them to the 
neighboring neurons via their processes closely unsheathing synapses (Allaman et 
al., 2011). Furthermore, while most brain energy is used by synapses, the unique 
brain energy store, glycogen, which can sustain neuronal functions for a few minutes 
when the glucose and oxygen supply is compromised (Choi et al., 2012), is mainly 
located in astrocytes (Gruetter, 2003), supporting their role in metabolite transfer to 
neurons. Moreover, neuronal activity elevates lactate levels in the brain and 
activation of astrocytes by glutamate increases lactate production subsequently 
secreted in the extracellular medium (Pellerin and Magistretti, 1994). Such processes 
could regulate the energy supplied to neurons in response to their activity, since 
glutamate released by active neurons could promote lactate production in astrocytes 
(Pellerin and Magistretti, 1994). Thus, an astrocyte-neuron lactate shuttle (ANLS) 
mechanism was proposed, whereby astrocytes generate lactate, eventually exporting 
it to neurons where it would be converted to pyruvate for ATP generation in 
mitochondria (Allaman et al., 2011; Pellerin and Magistretti, 2012). In this context, 
metabolic coupling between astrocytes and neurons was shown to be dependent on 
sAC signaling within astrocytes (Choi et al., 2012). Physiological increases in 
extracellular K+ concentration cause astrocyte depolarization and permit the entry of 
bicarbonate into astrocyte, resulting in the activation of sAC in astrocytes (Choi et al., 
2012). In turn, sAC activation causes glycogen breakdown, enhanced glycolysis, and 
the release of lactate into the extracellular space, which is subsequently taken up by 
neurons for use as an energy substrate (Choi et al., 2012). Soluble AC is mainly 
localized around and inside mitochondria (Bundey and Insel, 2004; Zippin et al., 
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2003). Hence, it is tempting to hypothesize that mtCB1 receptors could participate in 
the modulation of the metabolic coupling that occurs during transmission and thereby 
altering the maintenance of synaptic activity. In addition, recent evidence has 
revealed the role of astrocytic CB1 receptors and their strong participation in the 
(endo)cannabinoid-dependent modulation of synaptic plasticity and memory 
processes (Han et al., 2012; Navarrete and Araque, 2008, 2010). Thus, assuming 
that mtCB1 receptors are functional in astrocytes, we cannot discard the possibility 
that blockade of sAC activity by mtCB1 receptors activation could affect, in addition to 
the decrease of mitochondrial respiration, the metabolic coupling between astrocyte 
and neurons during synaptic activity. Despite the fact that only preliminary data show 
that mtCB1 receptors might be present also in astroglial cells, it is intriguing to 
speculate that bioenergetics control of astrocyte functions by (endo)cannabinoids 
might participate in their pharmacological or physiological effects. Also, it has been 
well established that astrocytes are endogenous regulators of synaptic transmission 
and plasticity (Araque et al., 2014; Panatier et al., 2011; Papouin et al., 2012). Future 
experiments are needed to explore the potential effect of mtCB1 receptors in 
astrocytes. Given that astrocytes have higher complex I activity and sAC expression 
than neurons, astrocytic mtCB1 receptors are potential good candidates to mediate 
some of the effects of cannabinoids on synaptic transmission and behavior. Our 
present experiments did not address this issue, as ubiquitous promoters were used 
to express CB1 and DN22-CB1 in the hippocampus. More specific approaches are 
currently being performed in the laboratory to address these possibilities. 
V.11 Hippocampal	  mitochondrial	  inhibition	  mediated	  by	  
mtCB1	  receptors	  impairs	  ORM	  performances	  
Cannabinoids are well known to impair ORM performance and this 
pharmacological effect was assigned to hippocampal CB1 receptors (Puighermanal 
et al., 2009). In the present study, we showed that post-training inhibition of 
mitochondrial activity trough mtCB1 receptor activation impairs ORM performance. 
This finding, linking mitochondrial activity with ORM, is consistent with the high 
energy requirement for recurrent firing that mediates memory processes (Rojas et al., 
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2012). Interestingly, a recent study conducted by Hara and colleagues suggested a 
key role of mitochondria in modulating synaptic transmission, brain function and 
cognition, revealing the relationship between abundance and morphology of 
presynaptic mitochondria and memory performance in monkeys (Hara et al., 2014).  
However, future studies are needed to further investigate the crucial role of 
mitochondrial activity in memory processes. 
V.12 CB1	  receptors	  in	  the	  SNr	  mediate	  cataleptic	  and	  
hypolocomotor	  effects	  of	  THC	  
Cannabinoid drugs display potential therapeutic applications in several 
diseases (Pacher et al., 2006). However, these therapeutic effects are often 
accompanied with undesired effects such as memory, motor impairments and 
psychotic-like states, mostly related to alterations of brain processes (Pacher et al., 
2006). For instance, CB1 receptor agonists are powerful analgesic drugs, but their 
use in clinics is limited by important side effects, including alterations in movement 
initiation and coordination (Howlett, 2002). In mice, cannabinoids impair spontaneous 
locomotor activity and induce catalepsy in a CB1-dependent manner (Monory et al., 
2007; Zimmer et al., 1999). My Thesis work identified the SNr as a crucial brain 
structure where CB1 receptor signaling is necessary for the induction of catalepsy 
and hypolocomotion by cannabinoids. Interestingly, the SNr has a central role in the 
basal ganglia circuits and local cannabinoid injections in this brain region affect motor 
performance (Fernandez-Ruiz, 2009; Sanudo-Pena et al., 1996). The SNr contains 
CB1 receptors on terminals of striatal projecting neurons co-expressing CB1 and D1 
receptors (the so-called ‘direct’ striatal efferent pathway), which use GABA as a 
neurotransmitter (Hohmann and Herkenham, 2000). Indeed, it was reported that the 
activation of CB1 cannabinoid receptors inhibits GABAergic neurotransmission in the 
SNr (Wallmichrath and Szabo, 2002). Interestingly, inhibition of GABAA receptors in 
the SNr is associated with the induction of catalepsy (Kolasiewicz et al., 1988) 
whereas elevation in intra-SNr GABA level promotes hyperactivity (Matsui and 
Kamioka, 1978). Moreover, deletion of the CB1 gene in D1-positive neurons in mouse 
(D1-CB1-/-) abolishes the induction of catalepsy by cannabinoids (Monory et al., 
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2007). This work shows that antagonizing CB1 receptors in the SNr prevents both 
hypolocomotor and cataleptic effects of THC. Thus, the present data show that 
pharmacological activation of CB1 receptors in the SNr mediates these effects of 
THC, likely via a modulation of striatonigral neurotransmission. 	  
V.13 Local	  inhibition	  of	  mitochondrial	  activity	  mediates	  
cannabinoid-­‐induced	  catalepsy	  and	  hypolocomotion	  
Neurodegenerative diseases are tightly linked to mitochondrial dysfunctions. 
Among them, Parkinson's and Huntington's diseases primarily compromise the basal 
ganglia circuit, thereby affecting motor behavior. Rotenone is a highly lipophilic 
compound and a classic complex I inhibitor that ultimately leads to energy deficiency. 
Interestingly, chronic rotenone injection is widely used as an animal model of 
Parkinson's disease because it progressively induces motor abnormalities, including 
delayed initiation of movement (Fleming et al., 2004), reduced motor activity and 
prolonged latency in the catalepsy test (Sharma and Nehru, 2013). Thus, 
mitochondrial inhibition is clearly linked to motor disabilities (Klein et al., 2011). In the 
current study, the combination of subthreshold doses of rotenone and cannabinoids, 
which both directly exert effects on complex I activity, results in the induction of 
hypolocomotion and catalepsy. Therefore, it is rational to suggest that these drugs 
have synergist effects due to the dual inhibition of Complex I activity. Importantly, 
intra-SNr inhibition of mtCB1 receptor signaling using the sAC inhibitor KH7 prevents 
catalepsy and decreases hypolocomotion induced by high doses of THC. Altogether, 
these results support the view that acute local inhibition of mitochondrial activity by 
mtCB1 receptors mediates the motor effects induced by cannabinoids. 
Motor impairment is generally considered as an important undesired side-effect 
of cannabinoids, profoundly limiting the use of these drugs for potential therapeutic 
effects (Pacher et al., 2006). In addition, CB1 receptor modulation have been 
proposed to offer a novel type of therapy for HD and PD, delaying, arresting or 
repairing the striatal and nigral damage and the associated symptoms (Lastres-
Becker et al., 2005; Sagredo et al., 2012). Thus, these data provide mechanistic 
theoretical ground for the future development of cannabinoid drugs inducing lower 
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side effects. For instance, recent studies revealed that the neurosteroid 
pregnenolone acts as an allosteric negative modulator of CB1 receptors in the brain, 
and this effect is at least partially exerted through mtCB1 receptors at the level of 
mitochondrial respiration (Vallee et al., 2014). Thus, our data and this recent study 
suggest that the combination of pregnenolone with cannabinoids might ameliorate 
side effects of therapeutic cannabinoids. 
 
Conclusion 
In summary, I believe that my Thesis work has contributed to a better 
understanding of the underlying mechanisms of cannabinoid effects on behavior. We 
have approached the role of mtCB1 receptors in different brain regions trough 
different and complementary methods. In isolated mitochondria, mtCB1 receptors 
Figure 35.mtCB1receptors and/or sAC signaling activation mediate behavioral effects of 
cannabinoids. 
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target complex I-dependent respiration through Gαi/o proteins. We then identified 
mitochondrial sAC as the target of mtCB1 receptor signaling. In addition, we 
generated DN22-CB1 mutant protein as a good strategy to study mtCB1 receptor 
function in vivo. By taking advantage of these novel approaches, we revealed the 
necessary role of sAC signaling and mtCB1 receptors in mediating specific central 
effects of cannabinoids including amnesia, catalepsy and hypolocomotion (Figure 
34). In vitro hippocampal electrophysiological recordings allowed us describing that 
mtCB1 receptor activation mediates the cannabinoid-induced decrease of excitatory 
transmission in the hippocampus. Overall, these functional analyses may serve as a 
representative example of how impairment in bioenergetic processes could affect 
neurotransmission, memory and motor control 
V.14 	  Perspectives	  
The recent discovery of the presence of mtCB1 receptors in the brain generated 
several important scientific questions; dealing with the “upstream” and “downstream” 
mechanisms linking cannabinoid signaling, cell bioenergetics processes and brain 
functions. To address these novel questions, specific innovative tools are needed. 
The present Thesis work, by generating some experimental tools and using them to 
investigate some specific effects of exogenous cannabinoids, represents just a first 
step in the quest of understanding the implications of that discovery. Obviously, much 
work is still to do. In the following, I propose some feasible directions for future 
experiments.  
• Development of precise genetic tools to study in vivo effect of mtCB1 
receptors 
More powerful and precise tools will be necessary to gather detailed information 
on the differential involvement of mtCB1 receptors in distinct synaptic processes.  
-­‐ Based on the present data, our lab is currently generating a conditional cell 
type-specific DN22-CB1 knock-in mutant mouse, which will express the mutant 
protein at the place of wild-type CB1. These mutant mice will be instrumental 
to dissect the specific roles of mtCB1 receptors.  
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-­‐ DN22-CB1 receptors are excluded from mitochondria and, thereby, can 
provide information on the necessary role played by mtCB1 receptors in brain 
functions. To address its potential sufficient role, we are in the process to 
generate additional genetic tools allowing an increase of CB1 receptor 
mitochondrial location. Mitochondrial leading sequences (MLS) will be fused to 
the CB1 protein to “force” mitochondrial localization (MLS-CB1). These 
constructs, if functional, will allow obtaining “exclusive mtCB1” mutant mice, 
which will provide highly valuable information on the sufficient roles played by 
mtCB1 receptors in brain functions. 
• Understanding the mechanisms of mitochondrial targeting of CB1 
receptors 
The cellular mechanisms promoting the mitochondrial localization of CB1 
receptors are not known. Specific cell biological studies are needed to disentangle 
these mechanisms, which, moreover, could lead to the generation of more precise 
tools to study the functions of mtCB1 receptors. 
• Test the role of mitochondrial sAC pathway in cannabinoid-dependent 
effects 
Down regulation or overexpression of mitochondrial sAC using viral or 
transgenic approaches will allow definitely establishing the role played by this 
enzyme in cannabinoid-induced effects, likely mediated by mtCB1 receptors. 
• Assess the role of mtCB1 receptors in other cannabinoid-­‐mediated 
effects	  
In particular, as cannabinoids are well-known food intake regulators, it will be 
very interesting to characterize the metabolic response of DN22-CB1 knock-in mutant 
mice after cannabinoids. Secondly, given that cannabinoids exert therapeutically 
relevant effects such as anti-convulsant and anti-nociceptive effects in animal models 
and patients, it will be interesting to test the whether these effects require the 
activation of mtCB1 receptors. 
• Physiological stimulation of mitochondrial activity	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In the brain it is well established that, in the absence of glucose, ketone bodies 
are used as an alternative source of energy. The ketone bodies are oxidized, 
releasing acetyl-CoA, which enters directly to the Kreb’s cycle, thereby shunting 
glycolysis. In particular, ketogenic diet appears to stimulate mitochondrial biogenesis 
and activity. Thus, ketogenic diet could permit highlighting the functions of mtCB1 
receptors in body physiology.   
• Testing “post-mitochondrial” mechanisms of action of mtCB1 receptors 
As mentioned above, several “post-mitochondrial” pathways can be involved in 
the brain functions of mtCB1 receptors. Pharmacological and genetic tools will be 
established to dissect the processes linking mtCB1 receptor activation to modulation 
of brain functions. 
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